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Abstract 
To evaluate and identify new candidate cancer drug targets, there is an 
ongoing need for a reliable, sensitive and quantitative assay that enables 
the analysis of larger numbers of compounds in preclinical research. This 
thesis has developed, and optimized a sensitive enzyme-release assay 
for monitoring natural cytotoxicity. It measures the release of the 
intracellular enzyme adenylate kinase into the culture supernatant after 
membrane rupture and is evaluated as an indicator of cell death. This 
assay was proven to correlate and compete with currently used 
methodologies for the assessment of cytotoxicity and with its superior 
sensitivity; convenience and in expense, it should be applicable to the 
study of other cytotoxicity reactions. The resulting ToxiLight® kit is now 
being sold world-wide and rapidly became the top selling product for 
Lonza Bio Science with many references to its use in publications.  
It was proven from this investigation that to truly comprehend the effect a 
cytotoxic drug has on cells, two assays are required in combination; one 
to measure cytotoxicity and a second to measure viability. The two most 
sensitive kits tested in this study, the ViaLight® Plus assay and the newly 
designed ToxiLight® assay were used in combination to monitor the 
effect of commonly used cytotoxicity drugs on melanoma cells. It was 
hoped to find both a sensitive and resistant cell line for further analysis by 
MALDI-MS. The study revealed how cells of the same histological and 
tissue type can respond differently to the same anticancer drug with one 
cell line revealing cell death after treatment and another remaining 
unaffected. This is representative of how individual patients may respond 
differently to the treatments given in vitro and explains the vast 
biochemical heterogeneity of tumour cells and the complexity involved in 
developing anticancer drugs that will specifically kill tumours arising from 
a given cell. The primary melanoma cells used for the research were 
representative of the clinical situation and were a kind gift from the 
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XX 
OYSTER (Outcome and Impact of Specific Treatment in European 
Research in melanoma) tissue bank; with the established cell lines 
obtained from ESTDAB. A selection of three of these cell lines (Ma Mel 
28, Ma Mel 26a and MEWO) were chosen after investigating their 
sensitive/resistant nature to certain chemotherapeutic drugs and were 
further investigated with a novel agent currently in its early stages of drug 
trials, the histone deacetylase inhibitor, trichostatin A.  
To investigate this resistance further, MALDI-MS was performed on the 
chosen melanoma cell lysates. The results demonstrated that good 
quality proteomic data could be achieved from cell lines and that it is 
possible to generate discriminatory protein profiles that correlate with the 
cytotoxicity assays when analysed using artificial neural networks 
(ANNs). Through the analysis of the proteome the ANNs was able to train 
itself using the raw dataset from the MALDI-MS analysis and distinguish 
differences between those samples that were drug-treated and those that 
were left untreated. The differences between the two classes of treated 
and untreated cells revealed biomarkers that may correlate to cell death 
and thus the effect of the drug trichostatin A. These findings could lead to 
the discovery of proteins that are up regulated when a patient is 
responding to therapy. This could be of prognostic and therapeutic benefit 
to patients enabling them to find out in the early stages of treatment if 
they are responding to a given treatment; the long term outcome leading 
to personalised treatments for individuals in which a decision can be 
made on the best suited treatment.   
1 
Susan Catherine Gill 
PhD Thesis, 2009 
Chapter 1 – Introduction 
 
1.1  Cancer Development and Progression 
Cancer is one of the most intractable diseases to man and comprises 
over 200 different forms. Together, they account for approximately one 
fifth of all deaths in the industrialized countries of the Western World 
(Schulz, 2007). Cancer is an extremely complex disease resulting from 
changes in gene expression of previously normal cells, where 
‘checkpoints’ control cell cycle progression. The cell cycle consists of four 
distinct phases: G1, S (synthesis), G2 (collectively known as interphase) 
and M phase (mitosis; figure 1.01). M phase is composed of two tightly 
coupled processes: mitosis, in which the cell’s chromosomes are divided 
between the two daughter cells, and cytokinesis, where the cell’s 
cytoplasm divides forming distinct daughter cells (Weinberg, 1994). The 
activation of each phase is dependent on the correct progression and 
completion of the previous phase. Cells that have temporarily or 
reversibly stopped dividing are said to have entered a state of quiescence 
called Go phase. 
 
 
 
Figure 1.01: Cell Cycle adapted from Kiaris, 2006 
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As the cell progresses from one phase to another, cell cycle checkpoints 
take place to ensure that damaged or incomplete DNA is not passed on 
to daughter cells. If damage is detected the cycle is halted, allowing for 
either repair or for programming the cell to die (apoptosis).  There are two 
main checkpoints in the cycle: the G1/S checkpoint and the G2/M 
checkpoint (figure 1.01). The tumour suppressor gene, p53 plays an 
important role in triggering the control mechanisms at both G1/S and G2/M 
checkpoints, halting further progression if damage is detected (Klatt and 
Kumar, 2009). If the cells are not halted when damage occurs or fail to 
repair any DNA damage, it may result in continued growth of ‘faulty’ DNA 
which continues to proliferate ‘unchecked’, resulting in the potential for 
unrestricted growth and tumour formation (Fenech, 2002).  
 
Although in theory three mutations could lead to cancer, it is thought that 
most common adult cancers result from five or more mutations. More 
than 100 cancer genes have been found, but many more are thought to 
yet be discovered (Weinberg, 2007). Most of the 100 known genes have 
been found in the relatively rare leukaemias and lymphomas, which 
account for less than 10 % of all human cancers. For the common adult 
epithelial cancers of the breast, colon, prostate, lung and ovary, which 
account for 80 % of the cancer burden, over 100 oncogenes are known 
(Richards, 2007).  
 
The key difference between cancerous and normal cells is that despite 
the abnormalities formed within the cancer cell, it continues to reproduce 
in an unrestricted manner. In addition to this continued growth, when cells 
become confluent, they continue to replicate, thus contradicting the 
normal laws of contact inhibition. Without contact inhibition to stop their 
progress, cancer cells are free to grow and although signs of 
differentiation may be observed, the cancer cells are not governed by the 
normal rules of cell or tissue growth. There are six main changes, 
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considered which are considered to be the ‘hallmarks of cancer’ 
(Hanahan and Weinberg, 2000) which include: 
 
• self-sufficiency in growth signals 
• insensitivity to anti-growth signals 
• evasion of apoptosis 
• limitless replicative potential 
• sustained angiogenesis 
• tissue invasion and metastasis 
 
1.1.1 Oncogenes and Tumour Suppressor Genes 
 
In the last forty years, two classes of genes now known to play a key role 
in cancer formation were discovered: the oncogenes and tumour 
suppressor genes. The first oncogene (the src gene: for sarcoma) was 
discovered as an oncogene in a chicken retrovirus induced tumour 
(Gonda et al., 1982). Since then, more than one hundred oncogenes 
have been discovered (Richards, 2008). An oncogene, upon mutation, 
may increase protein production or biological activity resulting in the 
transformation of a normal cell to a cancerous cell. It was demonstrated in 
1976, (Bishop and Varmus) that oncogenes were in fact defective proto 
oncogenes; caused by relatively small modifications of their original 
function, which could be either quantitative or qualitative changes. Proto 
oncogenes promote growth but they function under tight genetic control 
where tumour suppressor genes may function to restrict cell division 
(Weinberg, 1994). Any changes in either one or both of these sets of 
genes will result in uncontrolled growth and potentially cancer (Hodgson, 
2008). Quantitative changes in the proto-oncogenes result from point 
mutations that cause a modification in the protein structure leading to an 
increase in the activity of the protein and reduced regulation. In addition, 
an increase in the stability of a protein can prolong its existence and 
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therefore its activity. Qualitative changes result from a conversion from 
proto oncogene to a transforming gene (or cellular oncogene (c-onc)) with 
altered nucleotide sequence (Weinberg, 1994). An activated oncogene 
can cause a cell that would normally undergo a programmed form of cell 
death to survive and proliferate. Examples of oncogenes involved in 
breast cancer formation are shown in table 1.01. 
 
 
Myc (table 1.01) is among the most, if not the most potent human 
oncogene in terms of its ability to elicit tumourigenesis. The original 
implication of myc in carcinogenesis was suggested following its 
identification as a target of translocation in primary Burkitt’s lymphomas 
that results in over expression. Subsequently, it became clear that over 
expression of myc is common in human tumours, by mechanisms that 
involve its transcriptional activation, with the majority not being 
accompanied by amplification. Virtually all signalling pathways activated 
in carcinogenesis result in the direct induction of myc expression. Ras 
oncogenes (table 1.01) are among the most prominent oncogenes and 
are widely used as transforming proteins. They control divergent 
processes such as proliferation, angiogenesis and malignant 
transformation. 
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   Table 1.01: Oncogenes, their functions, and targeted therapies in breast cancer  
(Osbourne et al., 2004) 
 
ONCOGENE 
 
 
FUNCTION 
 
TARGETED THERAPY 
(2004) 
 
 
HER-2 
 
 
Tyrosine kinase receptor 
 
Anti HER-2 antibodies 
(trastuzumab, pertuzumab) 
Kinase inhibitors (Cl-1003, 
EKB-569, Lapatinib) 
E1A adenoviral gene therapy 
 
Ras 
 
 
G-protein 
 
Farnesyl transferase 
inhibitors (tipifarnib) 
 
PI3K 
 
Kinase 
Rapamycin/rapamycin 
analogues (CCI-779, RAD 
001, AP23573) 
 
Akt 
 
Kinase 
Rapamycin/rapamycin 
analogues (CCI-779, RAD 
001, AP23573) 
 
ElF-4E 
 
Initiator of protein 
translation 
 
No therapy 
 
Cyclin D1 
 
 
Cell-cycle mediator 
 
Flavopiridol, UCN-01 (7-
OH staurosporine), 
 
 
Cyclin E 
 
 
Cell-cycle mediator 
 
Ro 31-7453, specific CDK 
inhibitors 
 
 
c-myc 
 
 
Transcription factor 
 
Antisense 
 
c-fos 
 
 
Transcription factor 
 
Antisense 
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The second class of genes involved in carcinogenesis is tumour 
suppressor genes (anti-oncogenes) which play a role in inhibiting both 
growth and tumour formation. If a cell divides excessively, inhibiting 
factors act directly to prevent further cell cycle events (Weinberg, 1994). 
Unlike the dominant oncogenic changes, tumour suppressor genes are 
usually recessive requiring mutation to occur on both alleles, or loss of 
heterozygosity plus a mutation in a second allele which alter cell surface 
receptors involved in cell signalling (Schulz, 2007). They can also disable 
proteins, for example the tumour suppressor protein p53, a transcription 
factor encoded by the TP53 gene. This gene is known to trigger the cell to 
commit suicide (undergo apoptosis) if DNA damage occurs, or when 
signalling cascades are altered. Mutated p53 is found in 70% of colon 
cancers, over 30% of breast cancers and 50% of lung cancers and is also 
involved in leukemia, lymphomas, sarcomas and neurogenic tumours. 
Examples of tumour suppressor genes involved in breast cancer are 
illustrated in table 1.02.  
 
Two nuclear proteins known to be the most important regulators of the 
cell cycle are Rb and the previously mentioned p53 (table 1.02). Rb is 
responsible for G1 arrest and prevents entrance to the S phase of the cell 
cycle by inactivating E2F transcription factors (Ginsberg et al., 2002). 
Inactivation of Rb by phosphorylation is mediated by specific CDKs 
(cyclin dependent kinases), especially CDK4 and CDK6 that are under 
negative regulation (inhibition) of the p16 tumour suppressor gene (Jiao 
et al., 2008). P53 is the fundamental protein for encoding for a 53 kDa 
transcription factor that is considered the main mediator of the response 
of the cell to stress triggered by DNA-damaging agents, hypoxia, 
activated oncogenes and other genotoxic stress inducing factors (Rieber 
et al., 2001). Its activation results in cell cycle arrest or apoptosis by 
binding onto specific regulatory regions in the promoters of target genes, 
causing induction or suppression of their activity. 
                                                                                                         Chapter 1                                                                                                                               
 
7 
Susan Catherine Gill 
PhD Thesis, 2009 
 
  
TUMOUR 
SUPPRESSOR GENE 
 
FUNCTION 
 
TARGETED THERAPY 
(2004) 
 
 
p53 
 
Induces cell-cycle arrest, 
cell-cycle checkpoint 
activation 
 
Triggers/facilitates 
apoptosis 
 
 
Phase II p53 peptide 
vaccine with or without 
interleukin. 
 
p27 
 
Inhibit cyclin-dependent 
protein kinases; arrest cell 
cycle in G1 phase 
 
 
Phase II trials with CCI-
779 and RAD 001 
 
BRCA-1 
 
 
Regulates DNA 
transcription; acts to repair 
damaged DNA 
 
 
Phase II clinical trial with 
carboplatin 
 
BRCA-2 
 
 
Repairs damaged DNA 
 
 
No therapy 
 
CHK2 
 
Cell cycle checkpoint 
kinase, activates p53 after 
DNA damage 
 
 
No therapy 
 
ATM 
 
Checkpoint kinase, 
activates CHK2 
 
 
No therapy 
 
PTEN 
 
 
Phosphatase, negative 
regulator of Akt kinase 
 
 
No therapy 
 
Rb 
 
Retinoblastoma gene, 
repressor of cell cycle and 
protein translation 
 
 
No therapy 
c-fos 
 
Transcription factor No therapy 
 
 
Table 1.02: Tumour suppressor genes, their functions, and targeted therapies in breast 
cancer (Suter and Marcum, 2007; Osbourne et al., 2004). 
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1.1.2 Regulation of p53 
P53 normally exists bound to a protein called MDM2 or HDM2 in humans 
(Alacon-Vargas and Ronai, 2002). Under normal circumstances, p53 is 
under tight control through its partnership with mouse double minute-2 
(Mdm2). The Mdm2 oncogene not only binds and blocks the N terminus 
of p53 but also targets p53 degradation via the ubiquitin-proteasome 
pathway (figure 1.02 (b)), by acting as an E3 ligase (Kiaris, 2006; Alacon-
Vargas and Ronai, 2002).  Both p53 and Mdm2 (together with other key 
components of the network) are controlled through a series of regulatory 
post-translational modifications, for example changed by phosphorylation 
and dephosphorylation. Phosphorylation reactions are carried out in the 
cell by a family of enzymes called protein kinases (figure 1.02 (d)) and are 
dephosphorylated by protein phosphatases (Alacon-Vargas, D. and 
Ronai, 2002). Any change in MDM2 phosphorylation status consequently 
affects the activity of p53.  
 
 
 
Figure 1.02: Regulation of p53 adapted from Hainaut and Wiman, 2007 
 
(a) Mdm2 is 
activated by p53 
(b) Binding of p53 by Mdm2 
can trigger the degradation of 
p53 via the ubiquitin system 
(c) Phosphorylation of p53 
will disrupt its binding with 
Mdm2. 
(d) DNA damage may 
activate protein kinase to 
phosphorylate p53 thereby 
increasing p53 level and 
subsequently Mdm2  
 
After the DNA damage is 
repaired, the ATM kinase is no 
longer active.  P53 will be quickly 
dephosphorylated and destroyed 
by the accumulated Mdm2.   
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In normal replicating cells p53 remains dormant. Active p53 is induced 
after the effects of various cancer-causing agents such as UV radiation, 
oncogenes and some DNA-damaging drugs (figure 1.02). DNA damage is 
sensed by 'checkpoints' in a cell's cycle, and causes proteins such as 
ATM (Westphal et al., 1997), CHK1 and CHK2 (Gottifredi et al., 2001) to 
phosphorylate p53 at sites that are close to or within the MDM2-binding 
region of the protein. Oncogenes also stimulate p53 activation, mediated 
by the protein p14ARF. Some oncogenes can also bring about the 
transcription of proteins which bind to MDM2 and inhibit its activity. Once 
activated, p53 initiates the expression of several genes including one 
encoding for p21 which binds to molecules important for the G1/S 
transition in the cell cycle inhibiting their activity as shown in figure 1.03  
(Gottifredi et al., 2001).  
 
 
 
Figure 1.05 Regulation of p53 
 
 
 
 
Figure 1.03: Regulation of p53 
 
In its mutated form, p53 can no longer bind DNA in an effective way, and as a 
consequence the p21 protein is not made available to act as the 'stop signal' 
for cell division. Thus cells divide uncontrollably, and form tumours. The 
progression into the M phase requires Cdc2 which can be inhibited by p21, 
GADD45 or 14-3-3s (see figure 1.03). 
 
Growth Arrest 
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1.1.3 Angiogenesis and metastasis 
 
Other genes that play a role in carcinogenesis include angiogenic and 
metastatic genes (Aalinkeel et al., 2004). As the cancer cells become 
confluent and proliferation continues the daughter cells produce a mass. 
As this mass expands, an increase in the supply of oxygen and nutrients 
is required to maintain continued growth. Without extra nutrients, the cells 
will be unable to continue to grow and remain at a steady-state size 
where the number of new cells is balanced by the number of dying cells. 
These small carcinomas can remain in the body for months or years 
without gaining size, but upon further gene mutations in regulating 
angiogenesis, an increased supply of nutrients re-establishes cell and 
mass expansion. Angiogenesis is a normal process involved in the growth 
and development of new blood vessels (DeWitt, 2005) as well as being 
involved in wound healing. However, it is also a fundamental step in the 
transition of tumours from a dormant to a malignant state. When this 
occurs, new capillaries are formed around the tumour, allowing it to gain 
the supplies it needs to grow in size (Pecorino, 2005). Whereas normal 
cells are generally restricted to a certain tissue and stop proliferating and 
die if they become detached; a cancer cell can acquire mutations in 
genes involved in metastasis that enable the cell to undergo tissue and 
basement membrane invasion and spread to other parts of the body. 
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1.1.4 Carcinogenesis 
The possibility of developing cancer is, in the main, unpredictable; 
however, certain risk-factors can increase the chance of cell 
transformation due to: 
• Chemical carcinogens 
• Age and decrease in immununosurviellance 
• Lifestyle factors 
• Radiation 
• Oncogenic viral infection 
• Genetic pre-disposition 
(Pecorino, 2005) 
 
It is estimated that viral infections contribute to over 15% of all human 
cancers (Esteller et al., 2007; McLaughlin-Drubin et al., 2007). Three 
DNA viruses’ have been linked to tumours in humans; the human 
papillomaviruses (HPV), the Epstein-Barr virus (EBV) and the hepatitis B 
virus. Throughout the world the majority of the population are infected 
with these diseases; some develop into the disease and a few eventually 
obtain a viral-related cancer (e.g. lymphoma, liver cancer, cervical 
cancer). It is important to understand the molecular mechanisms of these 
infections and their ability to cause some cancers so new methods can be 
developed in attacking the virus and consequently preventing 
malignancies. There are many types of HPV which are known to be a 
high risk including types 16, 18, 31 and 45. These can lead to cervical, 
anal, vulvar and penile cancer (Parkin, 2006). HPV type 16 in particular 
has been shown to be linked with oropharyngeal squamous-cell 
carcinoma or head and neck cancer (D’Souza et al., 2007). HPV causing 
cancers generally have viral sequences integrated into the cellular DNA. 
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The protein products of genes E6 and E7 (known as early genes of HPV), 
bind to the protein products of two tumour suppressor genes that are 
crucial in cell apoptosis. E6 binds to the protein product of p53 and E7 to 
RB, resulting in their loss of action allowing the cell to grow and divide 
(Horner et al., 2004). 
 
The first virus to be identified as cancer causing is the Epstein-Barr virus, 
also called the human herpes virus 4 (HHV-4). It is widespread in all 
human populations, occurring generally during childhood but can be seen 
during adolescence resulting in infectious mononucleosis or glandular 
fever (Baumforth et al., 1999). The virus has been implicated in four 
human tumours: the African form of Burkitt lymphoma, B-cell lymphomas 
in individuals whose immune systems are blighted due to human 
immunodeficiency virus (HIV) or the use of immunosuppressant drugs in 
organ transplantation, nasopharyngeal carcinoma, and some kinds of 
Hodgkins disease (Thompson and Kurzrock, 2004; Carbone et al., 2008). 
It has been detected in approximately 10% of gastric tumours (Young and 
Rickinson, 2004; Truong et al., 2009). In addition, the virus has been 
shown to infect B lymphocytes, which play a key role in infection-fighting 
(white blood cells) by transforming the cells into lymphoblasts which have 
an indefinite life span rendering these cells immortal. 
 
Southeast Asia and sub-Saharan Africa have the highest occurrence of 
hepatocellular carcinoma (HCC) and liver cancer in the world. This is 
linked to the hepatitis B virus which is endemic throughout these 
countries (Seeff and Hoofnagle, 2006). Both hepatitis B and C viruses 
(HCV) are global health problems; they can lead to cirrhosis and liver 
cancer and cause millions of deaths each year (Sagnelli et al., 2009). The 
role hepatitis B and C play in developing liver cancer is not yet 
understood, with the virus carrying no known oncogenes. There is 
evidence to suggest that the presence of multiple integrated viral genes 
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create genomic instability in the host and may lead to loss of 
heterozygosity for tumor suppressor genes. Curing these infections has 
proved very difficult with the focus more on prevention than treatment 
(Lindenbach et al., 2005). A vaccine against HBV has been available 
since 1982, and early childhood vaccination programs have been the 
most effective strategy for reducing the prevalence of infection in high-risk 
populations. Prevention of hepatitis C (HCV) infection is more challenging 
due to HCV eliciting a weak immune response; however progress is being 
made (Kaplan and Chang, 2006). Universal precautions against exposure 
to blood borne infectious agents are the primary means of prevention. 
 
One key area of current research involves epigenetic properties of 
genomes. Epigenetics (greek for over/above (epi) genetics) refers to 
changes that occur in the phenotype (appearance) or gene expression as 
a result of mechanisms other than those occurring in the DNA sequence. 
The viral genome can be exposed to chemical modification revealing 
variations in different tissues of the same individual, between identical 
twins and in disease states. Dr. Manel Esteller of the Bellvitge Institute for 
Biomedical Research in Barcelona has determined the complete map of 
DNA methylation, a specific type of chemical modification, for the entire 
genome of the Epstein-Barr virus, the human papilloma virus, and the 
hepatitis B virus. Importantly, the researchers compared the DNA 
"methylomes" of asymptomatic carriers of each virus, patients with active 
infections, and patients harbouring cancerous tumors. When they looked 
at asymptomatic carriers of the virus compared to intermediate stages of 
the disease and established associated cancer, the genome of the virus 
did not change that much but its epigenome was completely different. It 
was discovered that the genomes of the virus become progressively 
methylated in patients who had developed cancer (Esteller et al., 2007). 
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1.2 Cell Death 
 
In the recent literature, cell death is said to occur by two alternative 
pathways: apoptosis, a programmed, managed form of cell death, and 
necrosis, an unordered and accidental form of cell death. Cells may die 
by either of these two mechanisms depending on the cellular context, or 
stimulus (Fiers et al., 1999; Tsujimoto et al., 1997). Apoptosis, is a 
multistep and highly organised process which avoids an immune 
inflammatory reaction by the activation of phagocytic cells (McCarthy, 
2002), autophagy which involves bulk degradation of cellular proteins, a 
process essential during both the growth and development of the 
organism, oncosis, an accidental form of cell death caused by the failure 
of the ionic pumps of the plasma membrane resulting in swelling. In 
comparison, necrosis is a violent form of cell death producing cellular 
debris and the induction of an immune response within the organism 
(McCarthy and Bennet, 2002). Apoptosis is characterized by membrane 
blebbing, shrinking and condensing of the cell and its organelles and 
internucleosomal DNA degradation. The cell finally disintegrates, and 
apoptotic bodies are consumed by phagocytes or neighbouring cells 
(Wyllie, 1980; figure 1.04).   
 
 
Figure 1.04: Cytospin preparations of HL60 cells stained and examined by light 
microscopy. The slide shows a cell with normal appearance progressing into apoptosis. 
The picture is taken from Techniques in Apoptosis; a user’s guide (Gorman et al., 1994). 
 
Both apoptotic and necrotic cell death have been observed within the 
same cell culture population. The severity of the initial insult or damage to 
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the cell is usually the deciding factor between necrosis and apoptosis 
(Hirsch et al., 1998). This would imply that there is a common pathway 
between these two modes of death until they are eventually triggered 
towards either necrosis or apoptotic demise. It has been proposed that 
cells exposed to the same stimulus undergo a necrotic death as opposed 
to an apoptotic death when ATP stores are depleted (Leist et al., 1997), 
Tsujimoto et al., 1997). The necrotic morphology does not involve DNA 
and protein degradation and is accompanied by swelling of the entire 
cytoplasm and mitochondrial matrix, which occurs shortly before the cell 
membrane ruptures (Kroemer et al., 1998); this process is not genetically 
controlled and results from injury or infection (Cooper, 1997).  The 
fundamental differences are summarised in table 1.03 below:  
 
APOPTOSIS NECROSIS SECONDARY 
NECROSIS 
Physiological or Pathological 
 
No mitochondrial swelling 
Accidental; always 
pathological 
Mitochondrial swelling 
Cytolysis secondary to 
apoptosis (when dying 
cells fail to be removed 
by heterophagy). 
Susceptibility tightly 
regulated 
Unregulated or poorly 
regulated 
 
Plasma membranes near-to-
intact until late 
Plasma membrane 
destroyed early 
 
No leakage of cell content; 
little or no inflammation. 
Leakage of cell content; 
inflammation. 
 
Chromatin condensation 
Cell shrinkage 
Swelling of the entire 
cytoplasm 
 
Nuclear fragmentation   
DNA fragmentation   
Selective protein degradation   
Subtle changes in plasma 
membrane 
  
 
Table 1.03: The fundamental differences between apoptosis and necrosis 
                                                                                                         Chapter 1                                                                                                                               
 
16 
Susan Catherine Gill 
PhD Thesis, 2009 
Visual examples of the morphology of cells during apoptosis and necrosis 
are shown in figure 1.05. Jurkat cells were stained with acridine orange 
(which will fluoresce green when bound to DNA) and ethidium bromide 
(which will fluoresce red when bound to DNA). Acridine orange is 
permeable to the cell membrane whereas ethidium bromide is excluded 
from cells with intact membrane. Using the two fluorochromes combined it 
is possible to distinguish between viable cells (green fluorescence with 
intact nucleus), early apoptotic (green fluorescence with chromatin 
condensation) and necrotic cells (orange fluorescence with an intact 
nucleus (Gorman et al., 1996)).  
Apoptotic cell 
Secondary Necrosis 
Secondary Necrosis 
Apoptotic cell 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.05: The above image was taken as part of the work in this thesis and shows 
Jurkat cells treated with vincristine; a mitotic inhibitor; stained with acridine orange and 
ethidium bromide and observed by confocal microscope (x 63 magnification). 
 
 
 
 
Viable cell 
Apoptotic cell 
Secondary Necrosis 
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Two principal pathways of apoptotic cell death have been described; 
(McCarthy and Bennett, 2002) the ‘extrinsic pathway’ which is initiated by 
specific death receptors that are activated by their ligands (tumour 
necrosis factor or TNF family) and the ‘intrinsic pathway’ involving the 
mitochondrion. Both pathways are shown in figure 1.06 which 
demonstrates the implementation of the apoptotic response in both 
intrinsic and extrinsic pathways involving the activation of specific 
proteases, termed caspases (Lamkanfi et al., 2003; Finucane et al., 
1999). Caspases are indispensable as initiators and effectors of 
apoptotic cell death and are involved in many of the morphological 
and biochemical features of apoptosis.  
 
 
 
Figure 1.06: To illustrate the two principal pathways of apoptotic cell death: intrinsic and 
extrinsic where IAP proteins are shown to be inhibiting by binding to activated caspases 
(taken from IMGENEX). 
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The name ‘caspase’ comes from the 'c' denoting a cysteine protease and 
the 'aspase' referring to the ability of these enzymes to cleave after an 
aspartic (Asp) acid residue (Nicholson, 1999). Cells contain inactive 
zymogen forms of pro-caspase that become activated following cleavage 
at aspartic acid residues.  
 
 
Figure 1.07: Structure of a procaspase (Nicholson, 1999). 
 
There are two major subfamilies of the caspase proteins; the ICE 
subfamily and the ced-3 subfamily (Nicholson, 1999), and further 
divisions can be made depending upon the length of their pro-domain 
(figure 1.07).  The ICE family contains the group I caspases which are 
involved in inflammation: caspase 1, 4, 5 and 13 (Nicholson, 1999). The 
ced-3 family contains both group II; caspase 2, 3 and 7 (effector 
caspases) and group III; caspase 6, 8, 9 and 10 (initiator caspases) both 
involved in apoptosis (Roy and Cardone, 2002). Caspases form an 
enzyme cascade with initiator caspases which instigate the processes 
(initiator caspases, activator caspases, upstream caspases), and others 
acting as downstream caspases involved in the execution of cell death 
(executioner caspases, effector caspases) (Taylor et al., 2008).  
 
In vitro studies of cell death in cell lines have revealed that inhibition 
of the classical caspase-dependent apoptotic pathway leads, in 
several cases to necrotic cell death. Thus, the same cell death 
Prodomain 
(3-24 kDa) 
Small subunit 
(10-13 kDa) 
Large subunit 
(17-21 kDa) 
N   C 
32-53 kDa 
Asp-X Asp-X 
Active site of 
caspase 
Cleavage point to produce 
active caspase 
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stimulus can result either in apoptotic or necrotic cell death, 
depending on the availability of activated caspase. Therefore, death 
domain receptors may initiate an active caspase-independent 
necrotic signalling pathway (Chautan et al., 1999).  
 
1.3 Cancer Therapy 
The majority of patients with cancer will require treatment with therapeutic 
agents at some point in the course of their disease. In principle, a range 
of different therapies can be employed but the choice depends strongly 
on the classification of the cancer by certain criteria (Wittig et al., 2002) 
including the patient's age, history and lifestyle. Currently clinical studies 
carried out on large patient populations provide an individual patient with 
a probability for effective recovery based on clinically observed response 
rates. There are currently many different ways to treat cancer by.  
• Surgery  
• Radiotherapy  
• Chemotherapy  
• Hormone therapy  
• Immunotherapy  
• Chemo immunotherapy 
• Gene therapy  
The objectives of cancer therapies are to prevent proliferation (cytostatic 
effect) and to kill the cancer cells (cytotoxic effect). Surgery or radiation is 
the treatment choice for localised cancers, in contrast, leukaemias and 
metastatic or locally advanced carcinomas require drug therapy, which in 
some cases is supplemented by surgery or radiotherapy (Pecorino, 
2005). Conventional chemotherapy, used in most cancer treatments, 
uses chemicals that target DNA, RNA and protein to disrupt the cell cycle 
in rapidly dividing cancer cells. Although conventional chemotherapies 
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have resulted in treating cancers and continue to extend lives, at the 
same time their efficiency remains low with debilitating side effects.  
 
Hormone therapy is being used for some cancer treatment including 
cortisone, used to treat some leukemia’s and lymphomas, and 'androgen-
ablation therapy' (which uses drugs to lower the amount of the male sex 
hormone testosterone) to treat prostate cancer (Mostaghel et al., 2009). 
In addition, immunotherapy treatment is currently underway with many 
clinical trials being conducted.  Antibodies specific for cancer cell-surface 
antigens can be useful in different ways; they can stop the cancer from 
growing by stopping other essential 'growth factors' from sticking to it and 
they can 'tag' the cancer for destruction by the immune system. The 
cancer drugs or radioactive particles are attached to the antibody; it can 
deliver them directly to the cancer cell without harming the rest of the 
body. An enzyme (a type of protein that can promote chemical reactions) 
can be attached to an antibody, and then given to a patient along with a 
chemical that can be turned into a powerful drug by the enzyme. This 
directs the drug to the cancer, and minimizes side effects. This process is 
known as Antibody-directed Enzyme/Pro-drug Therapy (ADEPT). Several 
antibody-based therapies are available, including the breast cancer drug 
Herceptin (Subramanian and Mokbel, 2008).  
 
In addition to immunotherapy, gene transfer approaches have found 
many applications at preclinical and clinical levels, in particular for the 
study and treatment of tumors, cardiovascular diseases and 
angiogenesis, infectious and other acquired diseases (AIDS, viral 
hepatitis), genetic disorders (e.g. cystic fibrosis) and various 
degenerative, chronic, inflammatory, and age-related diseases 
(Alzheimer’s, Parkinson’s, and Huntington’s diseases).  Vectors based on 
a new class of virus, the adeno-associated virus (AAV), have emerged as 
favoured gene vehicles (Shih et al., 2009). AAV is non-pathogenic, 
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replication-defective small human parvovirus (25 nm in diameter). In gene 
therapy the retrovirus is modified so that it is no longer capable of causing 
disease, but is able to insert new genes into a patient's chromosomes. 
However, there are many concerns over the safety of modifying a 
patients' DNA. To date, no successful gene-based treatment has been 
approved for routine use on cancer patients, but a large amount of 
research is being carried out in this area. Even where the full range of 
modern cancer therapies is available, many cancers still cannot be cured 
today (Dolken, 2001). In the majority of patients with malignant disease, 
state of the art therapies are at best palliative. Part of the explanation is 
believed to be tumour heterogeneity arising through genetic diversity as 
responsiveness to individual chemotherapeutic agents varies widely 
between tumours of the same histological type. This heterogeneity is 
present at the molecular, cellular, histological and clinical level and makes 
the choice of patients’ treatment extremely difficult since a given drug 
may work extremely well only for a subset of patients (Alexandrova, 
2001). Remarkable progress is being made in the development of 
therapeutic agents; however, an enormous amount of time and money 
must be invested before an agent is approved for clinical use (Kawada et 
al., 2002). 
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 1.4 Malignant Melanoma 
 
Melanoma is the rarest and most aggressive form of skin cancer and has 
been the focus of the majority of the research in this thesis. It was chosen 
due to the current lack of available treatments in metastatic melanoma 
and an opportunity arose to look into primary melanoma samples through 
collaboration with OYSTER (Outcome and Impact of Specific Treatment 
in European Research in melanoma) tissue bank. There are 3 types of 
skin cancer based in the epidermis of the skin; melanoma (the most 
aggressive form), basal cell skin cancer and squamous cell skin cancer. 
Melanoma has become increasingly prevalent over the last few decades 
with around 160,000 new cases diagnosed worldwide each year; mainly 
among caucasians (Ries et al., 2003). The median age of melanoma 
diagnosis is 45 years, almost twenty years prior to most other tumours 
(O’Day et al., 2001). The occurrence of the majority of melanoma cases is 
in normal skin; with a small percentage diagnosed in the eye (intraocular 
or ocular melanoma) or rectum (mucosal melanoma).  
 
The development of melanoma occurs from the pigment producing 
(melanin) cells of the skin (melanocytes), which upon transformation 
begin to grow and divide more quickly than usual spreading into the 
surrounding surface layers of the skin (Meyskens et al., 1999). Melanin, in 
humans is the primary determinant of skin, hair colour, and the pigmented 
tissue underlying the iris. Melanocytes insert granules of melanin into 
specialized cellular vesicles called melanosomes that are incorporated 
into dendrites and transferred by phagocytosis into the other skin cells 
(keratinocytes) of the human epidermis (Burns et al., 2004). The 
melanosomes in each recipient cell accumulate above the cell nucleus to 
protect the nuclear DNA from mutations caused by the ionising radiation 
of the sun's ultraviolet rays. There are two major forms of melanin 
produced in the epidermis and hair follicles - eumelanin and pheomelanin. 
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Eumelanin is brown to black in colour while pheomelanin is yellow to red. 
People whose ancestors lived for long periods in the regions of the globe 
near the equator generally have larger quantities of eumelanin in their 
skins (Berwick et al., 2004), affording protection against high levels of 
exposure to the sun, which more frequently results in melanomas in 
lighter skinned people. The four most common types of skin melanoma 
are: 
• superficial spreading melanoma (SSM) - the most common form 
(approximately 70%) of cutaneous melanoma (Forman et al., 2008) 
• nodular melanoma - most aggressive form of melanoma 
(approximately 15%) which grows quickly in a vertical direction from 
the outset. 
• lentigo maligna melanoma - usually found on chronically sun 
damaged skin such as the face and the forearms of the elderly 
(approximately 10%).  
• acral lentiginous melanoma - observed on the palms, soles and 
under the nails. It is the most common form of melanoma 
diagnosed amongst Asian and Black ethnic groups but constitutes 
less than 5% of overall cases (Krementz et al., 1982).  
(Reed and Martin, 1997) 
As melanoma is the most aggressive form of skin cancer due to its high 
resistance to currently available therapy early detection remains the best 
treatment (Peltonen et al., 2005). The ABCD rules illustrated in figure 
1.08 are the key changes to monitor during regular skin self-
examinations. 
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Figure 1.08: To show the “ABCD” method for remembering the signs and symptoms of 
melanoma adapted from the National Cancer Institute.  
 
The contributing factor bringing about the onset of basal and squamous 
skin cancer is exposure to ultra violet (UV) light, through natural sunlight 
or artificially from sun beds or lamps resulting in damage to the DNA 
(genetic material) in  skin cells (Zanetti et al.., 1992; Harrison et al., 
1994). UV light can directly induce melanocytic lesions and melanoma in 
human skin grafts (Sauter et al.., 1998; Berking et al.., 2002; Wolnicka-
Glubisz and Noonan, 2006). The mechanism, however, whereby UV light 
induces melanoma has not been determined, causing debate over 
whether melanoma is actually caused by UV light. Despite many reports 
that UV light damages the DNA in our skin cells causing melanoma, a 
recent report by Sam Shuster (2008) claims that there is insufficient 
evidence linking UV exposure to melanoma with 75% of melanomas 
occurring on relatively unexposed sites, especially the feet of dark 
skinned Africans. Previous reports have also reported this fact 
(Ragnarsson-Olding, 2004). 
 
• Diameter: moles greater than 
6 mm are more likely to be 
melanomas than smaller 
moles. 
  
 
 
.  
• Asymmetrical skin lesion.  
 
• Border of the lesion is 
irregular.  
  
    
   
 
 
• Colour: melanomas usually 
have multiple colours 
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The detection of melanoma is mainly visible using the ABCD 
methodology shown in figure 1.08. The diagnosis of melanoma requires 
experience, especially in its early stages when it may look identical to 
harmless moles or not have any colour at all. Confirmation of its 
malignant potential is carried out with a skin biopsy performed under local 
anesthesia and assists in defining the severity of the melanoma.  
Currently researched biomarkers including lactate dehydrogenase (LDH), 
S100B and melanoma-inhibitory activity (MIA) are being looked at but 
lack sensitivity (Matharoo-Ball et al., 2008). No blood test is available for 
detection, although an increase in LDH has been observed in metastatic 
disease often indicating spread of the disease to the liver (Agarwala et al., 
2009). It is used to follow-up cancer (especially lymphoma) patients, as 
cancer cells have a high rate of turnover with destroyed cells leading to 
an elevated LDH activity. However, many patients with metastases (even 
end-stage) have normal LDH levels.  
 
One of the main problems in detecting the progression of melanoma is its 
vertical growth through the skin. It is this “unseen” spread and growth that 
affects prognosis. Diagnostic and staging criteria includes tumour 
thickness in millimeters (Breslow's depth), depth related to skin structures 
(Clark level), type of melanoma, presence of ulceration, presence of 
lymphatic/perineural invasion, presence of tumour infiltrating lymphocytes 
(if present, prognosis is better), location of lesion, presence of satellite 
lesions, and presence of regional or distant metastasis (Berger et al., 
2003).  
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From this information melanoma can be staged: 
Stage 0: Melanoma in Situ (Clark Level I), 99.9% Survival 
Stage I/II: Invasive Melanoma, 85-95% Survival 
• T1a: Less than 1.00 mm primary, no ulceration, Clark Level II-III  
• T1b: Less than 1.00 mm primary, ulceration or Clark Level IV-V  
• T2a: 1.00-2.00 mm primary, no ulceration  
Stage II: High Risk Melanoma, 40-85% Survival 
• T2b: 1.00-2.00 mm primary, ulceration  
• T3a: 2.00-4.00 mm primary, no ulceration  
• T3b: 2.00-4.00 mm primary, ulceration  
• T4a: 4.00 mm or greater primary, no ulceration  
• T4b: 4.00 mm or greater primary, ulceration  
Stage III: Regional Metastasis, 25-60% Survival 
• N1: Single positive lymph node  
• N2: 2-3 positive lymph nodes or regional skin/in-transit metastasis  
• N3: 4 positive lymph nodes or lymph node and regional skin/in 
transit metastases  
Stage IV: Distant Metastasis, 9-15% Survival 
• M1a: Distant skin metastasis, normal LDH LDH  
• M1b: Lung metastasis, normal LDH  
• M1c: Other distant metastasis or any distant metastasis with 
elevated LDH.  
(Balch et al., 2001) 
 
Upon diagnosis, a treatment plan can be devised. For primary melanoma, 
the main treatment is complete surgical excision of the tumour resulting in 
>95% complete remission (O’Day et al., 2002; Soengas and Lowe, 2003)  
For regional and distant metastases, chemotherapy, radiotherapy and 
biological therapy is given to patients.  
 
 
                                                                                                         Chapter 1                                                                                                                               
 
27 
Susan Catherine Gill 
PhD Thesis, 2009 
1.4.1   Melanoma Treatment 
 
Treatment of melanoma can involve: 
• Initial Surgical Treatment (Wide-excision). The surgical removal of 
additional surrounding skin is necessary to reduce the risk of 
tumor regrowth, which is called "wide-excision." 
• Sentinel Lymph Node Biopsy – test to determine which lymph node 
may be involved with tumour  
• Surgical Treatment of Lymph Nodes 
• Chemotherapy 
• Radiation therapy 
• Biologic therapy 
• Chemoimmunotherapy 
Many clinical trials have and are still being carried out to determine the 
effects of drugs in single and combination therapy. Dacarbazine is the 
only one single-entity drug which has been approved in the UK for 
treatment of late-stage melanoma, but provides complete remission in 
only 2% of patients. The disappointing results of single-agent therapy led 
to the development of combination therapy in the 1980’s. Two published 
regimes have been trialled, the Dartmouth regimen (carmustine, cisplatin, 
vinblastine and dacarbazine) and CVD (cisplatin, vinblastine and 
dacarbazine) used for metastatic disease with some encouraging results 
but durable remissions remained very rare (O’Day et al., 2002).  The 
F.D.A. (federal agency charged with overseeing the safety of drugs, 
medical devices, food, cosmetics and many other health-related products) 
has approved both dacarbazine and Interleukin 2 (IL-2) for clinical use. IL-
2 was approved in the US based on a 6% complete response rate in a 
270-patient phase II study data set (O’Day et al., 2002). The absence of 
any phase III data demonstrating the benefit of any dose of IL-2 in 
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metastatic melanoma prevented approval in Europe, and it is unlikely that 
IL-2 would be approved at present as it is difficult to predict which patients 
will respond.  
 
Combination therapy with IL-2 has been an active area of research, with a 
recently completed phase I clinical trial funded by the Cancer Vaccine 
Institution (CVI). This was to determine the efficacy of Aldara and IL-2 
injections into lesions of melanoma. Aldara Cream activates the immune 
system and clinical results revealed that Aldara treatment was effective in 
controlling the growth of approximately 50% of cutaneous melanoma 
lesions (Green et al., 2007).  In addition, a recent trial has currently ended 
for the investigation of stage IV melanoma patients, who have failed 
chemotherapy, using a dendritic cell vaccine approach. This was 
developed by the Baylor Institute for Immunology Research (BIIR). 
Dendritic cells were loaded with melanoma cells from a cell line treated 
with heat prior to loading. This methodology of killing the cells initially has 
been shown be more efficient in priming the melanoma specific CD8+ 
cells. Results demonstrated that patients with low volume disease 
demonstrated longer survival compared with other therapies (Cancer 
Vaccine Institute, 2009). A variety of other agents have been used (e.g. 
carmustine (BCNU), vinblastine, cisplatin), including drug trials combined 
with hormonal based therapy, tamoxifen, but with no significant increase 
in patient response observed (O’Day et al., 2002).  Another 
chemotherapy drug, temozolomide (Temodal), taken in capsule form, has 
been used in trials for melanoma (Plummer et al., 2005) and was thought 
to have benefits over dacarbazine (Darkes et al., 2002), offering better 
protection from the development of brain metastases and with the 
advantage of being orally administered. It is not however currently 
licensed for metastatic melanoma and continues to be investigated both 
as a single and combined agent in therapy (Plummer et al., 2005). With 
the exception of the above mentioned trials, the actual treatment for 
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melanoma has remained unchanged for many years. No agent has been 
shown to have a significant impact on survival with stage IV melanoma 
which remains a very poor prognosis; a median survival of only 6-9 
months (Dothager et al., 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.04: An example of treatment for melanoma 
(Adapted from Logovic et al., 2005; Kim et al., 2002) 
 
 
 
THERAPY FOR PRIMARY 
MELANOMA 
 
THERAPY FOR 
REGIONAL METASTASES 
 
THERAPY FOR DISTANT 
METASTASES 
 
Complete surgical excision 
of primary tumour 
 
 
Surgery 
 
 
Surgery 
 
Elective lymph node 
dissection 
 
Isolated limb perfusion 
 
Radiotherapy 
 
Sentinel lymph node biopsy Adjuvent therapy 
(radiotherapy, 
chemotherapy, regional 
limb perfusion. IFN-alpha) 
 
Chemotherapy (single 
agent or combination 
including Dacarbazine 
(DTIC), Carmustine 
(BCNU), Loustine (CCNU), 
Trichostatin-A, Vindesine, 
taxanes, platinum 
compounds. 
Chemoimmunotherapy 
(IFN-alpha + 
chemotherapy) 
 
  Biologic therapy (IFN-
alpha, IL-2, monoclonal 
antibodies, melanoma 
vaccines. 
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1.4.2  Melanoma Tumourigenesis 
 
Several genes have been shown to be involved in malignant melanoma 
including germline mutations in cdkn2A, Arf, cdk4 and somatic mutations 
in Pten and BRAF but many are currently being researched (Dahl and 
Guldberg, 2007). As already mentioned UV light is specifically 
carcinogenic and can damage skin cells which then need to be eliminated 
by apoptosis (when the skin peels). The tumour suppressor p53 protein 
(previously mentioned and discussed earlier in this chapter) is an 
important regulator of apoptosis. However mutations to p53 have not 
been linked to melanoma but only to squamous and basal cell carcinoma 
(Pecorino, 2005). Inactivation of the INK4a/ARF (or CDKN2a) locus is a 
common and critical genetic event in the development of human and 
mouse melanoma. This locus engages the Rb and p53 tumor suppressor 
pathways through its capacity to encode two distinct gene products, 
p16INK4a and p14ARF. These two pathways are of potential importance in 
mediating UV-induced melanoma (Sharpless et al., 2003).  
 
Intermittently sun-exposed skin accounts for the majority of this cancer 
in caucasians and has been associated with BRAF mutations. Chronic 
sun damaged skin (lentigo maligna melanoma) seems to have 
significantly fewer chromosomal aberrations compared to acral and 
mucosal melanomas, with an absence in BRAF mutations but frequent 
gains in CCND1 and regions of chromosome 22, and losses from 
chromosome 4q. Acral ad mucosal melanomas occur in sun protected 
areas and have infrequent BRAF mutations and show greater numbers 
of chromosomal aberrations (Nouri, 2007). 
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There is also growing evidence suggesting that certain histone 
modifications and associated altered chromatin remodeling activities can 
play a key role in melanoma tumour progression. These epigenetic 
events are involved in different aspects of tumorigenesis including cell 
cycle control, apoptotic pathways (figure 1.09), cell signaling, tumor cell 
invasion and metastasis, drug resistance, and immune recognition. These 
findings suggest a promising future for the utility of drugs such as histone 
deacetylase (HDAC) inhibitors, in treating patients with evidence of 
histone deacetylation. 
 
 
 
 
 
Figure 1.09 Simplified schematic of apoptotic pathways in mammalian cells of both 
extrinsic (death receptor-mediated) and intrinsic (mitochondrial) apoptosis pathways. 
Examples of up regulated and down regulated apoptotic factors in melanoma are 
indicated on the right panel (Soengas and Lowe, 2003).   
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1.5 Chemo Sensitivity Assays 
Upon the development of chemotherapeutic agents reaching the clinical 
trial stage, rapid tests of drug sensitivity are of utmost importance for 
selecting the most promising agents for cancer treatments. A high 
percentage of patients with leukaemia, lymphoma and solid tumours 
achieve complete remission after initial treatment, but the majority of 
these patients will finally relapse due to the presence of residual tumour 
cells detectable in clinical remission only by the most sensitive methods 
(Cree 1998; Campana and Coustan-Smith, 2004; Kurth, 1997). These 
residual cells need to be detected and eradicated for the treatment to be 
successful. 
 
Assays of chemo-sensitivity are of the utmost importance to 
pharmaceutical companies as part of their strategy to discover new 
chemotherapeutics. Commercially, cytotoxicity assays are used to detect 
the killing of tumour cell lines by newly discovered or existing cytotoxic 
drugs. An important feature required for these assays is the ability of the 
assays to detect 100% cell death of a tumour population. If the results of 
an assay reveal all cells have been killed by a potential cytotoxic agent 
when in actual fact there are residual viable cells still present that the 
assay has been unable to detect, then these cells will eventually reform 
into a new tumour within a patient. Current assays used to demonstrate 
chemo sensitivity, have not been able to evaluate whether a given drug 
successfully targets 100% of a tumour cell population (Dworzak, 2001). 
The methods currently utilised to detect cell killing lack sensitivity, often 
as a result of high background readings and an unacceptable signal; 
noise ratio; it is therefore difficult to confirm the complete (100%) killing of 
tumour cells (Collie-Duguid et al., 2007; Motoko and Akihiro, 2004). There 
are several assays currently employed that can potentially be used for 
prediction of patient responses to single agent and combination therapy.  
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These include: 
 
1. Measurements of cellular necrosis: 
• Chromium-51 release 
• Propidium Iodide uptake    
• Lactate dehydrogenase (LDH) assessment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       Table 1.05:  Advantages and disadvantages of necrotic assays. 
Assay Advantages Disadvantages 
 
Chromium-51 
Stable 
Sensitive 
Radioactive 
High spontaneous 
release 
Time consuming 
 
Propidium Iodide uptake 
 
Very sensitive 
User friendly 
 
Requires specialist 
training 
Can be time consuming 
 
LDH 
 
User friendly 
Sensitive 
Rapid 
 
High signal:noise levels 
Affected by culture 
reagents containing 
pyruvate 
Stability of only 9 hours 
                                                                                                         Chapter 1                                                                                                                               
 
34 
Susan Catherine Gill 
PhD Thesis, 2009 
2.  Measurements of cell viability: 
 
• AlamarBlue 
• 3-(4,5-dimethylthiazol-2-yl)-2,5- 
• diphenyltetrazolium bromide, a tetrazole); MTT   
• 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy- 
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium); MTS   
• 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5- 
[(phenylamino) carbonyl]-2H-tetrazolium hydroxide); XTT   
• 2-[4-iodophenyl]-3-[4-nitrophenyl]-5-[2,4-disulfophenyl] 
-2H tetrazolium monosodium salt; WST-1 
• Adenosine triphophate; ATP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.06:  Advantages and disadvantages of viability assays. 
 
Assay Advantages Disadvantages 
 
Alamar Blue 
 
User friendly 
 
 
Lacks sensitivity 
Time consuming 
 
MTT/MTS User friendly 
 
Lacks sensitivity 
Time consuming 
 
XTT User friendly 
 
Lacks sensitivity 
Time consuming 
 
WST-1 User friendly 
 
Lacks sensitivity 
Time consuming 
 
ATP Sensitive 
Fast 
User friendly 
Rapid 
No substantial evidence of 
cell death 
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Chromium-51(Cr51), a radioactive element, has the ability to be taken up 
by healthy cells as an internal label. Target cells are pre-labelled with Cr51 
which is released for detection when cells are induced to lyse by effector 
cells (i.e. cytotoxic T cells, NK cells or activated macrophages). Upon 
lysis of the cell, the chromium is released and this can then be measured 
using a gamma scintillation counter (Bachy et al., 1999).  
 
The specific lysis was determined according to the formula:  
 
 
Total Lysis (%) = 100 × (Exp – Spo) 
                         (Max – Spo) 
Where:  
Exp = experimental release; Spo = spontaneous release; Max = maximum release. 
 
Figure 1.10: Formula for chromium51 detection     
 
 
Fluorescent dyes are a safe and convenient alternative to radioactive 
labels such as chromium for monitoring the fate of cells in vivo. The 
number of dead cells in a suspension is often estimated by counting the 
cells which take up an acidic dye, such as trypan blue. Assessment of cell 
viability by flow cytometry, using propidium iodide (PI) can also be used 
(Ormerod, 1999). PI is excluded by viable cells and when taken up by 
dead or dying cells, binds to nucleic acids and fluoresces red. Flow 
cytometry is a well established, multi-disciplinary technique in standard 
use in biological and clinical research. A typical flow cytometer will consist 
of an optical, electronic and fluidic system, which provides a visual picture 
of their relative size, granularity and fluorescent properties on a computer 
screen (Ormerod, 1999). The fluidic system contains an air pump, 
pressure regulator, sheath fluid reservoir, sample regulator, flow cell and 
a waste reservoir, where the speed at which the cells pass the laser can 
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be controlled by either increasing or decreasing the pressure (Becton 
Dickinson, 1997). This technology has been used to measure many 
processes during apoptosis and necrosis and measurements are 
recorded for each individual cell to obtain the percentages of necrotic or 
apoptotic cells within a population (Ormerod, 1998). The size, granularity 
and fluorescent properties of a cell can be investigated by the analysis of 
their forward scatter (FSC-H) indicating cell size, side scatter (SSC-H) 
showing granularity of the cell and different fluorescent parameters (FL-1, 
FL-2, FL-3) (Ormerod, 1998; Becton Dickinson 1997). Figure 1.11 is 
representative of the forward scatter and side scatter dot plot for a typical 
healthy population of cells when analysing for plasma membrane integrity 
(red; FL-2) (Becton Dickinson, 1997). 
 
Figure 1.11: Forward scatter (size) and side scatter (granularity) dot plot and FL-1 
(green) and FL-2 (red) dot plot showing a typical picture of healthy Jurkat cells stained 
with propidium iodide (red fluorescence) detecting loss of plasma membrane integrity, 
where each dot represents a single cell. 
 
The properties of the cell are clarified by the way in which the cells scatter 
the incident light (as demonstrated in figure 1.12) and emit fluorescence. 
Side scatter is proportional to granularity and is measured when the light 
is reflected at high angles (at 90o to the incident light axis (Becton 
Dickinson, 1997)). As cells become apoptotic they become increasingly 
granular as their chromatin becomes more condensed thereby showing 
an increase in side scatter (McCarthy, 2002). Low angle forward scatter is 
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roughly proportional to the diameter of the cell and is detected when light 
is diffracted at angles of between 1 and 10 degrees measured across the 
axis of the incident light (Becton Dickinson, 1997).  
 
 
 
 
 
 
 
 
 
Figure 1.12: Diagram to illustrate how cells scatter light and emit fluorescence in flow 
cytometry. 
 
FL-1 and FL-2 are detected through the absorbance of energy from the 
laser by fluorochromes added to the cell sample. This absorbance of 
energy elevates the fluorochrome to a higher energy level when the cell 
has passed by the laser this energy is released in the form of a photon of 
light emitting in the red or green spectra (Becton Dickinson, 1997). 
 
In addition to these methodologies, the LDH (CytoTox OneTM, Promega) 
fluorescent assay measures necrosis by the release of the enzyme 
lactate dehydrogenase into the culture medium. LDH is a stable enzyme 
normally found in the cytosol of all cells, converting lactic acid to pyruvic 
acid (figure 1.13) in the electron transport chain (Ewaschuk et al., 2005; 
Herrera et al., 2008). This assay measures the released LDH from cells 
with damaged membranes. Released LDH is measured directly in the cell 
culture wells with a coupled enzymatic assay that results in the 
conversion of a non-fluorescent compound (resazurin) to a fluorescent 
compound (resorufin), which can be detected by fluorometry 
(Korzeniewski and Callewaert, 1983; Decker and Lohmann-Mathes, 
Laser Light 
Side Scatter 
Forward Scatter 
.  .  . 
. .      
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1988; Sasaki et al., 1992).  
 
 
       LDH 
         
 
 
NAD+   NADH+ H+ 
 
   Resorufin                            Resazurin 
          
    Diaphorase 
 
Figure 1.13: Detection of LDH demonstrated by the conversion of resazurin to a 
fluorescent compound, resorufin. 
 
Many assays utilise the electron transport chain illustrated in figure 1.14 
to measure changes within cells. ATP, the energy source of all cells is 
produced from the donation of H+ ions from the reduction of NADH and 
FADH2. It is this reaction that the LDH assay is monitoring converting the 
resazurin to resorufin. The electron transport chain consists of four 
complexes: 
 
• NADH dehydrogenase complex 
• cytochrome reductase complex 
• cytochrome oxidase complex 
• ATP synthetase complex 
(Alberts et al., 1989) 
 
During electron transport, the enzymes of the electron transport chain 
(e.g. NADH, FADH2) create a proton gradient across the inner 
mitochondrial membrane. This proton gradient is subsequently used by 
the enzyme ATP synthase to produce ATP (Alberts et al., 1989). 
Pyruvic 
acid 
 
Lactic 
acid 
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Figure 1.14: Illustration of the Electron Transport Chain (taken from HOPES website: 
Huntingdon’s outreach project for education at Stanford). 
 
Another fluorescence assay, alamarBlue, along with the absorbance 
assays WST-1, MTT and MTS also utilise the natural reducing power of 
living cells to measure cell viability. Unlike the LDH assay which 
measures cell permeability, these are viability assays. AlamarBlue is a 
non-toxic metabolic indicator of viable cells that becomes fluorescent 
upon mitochondrial reduction (Nociari et al., 1998). The alamarBlue 
indicator detects changes in oxidation as a result of the electron transport 
chain (figure 1.14) by monitoring the change of a blue and non-
fluorescent dye resazurin, to a pink and fluorescent dye resorufin in 
response to chemical reduction of growth medium resulting from cell 
growth. Continuous cell growth maintains a reduced environment while 
inhibition of growth maintains an oxidised environment. Reduction related 
to growth causes the REDOX indicator to change from the oxidized blue 
form to the reduced pink form.  
 
 
 
    mitochondria 
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The colorimetric or absorbance assays (MTT, XTT, WST-1) measure the 
intracellular reduction of a soluble yellow tetrazolium dye to a purple 
product, based on the cleavage of a tetrazolium salt by mitochondrial 
dehydrogenases in viable cells (Marshall, 1995). Upon reduction by 
electrons flowing through the electron transport system and by 
superoxide radicals produced, this change of colour can be detected. The 
formazan dyes derived from each tetrazolium salt are completely different 
in terms of solubility. The MTT assay contains insoluble crystals and must 
be solubilised with surfactants or organic reagents. The XTT and MTS 
assays are soluble but the most water-soluble and stable of the salts is 
WST-1 (Clontech, 2007). 
 
All living cells contain ATP produced by the electron transport chain 
(Krebs, 1970), making it a good presumptive marker for cell number and 
cell condition (Crouch et al., 1993). Assessment of ATP, using 
established methods, enables the measurement of the effects of cytotoxic 
agents on cell lines and tumours to determine the cellular outcome after 
treatment. These effects could be apoptotic, growth inhibiting or no effect 
at all therefore resulting in continued proliferation (Cree, 1995). When 
cells are subjected to stress; the process of oxidative phosphorylation 
breaks down, so that ATP is no longer produced. It has been observed 
that apoptotic and necrotic cells give out different ATP relative light units 
(RLUs) when measured by bioluminescence. These changes in the ATP 
levels brought about by programmed cell death may be early indicators of 
apoptotic or necrotic changes within the cells (Crouch et al., 1993; 
Bradbury et al., 2000; Tsujimoto, 1997). Bioluminescence is the 
production of light by living organisms. Bioluminescence is used by 
fireflies to attract mates, anglerfish to lure prey, railroad worms to scare 
predators and pelagic squid as camouflage (Pazzagli et al., 1988). 
Probably the best known example of bioluminescence is in the North 
America Firefly (Photinus pyralis, shown in figure 1.15), whose 
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development of a highly efficient bioluminescent system is employed 
when attracting a mate (Lundin, 1982 and Lundin, 1993). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15: The male species of the north-American firefly Photinus pyralis is shown 
emitting the familiar yellow-green light.  
 
Luciferase is a generic term for an enzyme that can generate light as a 
product in luminous organisms. These luminous organisms have over 700 
genera representing 17 phyla including plants, fish, bacteria, worms and 
beetles (Hastings, 1983). The first applications using luciferase were 
based upon biomass measurement in the food industry for microbial 
contamination in food products such as milk, (Bossuyt, 1982) carbonated 
drinks, (Little and LaRocco, 1986) and meat (Stannard and Wood, 1983).  
 
A typical detection system for the measurement of ATP using 
bioluminescence is the luminometer.  This consists of a sample chamber, 
a photomultiplier tube (PMT) for the detection of the light produced and a 
means of recording the amount of light released. The sample chamber is 
responsible for receiving and presenting the microplate to the detector. It 
is important that this is completely sealed to minimise interference from 
ambient light. In order to produce precise, rapid measurements the 
sample chamber must be positioned as close to the detector as possible 
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as this positioning gives the optimal signal to noise ratio. The detection 
system of the luminometer consists of a photomultiplier tube (PMT) where 
a single photon of light triggers a rapid amplified cascade of electrons. 
The resulting electrical current created when the photons strike the PMT 
is measured by the luminometer and expresses this information as 
arbitrary light units, referred to as relative light units (RLUs). 
Luminometers can detect an even collection of light from the smallest of 
samples, obtained by either positioning the PMT side on or end on within 
the machine. The bioluminescent ATP assay, ViaLight HS (Lonza 
Bioscience Inc.), was developed to detect ATP released from cells as an 
indication of viable cell number in the following reaction: 
 
 
                          Luciferase 
     ATP + Luciferin + O2                Oxyluciferin + AMP + PPi + CO2 + Light 
 
                             Mg++ 
 
 
Figure 1.16: The reaction resulting in conversion of ATP to light 
 
Samples of cells are treated with a lysis reagent (detergent based) and a 
formulation of luciferase, luciferin and magnesium is then added to the 
lysate to measure the light emitted. The light produced is directly 
proportional to the amount of ATP, which in turn is proportional to the 
number of viable cells. If all factors in the above reaction mechanism are 
saturated it can be deduced that the light emission is linearly related to 
the concentration of ATP present within the sample. The emitted light is 
then detected by a luminometer and expressed as the relative light units 
(RLUs). 
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1.6 Analysis of the Cancer Proteome 
 
The cancer proteome is now becoming a significant area of research for 
many researchers, with early detection remaining the most promising 
approach to improve long term survival for patients with cancer 
(Diamandis, 2004; Zhang et al., 2004). Wilkins and colleagues in the 
early 1990’s used the terms ‘proteomics’ and the ‘proteome’, reflecting 
the area of ‘genomics’ and the ‘genome’ (Liebler, 2002; Baak et al., 
2003). Genomics (the study of the human genome) and proteomics (the 
analysis of the protein complement of the genome) now play a major 
role in advancing scientific understanding, diagnosis, prognosis and 
potentially also the treatment of cancer (Baak et al., 2003). 
Methodologies in proteomics are being enhanced year on year for the 
analysis of the serum proteome in identifying signature biomarker 
patterns that may be symptomatic of cancer. Blood contains many 
proteins which could represent potential biomarkers for a particular 
cancer type or stage (i.e. primary or metastatic cancer).  
Overexpression of carcinoembryonic antigen or CEA was first reported 
by Gold and Freedman in 1975 (Fuks et al., 1975). It is a protein 
molecule that can be found in many different cells of the body, but is 
typically associated with certain tumours mainly of the gastro intestine. 
Another example is the isolation and purification of prostate specific 
antigen or PSA which is currently the only biomarker for prostate cancer 
(Leman and Getzenberg, 2009). Blood and urine is routinely analysed 
for potential or known biomarkers that could reflect the state of an 
individual. From blood samples serum, plasma and peripheral blood 
mononuclear cells (PBMCs) can be extracted and routinely monitored 
for undefined or renowned biomarkers for diagnostic and therapeutic 
purposes (Mian et al., 2005).   
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1.61 Mass Spectrometry 
One of the main reasons proteomics has become an extremely active 
area of research for biomarker discovery in recent years is the 
development of mass spectrometer technologies. Conventionally two-
dimensional polyacrylamide gel electrophoresis (2D-PAGE) is used in 
the discovery of proteins associated with disease (Petricoin and Liotta, 
2003; Li et al., 2002)). The negative side to this methodology, despite 
its ability to identify thousands of proteins, is that it is labour-intensive 
and necessitates considerable amounts of protein. Recent progress 
made in mass spectrometry is beginning to offer an alternative to 2D-
PAGE (Li et al., 2002). Mass spectrometers represent an analytical tool 
used for measuring the molecular mass/weight (MW) of a sample and 
are able to measure bio molecules to within an accuracy of 0.01% of 
the total MW of the molecule (Ashcroft, 2005). There are many different 
mass spectrometers currently employed in the analysis of the human 
cancer proteome that are used for early detection, therapeutic targeting 
and patient-tailored (personalised) therapy (Petricoin and Liotta, 2003). 
Identification of a protein biomarker may not only enable the 
development of assays for the early detection of cancer, but its physical 
properties and function may be used as a target for therapy or to predict 
a patient’s likely response to a particular drug or treatment. The majority 
of studies carrying out this research use Matrix Assisted or Surface 
Enhanced Laser Desorption Ionisation Time of Flight Mass 
Spectrometry (MALDI-TOF-MS or SELDI-TOF-MS) (Cazares et al., 
2008).  
 
The term matrix-assisted laser desorption ionization (MALDI) was first 
utilised in 1985 by Franz Hillenkamp, Michael Karas and colleagues 
(Karas et al., 1987). The sample preparation of MALDI includes the 
mixing of the protein or peptide sample with a matrix in solution. This 
mixture is then spotted in small amounts onto a specialised 384 target 
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plate and allowed to dry. The sample and matrix co-crystallise as the 
solvent evaporates (Mann et al., 2001). The main purpose of a matrix is 
to stabilise the proteins in the sample on the plate which would 
otherwise be destroyed by the laser upon analysis. The target plate is 
then inserted into the mass spectrometer which is sealed and a vacuum 
created. The research team at the Nottingham Trent University has 
employed a combination of automated robotic chromatographic ZipTip 
format and MALDI-ToF-MS producing a powerful and sensitive analysis 
of pre-fractionated samples, a whole protein based top-down separation 
strategy for the identification of markers (Matharoo-Ball et al., 2007). 
The originality of this method is the ability to be able to measure the 
samples at the protein level for screening biomarkers, followed by 
tryptic digestion of the same sample (bottom-up) as shown in figure 
1.17. This methodology helps identification of biomarkers by measuring 
tryptic peptides which can be separated out better due to their smaller 
size by MALDI-MS (reflectron mode) than whole protein based studies.  
  
 
  
Figure 1.17: A flow diagram to illustrate the procedure of mass spectrometry 
 
In comparison, SELDI technology, developed by William T. Hutchens at 
Baylor College of Medicine later in 1993 uses a target modified to 
achieve biochemical affinity with the analyte compound. This is carried 
out by preparing a specialised chip that contains different chemical 
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functional groups individually spotted onto the chip and then mixed with 
the protein sample to be analysed (Hutchens and Yip, 1993). Chip 
surfaces that are available include; hydrophobic ProteinChip, weak 
cation exchange ProteinChip, strong anion exchange ProteinChip, 
immobilised metal affinity ProteinChip (IMAC) and an immobilized 
copper ProteinChip (IMAC3). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.18: A SELDI ProteinChip 
 
The proteins contained within the sample will bind to the different 
surfaces on the chip, depending on their specialised structures. Some 
proteins in the sample will bind to the surface, while others are removed 
through washing (Li et al., 2002). Only proteins complementary to the 
chip surface are retained and analysed (figure 1.18). As with the MALDI 
methodology, matrix is applied to the surface after washing and allowed 
to crystallise with the sample peptides. Binding to the SELDI surface 
acts as a separation step and the subset of proteins that bind to the 
surface are easier to analyse. An overview of the processes involved in 
both MALDI and SELDI mass spectrometry are illustrated in figure 1.19. 
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Figure 1.19: A flow diagram to outline SELDI and MALDI mass spectrometry edited 
from Sidawi and Derra, 2009. 
 
The ‘high throughput robotic sample processing’, illustrated in figure 
1.19 is used to standardise procedures prior to sample analysis. These 
robotic systems can precisely pipette, mix and spot samples, reducing 
the amount of time, improving the dimensionality of the data and the 
reproducibility of experiments. 
 
Mass spectrometry (MS) is an analytical technique for determining the 
composition of a sample or molecule and consists of three modules; the 
ion source, mass analyzer and the detector. Initially, the sample is 
ionised and vaporised by a laser in the ion source, which converts it into 
electrically charged particles. These particles then enter a mass 
analyser, which contains electric and magnetic fields. By Newton’s 
second law of motion, lighter ions are deflected more and travel faster 
then the heavier ions. Both the speed and direction of the charged 
particle can be increased or decreased while passing through the 
electric field but the magnitude of the deflection is dependent on the 
ions mass-to-charge (m/z) ratio. It is this ratio that identifies individual 
proteins or peptides (Henrickson and Pandey, 2001). The streams of 
     Serum samples 
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sorted ions pass from the analyser to the detector (figure 1.19), where 
the results are recorded and illustrated as peaks grouped together in a 
‘spectrum’ representing the protein or peptide fingerprints. A typical 
spectrum obtained from mass spectrometry is shown in figure 1.20 
below where the m/z ratios of the prominent ions are labeled. 
 
Figure 1.20: Example of spectrum seen after mass spectrometry analysis. 
 
The sample can be measured directly by the mass spectrometer or it 
can be fractionated to make sample identification more sensitive. This 
usually involves the mass spectrometer being coupled directly to a high 
pressure liquid chromatography (HPLC), gas chromatography (GC) or 
capillary electrophoresis (CE) separation column, separating the 
sample into a series of components which are measured by the mass 
spectrometer sequentially for individual analysis (Petricoin and Liotta, 
2003; Diamandis, 2004).   
 
MALDI has been used as a high throughput and extremely sensitive 
tool to generate proteomic patterns from a variety of biological samples 
ranging from serum, plasma, cerebrospinal fluid and urine to tissue in 
order to detect biomarkers of disease (Veenstra et al., 2005). Many 
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biomarkers have been identified in prostate (Adam et al., 2003), 
polycystic ovary syndrome (Matharoo-Ball et al., 2007), breast (Mian et 
al., 2003; Traub et al., 2005), ovarian (Petricoin et al., 2002), colorectal 
(de Noo et al., 2006) and melanoma (Matharoo-Ball et al., 2007; 
Hutchens and Yip, 1993). MALDI-MS is an ideal methodology for 
analysing simple peptide mixtures but for more complex samples, 
especially for protein identity, liquid chromatography-electrospray 
ionisation combined with mass spectrometry (LC-ESI-MS) may be 
required (Huang et al., 2002; Karas and Hillenkamp, 1988). One of the 
major limitations of the MALDI-based technique is its relative poor 
reproducibility in measuring m/z abundances (peak intensity), which 
may be essential in biomarker discovery. In addition, LC-MALDI-
TOF/TOF analysis generally takes a long time, which is hardly practical 
when analysing large numbers of samples. However, this technique is 
recognized for its high mass accuracy (typically in the range of 5 ppm to 
20 ppm routinely). Another area of contention is the tools used to 
analyse the complex data in MALDI. Re-analysis of the raw data from 
Petricoin’s study in 2002 with different bioinformatics tools failed to 
validate the initial findings causing much dispute over techniques and 
validation used on data sets (Baggerly et al., 2004; Sorace et al., 2003).  
 
The development of electrospray ionisation for the analysis of biological 
macromolecules was awarded the Nobel Prize in Chemistry to John 
Bennett Fenn in 2002. There are a wide range of basic electrospray 
techniques primarily microspray and nanospray but they all involve the 
transfer of ions from solution to a gas phase (Kebarle, 2000). There are 
many variations on the basic electrospray technique. Microspray and 
nanospray have better sensitivity due to the reduction in the flow rate of 
the analyte containing liquid. The main process involves applying an 
electric field to the tip of a capillary which contains a solution of 
electrolyte with the substance or analyte to be studied (Karas and 
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Hillenkamp, 1988). The solvent used is normally much more volatile 
than the analyte which exists as an ion in solution (either an anion or a 
cation). Volatile acids, bases or buffers are added to this solution and 
due to forces of charge repulsion, the liquid pushes itself out of the 
capillary and forms a ‘mist’ of droplets approximately 10 µm across. 
This forces the molecules together which are continually trying to repel 
each other as they evaporate, thus breaking up the droplets. This is 
known as Coulombic fission because it is driven by repulsive Coulombic 
forces between charged molecules (Kebarle, 2000). This continues until 
the analyte is free of solvent and enters the mass analyser to be 
measured, and shown on spectra containing peaks as previously 
demonstrated in figure 1.20. 
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1.62 Bioinformatics approaches for data analysis 
With the introduction of mass spectrometers and the vast amounts of 
data produced; analysing the data became a minefield, introducing a 
high degree of complexity into the results (Lancashire et al., 2005). 
However, recent advances in computer algorithms and informatics, 
combined with biological knowledge are enabling this data to be 
analysed (Ball et al., 2002; Diamandis, 2004).  This requires the use of 
highly sophisticated statistical methods with high computational power 
such as Bayesian analyses, fuzzy logic and artificial neural networks or 
ANNs (Matharoo-Ball et al., 2007). There are many proteomics tools 
that can be employed providing a wealth of information and rapid 
interpretation of the large quantities of data analyzed (Bensmail et al., 
2005). There has to be an accurate interpretation of the ‘curse of 
dimensionality’ (Ball et al, 2002) which refers to the asymmetry seen 
between the number of input features (e.g. peaks) and the number of 
exemplary features (e.g. samples). Overcoming this problem is 
challenging but necessary and some of the bioinformatics tools 
developed to successfully analyse complex data sets include: 
 
1. Artificial neural Networks (ANNs) – identifies peaks that are 
statistically different between two groups. Links are used within 
the computer model which are strengthened or weakened 
depending on their frequency of use (Lancashire et al., 2005).  
2. Principle Component Analysis or PCA – used to sort data by 
finding the fewest dimensions. Data is sorted into axes that best 
represent the differences between groups and represented 
visually on 2D or 3D scatter-plot graph (Lesk, 2005). 
3. Cluster Analysis – involves placing data into distinct groups 
based on the similar characteristics shared between individuals. 
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4. Support Vector Machines (SVM) – correctly separates into 
classes but can also identify classifications not supported by the 
data. 
5. Decision Trees – can be applied to problems such as protein 
function. 
 
Generally data mining approaches fall into two categories: 
unsupervised and supervised. Unsupervised data (e.g. PCA and cluster 
analysis) do not take into account class labels, while supervised (e.g. 
ANNs, SVMs) approaches do. For initial assessment of the quality of 
data unsupervised approaches can be carried out to visualize the 
overall distribution of the data (Fung et al., 2005). They can also 
provide a qualitative assessment of the data by superimposing the 
sample labels. All of these tools have the capability to aid the 
researcher in accurately identifying biomarkers from data retrieved from 
mass spectrometry (Fogel, 2004). Prior to analysis of the data by 
informatics, data are manipulated or preprocessed by removing any 
unwanted and inconsistent data as shown in figure 1.21. This involves 
selecting peaks and removing any m/z ratios that are outside the 
targeted range (Fung et al., 2005). The data are smoothed to allow 
comparisons between spectra and baseline corrected to eradicate 
insignificant datasets. 
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Figure 1.21: Mass spectra analysis work flow taken from Norris et al., 2007. 
 
Analysis of MALDI data can be separated into two distinct steps: pre-
processing and processing or statistical analysis. Pre-processing has 
been the focus of much variance within a data set. This procedure plays a 
key role in reducing experimental variance, and preparing the subsequent 
data for statistical analysis. The spectra obtained are conditioned through 
the removal of background, normalization of intensity, and alignment. The 
analytical goals of profiling experiments can be two-fold: the classification 
of samples into two or more classes such as diseased/non-diseased, and 
the identification of biomarkers characteristic to each class (Yanagisawa 
et al., 2003). Identification of disease specific proteins could reveal much 
information from protein mechanisms to potential diagnostic markers or 
drug targets. Recognising this importance is highlighted in comparative 
analyses of profile spectra (Markey et al., 2003), whereby varied 
biostatisticians all reported an accuracy >90% in classifying the same 
profile spectra from either tumour or non-tumour samples. The 
controversy however lies in identifying which ions are the most significant 
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to determine the classifications in which there was little to no agreement. 
These inconsistencies cause much consternation particularly since these 
same ions are prime candidates for further identification and study as 
disease biomarkers. This debate over data interpretation limits mass 
spectrometry as a powerful technique which needs to be taken into 
account when analysing data (Westhead and Twyman, 2002) 
  
Upon finding important peaks using computer algorithms, that have 
significant differences between cancer and control groups, the next step 
is to characterise and identify the proteins that they represent. There are 
several web-based databases e.g. Mascot, ProFound or MOWSE 
(Matharoo-Ball et al, 2007) that provide complete listings of all known 
proteins’ sequences. Intact proteins are incompatible with these 
databases; therefore a digest of the protein is carried out using a specific 
protease such as trypsin. The mass measurements of the digested 
fragments are more precise, whereas the various forms of proteins that 
exist due to post-translational modifications make identification by this 
method unclear (Wu et al., 2002). Where such modifications are known, 
exact mass differences between unmodified and modified amino acids 
can be predicted. Algorithms such as SEQUEST have built-in parameters 
for detecting such modifications. The presence of a modified residue 
should always be confirmed experimentally (Westhead and Twyman, 
2002). Imperfect matches can also result because the actual protein does 
not exist on the database but a close homolog from the same species 
does exist. This is often the case if a protein contains a single nucleotide 
polymorphism leading to two or more variants. Another technique often 
used for identity is electrospray ionisation tandem mass spectrometry 
(EITMS) which produces amino acid sequences of each peptide fragment 
based on its net charge, which can be entered into the online data bases 
and compared to all known proteins. 
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1.7  Aims and Objectives  
Cancer is a complex disease that presents many challenges to clinicians 
and cancer researchers who are constantly searching for more effective 
ways to combat its often devastating effects. The majority of patients with 
cancer will require treatment with chemotherapeutic agents at some point 
in the course of their disease. A significant percentage of these patients 
can achieve a complete remission after initial treatment but a high 
proportion of these will finally relapse due to the presence of residual 
tumour cells that resist drug treatment (Dolken, 2001). The methods used 
to detect cell killing, lack sensitivity, often as a result of high background 
readings and the unacceptable signal: noise ratio. This means it is often 
difficult to confirm the complete (100%) killing of tumour cells. 
 
The initial aim of this research was to produce a novel assay that would 
be a quick, safe and highly sensitive alternative to traditional assays such 
as MTT or chromium-51 that is historically used to measure cell viability. 
With the increase in the use of ATP as a detection system for viable cells 
(due to ease of use and the speed and accuracy of the detection) an 
investigation was conducted into an extension of this technology. A paper 
was found by Squirrel and Murphy (1997) which looked into the use of 
adenylate kinase (AK) for hygiene monitoring in the food and beverage 
industry. One molecule of AK could turn over 1000 molecules of ATP. As 
ATP had already been shown to be sensitive in detecting cell viability, the 
measurement of AK leakage from cells could result in a more sensitive 
assay for measuring cell death. It was therefore decided to produce a 
novel assay using AK and if successful, compare its sensitivity against 
the well-established methodologies. AK belongs to the class of enzymes 
known as phosphotransferases, specifically those that use a phosphate 
group as an acceptor (Rosenfelt and Hubler, 1999). It is a ubiquitous 
protein present in all eukaryotic cells. The principle behind the assay is 
based on the leakage of the enzyme into the culture supernatant through 
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lysis of the cell membrane (Squirrel and Murphy, 1997). Due to its small 
size (36 KDa), measurement of this enzyme should be more accurate and 
sensitive for the determination of cytotoxicity and cytolysis, than those 
presently available (i.e. LDH is 140 KDa). An AK detection reagent 
(named ‘ToxiLight’ in this thesis), would be designed to be added to a cell 
culture and allow for the detection of AK leakage from damaged cells by 
bioluminescence.  The detection limits of this assay will be investigated 
and compared to the commonly used cytotoxicity assays.  
 
The second part of the research was to utilise the most responsive 
assays tested in the initial investigation to establish sensitive and 
resistant melanoma cell lines. The cell lines will be chosen based on their 
responses to various well-known chemotherapeutic drugs using the 
chosen assays. When a resistant and sensitive cell line has been chosen, 
the investigation will be continued to test the effects of the drug 
trichostatin A (a reversible inhibitor of the histone deacetylase (HD)) upon 
these cells. The effects of trichostatin A has been researched widely on 
melanoma cells including its investigation into the role of p53 (Halaban et 
al, 2009) and p21 (Boyle et al, 2005) with evidence suggesting that it may 
play an important role in carcinogenesis. Trichostatin A has been shown 
to induce differentiation in acute myeloid leukemia and displays potent 
antitumor activity against prostate and breast cancer cells in vitro and in 
vivo. This experiment would involve treating the chosen melanoma cells 
with trichostatin A, testing them with the cytotoxicity assays with further 
confirmation by using PI uptake, light microscopy and trypan blue. The 
cell lysates from these drug-treated and untreated melanoma cell lines 
would be frozen down and utilised for further research. 
  
The final part of this study was to utilise the frozen lysates obtained from 
the cytotoxicity experiments to assess the molecular effects of trichostatin 
A on the melanoma cells by MALDI-TOF-MS. By identifying patterns in 
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proteomic profiles it may be possible to identify possible biomarkers 
reflecting differences between sensitive and resistant drug-treated cell 
lines. The spectra obtained from the MALDI-MS analysis will then be 
analysed using ANNs to determine if patterns can be found within the 
data that can classify blind samples according to drug-treated and 
untreated cells. The MALDI spectra will be analysed using the same 
ANNs parameters and the results of the analyses with the MALDI 
methods compared to the previous cytotoxicity assays. 
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Chapter 2 – Materials and methods 
 
2.1  Materials  
 
 
Material 
 
 
 
Supplier 
 
 
FACS Flow 
FACScan tubes 
 
BD BioSciences 
Between Towns Road 
Oxford 
  
5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethylbenzimidazolylcarbocyanine iodide 
(JC-1) 
Cambridge BioScience 
Newmarket Road 
Cambridge 
  
Dimethyl sulphoxide (DMSO) 
Foetal Bovine Serum (FBS) 
Harlan Sera Labs 
Loughborough 
Leicestershire 
  
Acetonitrile (ACN):HPLC grade 
Trifluoroacetic acid (TFA): HPLC grade 
Fisher Scientific 
Bishop Meadow Road 
Leicestershire 
  
α-cyano-4-hydroxycinnamic acid (CHCA) 
Peptide calibration mix 
Protein calibration mix 2 
Sinapinic acid 
Laser Bio Labs 
Cedex 
France 
  
ATP 
ToxiLight 
ViaLight HS 
Lonza BioScience 
Wokingham 
Berkshire 
  
ADP 
Camptothecin 
Dexamethasone 
Vindesine 
Merck BioSciences Ltd 
Beeston 
Nottingham 
  
Zip Tip pipette tips Millipore UK Ltd 
Units 3 and 5 
The Courtyards 
Hatters Lane 
Watford 
  
Bovine Serum Albumin (BSA) 
 
MP Biomedicals 
Wellington House 
Cambridge 
  
96 well cell culture plates 
96 well luminometer plates 
Porvair Sciences Ltd 
Govett Avenue 
Sheperton 
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Material 
 
 
 
Supplier 
 
 
 
Cytotox One 
MTS 
 
Promega UK 
Chilworth Science Park 
Southampton 
  
WST-1 
XTT 
Roche 
Switzerland 
  
Cell culture flasks (T25 and T75) 
Sterile universal tubes (25ml and 50ml) 
10ml pipettes 
Sarstedt Ltd 
Beaumont Leys 
Leicestershire 
  
12 well tissue culture plates Scientific Laboratory Supplies 
Wilford Industrial Estate 
Nottingham 
  
Acridine orange 
Cisplatin 
Dacarbazine 
Dimethylsulfoxide (DMSO) 
Dithiothreitol (DTT) 
Doxorubicin 
Ethidium bromide 
L-Glutamine 
Myokinase Standards 
n-octyl-beta-D-gluco-pyranoside (OGP) 
PBS tablets 
Penicillin and Streptomycin 
Propidium Iodide 
RPMI-1640 
Trichostatin A 
Trypan Blue 
Sigma-Aldrich 
Poole 
Dorset 
  
Axima CFR+ MALDI TOF mass 
spectrometer 
384 MALDI target plate 
Shimadzu 
Manchester 
  
Statistica 7.0 software StatSoft Inc. 
Tulsa 
OK 
  
 
 
Table 2.01: List of materials used within this study and their supplier. 
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2.2 Preparation of buffers, stains and kits 
 
 
2.2.1 Preparation of phosphate buffered saline (PBS) 
 
1 tablet was dissolved in 200 mL of dH2O to give 0.01 M phosphate 
buffer, 0.0027 M potassium chloride and 0.137 M sodium chloride at pH 
7.4 (25oC). 
 
2.2.2 Preparation of Acridine Orange/Ethidium bromide and 
fluorescent microscopy 
 
Preparation of stock solution. 
The stock included: 15 mg Acridine orange, 50 mg Ethidium bromide 
which was dissolved in 1 mL of 95% (v/v) ethanol. 49 ml of d.H2O were 
added. 
Preparation of working solution. 
The stock solution was diluted 1:100 with PBS to give a final working 
concentration of 3 μg.ml-1 Acridine orange and 10 μg.ml-1 Ethidium 
bromide. 
 
2.2.3 Preparation of JC-1 Staining  (5,5',6,6'-tetrachloro-1,1',3,3'-
tetraethylbenzimidazolocarbocyanide iodide) 
 
Preparation of stock solution. 
 JC-1 was dissolved in DMSO to give a 1mg.ml-1 solution. 
Preparation of working solution. 
The stock solution was diluted 1:50 in PBS and filtered using a 0.45 μm 
filter.  
250 µl of the filtered JC-1 was added to 125 µl of the cell suspension and 
incubated for 30 minutes at 37oC in a 5% (v/v) CO2, humidified incubator. 
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2.2.4 Preparation of Propidium iodide (PI) – PI was reconstituted in 
DMSO to give a stock of 1mg.ml-1 which was diluted 1:20 in PBS to give a 
working concentration of 50 μg.ml-1. 
 
2.2.5 Preparation of Trypan Blue – Trypan Blue was obtained ready to 
use at a 0.4% (w/v) solution (0.81% (w/v) sodium chloride and 0.06% 
(w/v) potassium phosphate). 
 
2.2.6 Preparation of ViaLight® Plus kit 
 
• Nucleotide Releasing Reagent – Provided ready to use. 
• Tris Acetate Buffer – Provided ready to use. 
• ATP Monitoring Reagent (AMR) – AMR was reconstituted by the 
addition of 50 mL of Assay Buffer to the bottle. This was 
equilibrated for 15 min at room temperature to ensure complete 
rehydration, as to the manufacturers’ specifications. 
 
2.2.7 Preparation of ToxiLight® kit 
 
• AK Assay Buffer – Proprietary information.  
 Provided ready to use. 
• Adenylate Kinase Detection Reagent (AK-DR) - Proprietary 
information. 
AK-DR was reconstituted by the addition of 10 mL of AK Assay 
Buffer to the bottle.  
This equilibrated for 15 min at room temperature to ensure complete 
rehydration, as to the manufacturer’s specifications. 
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2.2.8 Preparation of CytoTox-ONE kit 
 
• CytoTox-ONE assay buffer – Provided ready to use. 
• CytoTox-ONE Reagent – CytoTox-ONE was reconstituted by the 
addition of 10 mL of CytoTox-ONE assay buffer to the bottle. This 
was then allowed to equilibrate for 15 min, as to the manufacturers 
specifications. 
• Stop solution – Provided ready to use. 
 
2.2.9 Preparation of MycoAlert kit 
 
• MycoAlert Assay Buffer – Provided ready to use. 
• MycoAlert Substrate - substrate was reconstituted by the addition of 
6000 µL of MycoAlert Assay Buffer to the bottle.  
This equilibrated for 15 min at room temperature to ensure complete 
rehydration, as to the manufacturer’s specifications. 
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2.3 Cell lines 
 
The cell lines used in this study were all obtained from ECACC apart from 
the melanoma cell lines, which were a kind gift from Professor Rees at 
Nottingham Trent University.   
 
2.3.1 Freezing and thawing of cells 
 
The cells were frozen in 1ml aliquots at concentrations between 2 - 5 x 
107cells.ml-1 in the appropriate media, containing 10% (v/v) foetal calf 
serum (FCS) and 10% (v/v) dimethyl sulphoxide (DMSO). The cells were 
thawed in a 37oC water bath and washed in warmed media and 
centrifuged for 5 minutes at 400 x g to remove any excess DMSO. The 
cells were then placed in 10 mL of fresh media and then into a T25 tissue 
culture flask.  
 
2.3.2 Cell culturing Suspension Cells 
 
All cells were cultured in a humidified, 5%(v/v) CO2 incubator at 37oC in 
the appropriate complete media containing 10% (v/v) FCS, 2 mM L-
Glutamine, 50 units mL -1  penicillin and 50 µg.ml-1  streptomycin. The cell 
lines were sub cultured twice weekly or when they had reached an 
approximate cell density of 1 x106 mL1. 
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2.3.3 Cell lines Used 
 
Cells Cell Type Culture 
Media 
Suspension/Adherent Source 
Jurkat Acute human T cell 
lymphoblast 
RPMI Suspension ECCAC 
U937 Human histiocytic 
lymphoma 
RPMI Suspension ECCAC 
K562 Human chronic 
myelogenous 
leukaemia 
RPMI Suspension ECCAC 
CEM-7 Human acute T cell 
lymphoblast 
RPMI Suspension ECCAC 
HL60 Human 
promyelocytic 
leukaemia 
RPMI Suspension ECCAC 
FM-3 Human breast 
mammary cells 
 Adherent ECCAC 
A549 Human small cell 
lung cancer cells 
DMEM Adherent ECCAC 
Hep G2 Hepatocellular 
carcinoma 
 
DMEM Adherent ECCAC 
Ma Mel 26a 
Ma Mel 28 
Melanoma (human) 
Melanoma (human) 
RPMI Adherent Nottingham 
Trent 
University 
(OYSTER) 
 
MEWO 
COLD 794 
ESTDAB-
105 
WM 1205 
Melanoma (human) 
Melanoma (human) 
Melanoma (human) 
 
Melanoma (human) 
RPMI 
RPMI 
RPMI 
 
RPMI 
Adherent 
Adherent 
Adherent 
 
Adherent 
Nottingham 
Trent 
University 
(ESTDAB) 
     
 
Table 2.02: Cell Lines Used 
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2.3.4 Culturing Adherent Cells 
 
With the exception of the melanoma cell lines which were cultured in the 
same media as the suspension cells above, all of the adherent cell lines 
were cultured in 75 cm2 cell culture treated flasks in Dulbecco’s Modified 
Eagles Medium (DMEM) media supplemented with 10% (v/v) heat 
inactivated foetal bovine serum, 1% (v/v) L-Glutamine (2 mM), 1% (v/v) 
penicillin (50 U.ml-1) / streptomycin (50 μg.ml-1).  The culture supernatant 
was carefully poured off and discarded. Enough trypsin EDTA solution 
(100 mg porcine trypsin, 40 mg EDTA) was added to cover the bottom of 
the flask in use. The flask was then placed at 37oC in 5% (v/v) CO2 in a 
humidified atmosphere until the cells became detached from the bottom. 
The detached cells were transferred to a sterile universal tube (25 cm2), 
media added to wash off the trypsin and centrifuged for 5 minutes at 400 
x g. The supernatant was removed from the tube and the cell pellet re-
suspended in fresh media. The cells were sub cultured from this into a 
fresh flask containing media. Generally a 1:10 dilution is carried out.  
 
2.3.5 Counting cells 
 
50 μl of cells were diluted with 50 μl of 0.4% (w/v) trypan blue and the 
cells were counted on a haemocytometer. This 1:2 dilution factor was 
incorporated into the calculation below. The cells with damaged 
membranes take up trypan blue and appear violet in colour. Normal cells 
do not take up trypan blue and appear colourless when viewed with the 
aid of a light microscope. Cell counts were taken both of viable and non-
viable cells by: 
 
Average of number of cells x dilution factor x 104 = cell count per mL.  
 
Figure 2.01:  Calculation for the counting of cells (Sigma). 
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2.3.6 Mycoplasma Testing 
 
Mycoplasma species can be found in many research laboratories. A cell 
culture with mycoplasma occurs due to contamination from individuals or 
contaminated cell culture medium ingredients. As they are physically 
small (< 1 µm) and cause no visible changes to the cell culture media, 
they are very difficult to detect with only a conventional microscope. 
Eventually severe mycoplasma contamination will destroy the cell line. 
MycoAlert® has been designed to detect cellular contamination by 
bioluminescence within 15 min.  
 
All reagents were initially brought up to room temperature prior to 
reconstituting the MycoAlert® substrate in 600 µl of MycoAlert® assay 
buffer. After 15 min of rehydration, 2 mL of cell culture was transferred 
into a centrifuge tube and the cells spun at 200 g for 5 min. 100 µL of 
supernatant was then transferred into a luminometer cuvette and the 
luminometer programmed to take a 1-second integrated reading. 100 µL 
of MycoAlert® Reagent was added to each sample and after 5 min a 
reading taken (reading A). 100 µL of MycoAlert® substrate was added to 
the same tube and after 10 min a second reading is taken (reading B). 
The ratio of reading B to A is used to determine whether a cell culture is 
contaminated by mycoplasma. The test is designed to give a ratio of less 
than 1 with uninfected cultures and a ratio of greater than 1 for cells 
infected with mycoplasma. 
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2.4 The structure, mechanism and preparation of the Apoptosis 
inducing agent 
 
The following apoptosis inducing agents were well known cytotoxic 
agents used by Lonza Bio Science. The required cytotoxic concentrations 
of the drugs with the majority of cell lines assayed in this project had 
already been researched and were reliable cell models that could be used 
in the wok-up of the ToxiLightTM assay. 
 
2.4.1 Structure and mechanism of apoptotic agents 
 
   
 
Figure 2.02:  Structure of Camptothecin 
 
Camptothecin is a pale yellow solid and a DNA topoisomerase I 
inhibitor. The unique mode of action for this potent cytotoxic compound 
was found to be the inhibition of an enzyme known as DNA 
topoisomerase I. Camptothecin traps this enzyme, inhibiting DNA 
replication and killing the cancer cells. (Calbiochem, 1999) 
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Figure 2.03:  Structure of Vindesine 
Vindesine is a vinca alkaloid, which is a synthetic derivative of 
vinblastine. It binds to the microtubular proteins of the mitotic spindle, 
leading to crystallisation of the molecule and mitotic arrest or cell death 
in metaphase. The vinca alkaloids are considered to be cell cycle 
phase-specific.  
 
Doxorubicin 
 
 
Figure 2.04:  Structure of Doxorubicin 
 
Doxorubicin is an anthracycline antibiotic produced by the fungus 
streptomyces peucetius. Doxorubicin damages DNA by intercalation of 
the anthracycline portion, metal ion chelation, or by generation of free 
radicals. It has also been shown to inhibit DNA topoisomerase II which 
is critical to DNA function. Cytotoxic activity is cell cycle phase-
nonspecific. (Thakkar and Potten, 1993). 
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Cisplatin 
 
 
 
Figure 2.05:  Structure of Cisplatin 
 
Cisplatin was first synthesised in 1845, but its cytotoxic properties were 
not described until 1965. Cisplatin is an inorganic complex formed by 
an atom of platinum surrounded by chlorine and ammonia atoms. 
Intracellularly, water displaces the chloride to form highly reactive 
charged platinum complexes. These complexes inhibit DNA through 
covalent binding leading to intrastrand, interstrand, and protein cross-
linking of DNA. Experimental and clinical data suggest that cisplatin 
enhances radiation therapy effects. Early studies suggested that 
cisplatin was cell cycle phase-nonspecific, while more recent studies 
have shown complex and variable effects on the cell cycle. 
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Dexamethasone 
 
 
 
 
Figure 2.06:  Structure of Dexamethasone 
 
This white solid is an active and highly stable glucocorticoid. It inhibits 
the expression of inducible but not constitutive nitric oxide synthase in 
vascular endothelial cells. Dexamethasone is also known to enhance 
active cation transport in aortic smooth muscle cells by stimulating the 
sodium-potassium pump. It is a drug used to induce apoptosis in 
human thymocytes.  
 
 
Trichostatin A 
 
 
 
 
 
Figure 2.07 Structure of Trichostatin A 
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Trichostatin A is a potent reversible inhibitor of histone deacetylase 
(HD) and selectively inhibits the removal of acetyl groups from the 
amino-terminal lysine residues of core histones, which modulates the 
access of transcription factors to the underlying genomic DNA. 
Trichostatin A mediates the activation of O6-methylguanine-DNA 
methyltransferase (MGMT). It may be involved in cell cycle progression 
of several cell types, inducing cell growth arrest at both G1 and G2/M 
phases. In some cases it can induce apoptosis. 
 
2.4.2 Preparation of the apoptosis inducing agents 
 
All the cytotoxic agents below were reconstituted in DMSO to produce the 
stock concentrations listed:  
 
 
 
 
 
 
 
 
Table 2.03: Table to illustrate the cytotoxic drugs used. 
 
 
2.4.3 Preparation of apoptotic models 
 
The cells were seeded at 5 x 105 cells.ml-1. 1 ml of the cell suspension 
was transferred into 8 wells of a 12 well plate and the cells were dosed 
with the following concentrations of cytotoxic drug depending upon the 
model being prepared. 
 
Cytotoxic Agent Stock Concentration 
Camptothecin 5 mM 
Cisplatin 1 mg. ml-1 
Dacarbazine 20 mM 
Dexamethasone 25 mM 
Doxorubicin 10 mg.ml-1 
Trichostatin A 1 mM 
Vindesine 1 mg. ml-1 
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Following dosing, the cells were incubated at 37oC in a humidified 
atmosphere of 5% (v/v) CO2, 95% (v/v) air for the required incubation 
time indicated in table 2.04. 
 
Cytotoxic Drug Incubation Time (h) Dosing Range (μM) 
Camptothecin 24 0, 0.5, 0.1, 1, 2, 5, 10 
Cisplatin 24, 48, 72 0, 0.1, 0.2, 0.5, 0.8, 1 
Dacarbazine 24, 48, 72 0, 0.03, 0.06, 0.13, 0.25, 0.5, 1, 2 
Dexamethasone 72 0, 10, 25, 50, 75, 100, 150, 200 
Doxorubicin 24, 48, 72 0, 0.1, 0.2, 0.5, 0.6, 0.8, 0.9, 1 
Trichostatin A 24, 48, 72 0, 0.2, 0.4, 0.6, 0.8, 1, 2, 5 
Vindesine 24, 48, 72 0, 0.2, 0.5, 1.0, 2, 5 
 
Table 2.04:   Table to show the cytotoxic cell models used to induce cell death. 
 
2.4.4 Preparation of Necrotic model 
 
2.4.4.1 Freeze-thaw Method 
 
2mls of suspension (1 x 106 cells.ml-1) were placed into two cryotubes. 
Another 2 mL was placed in a 25 ml universal tube and left at room 
temperature to give healthy control cells. The cryotubes were placed in 
liquid nitrogen until frozen and then immediately immersed in a water bath 
at 370C. This was repeated six times until all the cells had burst open. 
Using trypan blue exclusion the viability of the cells was checked. When 
100% cell death had occurred the healthy and necrotic cells were mixed 
as shown in table 2.05 to make up 1 ml samples and 100 μl placed in 
triplicate into a 96 well white walled plate. 
 
The cells were then mixed as per the following table (for a total 1 ml 
volume). A 100 μl volume was taken and placed in triplicate into a 96 well 
white walled plate for analysis. 
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% 
Necrosis 
0 10 30 50 60 80 90 100 
Volume 
necrotic 
cells (μl) 
0 100 300 500 600 800 900 1000 
Volume 
healthy 
cells (μl) 
1000 900 700 500 400 200 100 0 
 
Table 2.05:  Table to show the volumes required for differing percentage necrosis 
samples. 
 
2.5 Cell Number Dilutions 
 
Cells were diluted 1:10 in complete media as per the table below. A 100 
μl sample was placed in triplicate into a 96 well white walled plate for 
analysis.  
 
Cell Number (mL.-1) Volume of cell suspension 
(μl) 
Volume of complete media 
(μl) 
1 x 106 1000 0 
1 x 105 100 (of above) 900 
1 x 104 100 (of above) 900 
1 x 103 100 (of above) 900 
1 x 102 100 (of above) 900 
1 x 101 100 (of above) 900 
0 0 1000 
 
Table 2.06 Table to show the volumes required for a cell number curve. 
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2.6 Effect of measuring the ToxiLight® assay with / without 
cells present in the test sample. 
 
Two tubes containing K562 cells seeded at 5 x 105 cells.ml-1 were spun 
down to eradicate any cells present in the media. One tube was sampled 
for the supernatant in 100 µl volumes in triplicate into a 96 well plate. The 
second tube was vortexed to re-suspend the cells, then sampled in 100 µl 
volumes in triplicate as per the first tube. The samples in the 96 well plate 
were then analysed by ToxiLight® as described in section 2.8.3.3.  
 
2.7 Preparation of Standards 
 
2.7.1 ATP Standards 
 
From a stock concentration of 10 μmol.ml-1, ATP was diluted 1:10 in Tris 
Acetate Buffer or complete media as shown in the table below to produce 
the required concentrations of ATP. A control was set up consisting of 
Tris Acetate Buffer or complete media alone. 
  
 
ATP Standard (nmol.ml-1) Volume of ATP 
(nmol.ml-1) (μl) 
Volume of complete media 
or Tris acetate buffer  (μl) 
10,000 1000 0 
1000 100 (of above) 900 
100 100 (of above) 900 
10 100 (of above) 900 
1 100 (of above) 900 
0.1 100 (of above) 900 
0 0 1000 
 
Table 2.07: Table to show the dilutions and volumes required for ATP standards. 
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The standards were left on ice throughout the procedure until required 
when 100 μl was placed in triplicate into a 96 well white-walled 
bioluminescent plate. 
 
2.7.2 Myokinase standards 
 
AK standards from a stock concentration of 1 M were diluted down 1:2 
from 1 x 10-3 U.μl -1 in Tris Acetate Buffer as shown in table 2.08 to 
produce the following concentrations of AK with a blank consisting of Tris 
Acetate Buffer. The standards were left on ice throughout the procedure 
until required when 100 μl was placed in triplicate into a 96 well white-
walled plate. 
 
 
 
 
 
 
 
 
 
 
Table 2.08:  Table showing the dilutions and volumes required for differing AK 
standards 
AK Standard (U.μl-1) Volume of AK (U.μl-1) 
(μl) 
Volume of  Tris acetate 
buffer  (μl) 
1x10-2U.μl 1000 0 
1x10-3U.μl 400 (of above) 3600 
5x10-4U.μl 2000 (of above) 2000 
2.5x10-4U.μl 2000 (of above) 2000 
1.25x10-4U.μl 2000 (of above) 2000 
6.25x10-5U.μl 2000 (of above) 2000 
0 0 2000 
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Methods 
 
2.8 Measurement of cell viability 
 
The ability of the cell to exclude various dyes indicates the maintenance 
of the cell membrane integrity and hence the viability of the cell. 
 
2.8.1 Measuring Cell Permeability with PI 
 
PI is also used to assess plasma membrane integrity and cell viability. 
200 µl of cell suspension was placed into a round bottom FACscan tube 
and 200 μl of PI (50 μg.mL-1) added, mixed and incubated for 10 min at 
room temperature. The cells were analysed to assess PI uptake with a 
Becton Dickinson FACScanTM Flow Cytometer where 5,000 events were 
counted. The compensation settings were not required due to only one 
fluorescent dye being monitored in this project (Darzynkiewicz et al., 
1992). 
 
2.8.2 Uptake of Trypan Blue 
 
Cells were mixed with Trypan blue as detailed in section 2.3.5. The cells 
were counted and analysed under a light microscope. Membrane integrity 
was assessed by the number of cells that could take up the dye 
(appearing blue under the microscope (Gorman et al., 1996)). 
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2.8.3  Assays used to measure cytotoxicity 
 
2.8.3.1 Measurement of ATP (ViaLight HS, Lonza BioSciences) 
 
ATP was measured using bioluminescence based on the luciferin-
luciferase reaction: 
 
                                  Mg++ 
ATP + Luciferin + O2                Oxyluciferin + AMP + PPi + CO2 + LIGHT 
                               Luciferase 
 
ATP was measured using the ViaLight BioAssay Kit (Lonza BioScience) 
according to the manufacturer’s instructions. Briefly, 100 μl of Nucleotide 
Releasing Reagent (NRR) were added manually to 100 μl of cells and 
incubated at RT for 5 minutes. If cells had been grown up in volumes 
greater than 100 μl, an equal volume (to the culture volume) of NRR were 
added and the sample incubated for 5 minutes at RT. 180 μl of the cell 
lysate was subsequently transferred to a luminometer compatible plate. 
The plate was read in a luminometer, programmed to inject 20 μl of 
reconstituted ATP Monitoring Reagent (AMR) to each well and an 
immediate 1-second integrated reading was taken and expressed as 
relative light units (RLUs). Data were expressed as mean +/- SD of 
triplicates.  
 
2.8.3.2 Measurement of ATP (ViaLight Plus, Lonza BioSciences) 
 
This method was used as an alternative to the original ViaLight Plus in 
the latter parts of the study. The ideology is the same but the 
methodology slightly different. It was used due to its good stable readings 
in comparison to ViaLight Plus, making it more flexible.  
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Briefly, 100 μl of cells to be measured were added manually into a cell 
culture plate. If an experiment is already set up then a total well volume of 
100 μl is required. 50 μl of cell lysis reagent is added to the wells and 
incubated at RT for 10 minutes. 100 μl of the reconstituted ViaLight Plus 
reagent is then added manually to the wells and after 5 min incubation at 
RT the amount of ATP in the cell was measured on a luminometer, using 
a 1 second integral reading and expressed as relative light units (RLUs). 
Data were expressed as mean +/- SD of triplicates. 
 
2.8.3.3 Measurement of Adenylate Kinase (AK) (ToxiLight, 
Lonza BioScience) 
 
The adenylate kinase assay was developed over an initial period of two 
years as part of my PhD research and was undertaken by myself. The 
optimisation of the assay was carried out using various concentrations of 
luciferin, luciferase, ADP, and magnesium (proprietary information) with a 
preliminary release of the assay (ToxilightTM) at the end of 2002. The 
second phase of the assay included the optimisation of the assay buffer 
to improve the signal stability along with the introduction of a 100% cell 
lysis reagent prior to a second launch in 2004. Due to confidentiality with 
respect to the product formulation, the initial work-up and concentrations 
tested are not shown in this thesis but the assay performance and steps 
undertaken at each level is shown at each point of assay development.  
 
The basis of the novel AK assay was to measure the release of the 
enzyme adenylate kinase (AK) from cytolytic cells using bioluminescence 
based on the conversion of ADP to ATP. This is detected by the luciferin-
luciferase reaction and measured as light: 
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                   AK 
Mg++ATP + AMP    Mg++ADP + ADP 
 
 
This was measured using the Toxilight BioAssay Kit (Lonza Bio Science) 
according to the manufacturer’s instructions. Briefly, 100 µl of 
reconstituted AK Detection Reagent (AKDR) were added manually to 
triplicate samples of 100 µl or 20 µl of experimental cell supernatant in a 
96 well plate. After a 5-min incubation period, the amount of AK released 
from the cell was measured on the luminometer, using a 1 s integral 
reading and expressed as relative light units (RLUs). Data were 
expressed as mean +/- SD of triplicates. 
 
 
2.8.3.4 CytoTox-OneTM Homogenous Membrane Integrity Assay 
(LDH) 
 
LDH released from cytolytic cells was measured using CytoTox-OneTM 
Homogenous Membrane Integrity Assay (Promega) according to the 
manufacturer’s instructions. The experiments were either set up in 
triplicate in 96 well clear bottom plates in the case of adherent cells or 12 
well or 6 well clear, tissue culture plates when using suspension cell 
cultures. The suspension cultures were pipetted into 96 well plates after 
treatment.  
 
To each well of the 96 well plate containing 100 μl of cell suspension 100 
μl of CytoTox-OneTM. Reagent were added and incubated at room 
temperature for 10 min. At the end of 10 min, 50 μl of stop solution were 
added and the fluorescence was measured at an excitation wavelength of 
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590 nm. The amount of LDH release was measured using the Wallac 
Victor2 1640 work station and expressed as fluorescent light units (FLUs). 
 
2.8.3.5 Cell Proliferation Reagent WST-1 assay (4-[3-(4-
iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) 
 
The ability of viable cells to metabolise a formazan dye to induce a colour 
change was measured using WST-1 (Roche) according to their 
instructions. Cells were cultured in 100 µl volumes in clear-bottomed 96 
well plates. 
After the incubation period, 10μl of cell proliferation reagent WST-1 was 
added to each well and the cells were incubated for a further 30 min to 4 
h in a humidified atmosphere. 
The plate was then shaken for 30 s and read on a spectrophotometer at 
an absorbance of 470 nm. The cell viability was measured and expressed 
as the absorbance (Abs.) Data were expressed as mean +/- SD of 
triplicates. 
 
2.8.3.6 Cell Proliferation assay XTT (sodium 3’-[1-phenylamino)-
carbonyl]-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzene-sulfonic acid 
hydrate 
 
The ability of viable cells to metabolise a formazan dye to induce a colour 
change was measured using XTT, a colourimetric assay available from 
Roche according to their instructions. The experiments were either set up 
in triplicate in 96 well clear bottom plates or 12 well or 6 well clear, tissue 
culture plates. If in 12 or 6 well plates, the suspension cultures were then 
pipetted into 96 well plates.  
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XTT labelling reagent and electron coupling reagent were prepared by 
adding 0.1 mL of electron coupling reagent to a test tube containing 5mls 
of XTT labelling reagent and swirling to mix thoroughly. 
 
To each well containing 100 μL of cells 50 μL of XTT labelling mixture 
was added. The plate was incubated for 4 to 24 h in a humidified 5% CO2 
(v/v) atmosphere. Readings were taken using a spectrophotometer at a 
wavelength between 450 to 500 nm. The cell viability was expressed as 
the absorbance (Abs.). Data were expressed as mean +/- SD of 
triplicates. 
 
2.8.3.7 Cell Titer 96 AQueous Non-Radioactive Cell Proliferation 
Assay  
 
The ability of viable cells to metabolise a formazan dye to induce a colour 
change was measured using the Cell Titer 96 assay. It works by utilising 
the tetrazolium compound, MTS ([3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; 
MTS) (Promega) and the electron coupling reagent phenazine 
methosulfate (PMS).  MTS is chemically reduced by cells into formazan, 
which is souble in tissue culture medium. The assay measures 
dehydrogenase enzymes found in metabolically active cells.  
 
The assay was carried out according to the manufacturer’s instructions. 
The experiments were either set up in triplicate in 96 well clear bottom 
plates or 12 well or 6 well clear, tissue culture plates. The suspension 
cultures were then pipetted into 96 well plates. If in 12 or 6 well plates, the 
suspension cultures were then pipetted into 96 well plates.  
 
100 μl of the PMS solution were added to the test tube containing 2 mL of 
MTS solution and swirled to completely mix the MTS and PMS solution. 
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To each well containing 100 μl of cells 20 μl of combined MTS/PMS 
solution were added. The plates were incubated for 1 – 4 h at 37oC in a 
humidified, 5% CO2 (v/v) atmosphere. Following this, the absorbance was 
measured at 490 nm using an ELISA plate reader. 
 
 
2.8.3.8 Inducing Necrotic Cell Death  
 
To obtain 100% cell death by primary necrosis several methods were 
employed: 
 
• Freeze-thaw fracture - the cells were frozen in a 1ml cryotube and 
immersed in the container containing liquid nitrogen for 5 min, 
followed by thawing in a water bath at 56oC. This process was 
repeated five to six times to ensure that all the cells are lysed. This 
was checked using Trypan Blue exclusion, which can rapidly 
assess cell viability and thus confirm whether or not 100% necrosis 
had occurred. (Necrotic cells are stained blue by this dye). 
• Heating at 56oC (in a water bath) for an hour assessed by Trypan 
Blue exclusion  
• Lysis with detergent – to the wells containing culture sample, 100 µl 
of detergent (nucleotide releasing reagent) was added and left for 
at least 10 min at room temperature. 
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2.8.3.9 Fluorescent Microscopy Assessment 
2.8.3.9.1 Acridine Orange/Ethidium bromide and fluorescence 
microscopy 
 
Staining of suspension culture cells. 
The cell suspension was spun at 400 x g for 5 min and the supernatant 
carefully removed. 100 μl of the working solution (3 μg.mL Acridine 
orange and 10 μg.mL Ethidium bromide) was added. Approximately 50 μl 
of stained cell suspension was placed onto a slide and covered with a 
cover slip. The edges of the cover slip were sealed with clear nail varnish 
and examined using a fluorescent microscope.  
 
Staining of adherent cells. 
The adherent cells were cultured on chamber slides. The culture medium 
was removed and replaced with just enough working solution (3 μg.mL 
Acridine orange and 10 μg.mL Ethidium bromide) to cover the slides. It 
was mounted with a cover slip and sealed round the edges with nail 
varnish. The slide was examined as soon as possible using a 
fluorescence microscope. 
 
2.8.3.9.2 JC-1 Staining  
 
Staining cells.  
250 μl of the filtered JC-1 were added to 120 μl of the experimental cells 
to be analysed prior to incubating for 30 min at 37oC in a 5% (v/v) CO2, 
95% (v/v) air humidified incubator.  
 
The percentage of red and green fluorescence was estimated by flow 
cytometry or by fluorescence microscopy.   
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2.8.4  Preparation of Chromium51 release Cytotoxicity Assay  
 
This assay was carried out by Murrium Ahmad as part of her PhD work at 
the Nottingham Trent University under Home Office approval. No 
radioactive suite was available at Lonza Bio Science. 
The project licence number was 40/2414. 
 
2.8.4.1 Tumour Therapy Procedure 
 
CT26 tumour cells were cultured until they reached 75-80% confluence in 
a T75 tissue culture flask. The cells were harvested and used to inject the 
mice by shaving the site of injection. Subcutaneous CT26 tumours were 
induced by injection of 8 x 104 cells into the shaved right hand side flank 
of the animal. The tumours were allowed to develop for approximately 7 
days prior to the initiation of immunotherapy. 
 
2.8.4.2 Immunotherapy with DISC/mGM-CSF 
 
At the time of therapy (day 7-10), the tumours were approximately 0.04-
0.36 cm in diameter. The animals were injected intratumourally with 
approximately 2.5 x 107 PFU (plaque forming units) of DISC/mGM-CSF. 
A second injection was administered 3 days later. The animals were 
monitored for tumour growth and general health twice weekly. 
 
2.8.4.3 Chromium Release Cytotoxicity Assay 
 
Splenocytes were harvested, washed twice in serum-free medium, 
counted, re-suspended in CTL media at the appropriate concentration 
and used as the effector cells. The target cells were harvested by 
trypsinisation (for adherent cells), washed and labelled with chromium-51 
(Amersham, UK) for 1 hour in a 37oC water bath. The cells were washed 
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twice in serum-free media and centrifuged at 400 x g for 3 minutes to 
yield a cell pellet. The cells were re-suspended in CTL media to the 
appropriate concentration and used as the target population. The effector 
and target cells were co-cultured in a 96 well plate for 4 hours in a 
humidified lead container. Following the standard 4 hour Chromium 
release assay at 37oC, approximately 50µl of supernatant was transferred 
to a lumaplate (Packard, UK) and dried overnight in a drying cabinet prior 
to being counted on a Top-Count scintillation counter (Packard). 
 
The percentage cytotoxicity was determined using the following formulae: 
 
Percentage Cytotoxicity =  
 
(Experimental release – Spontaneous release) 
   (Maximum release – Spontaneous release) x 100% 
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2.9     Proteomic Samples 
 
2.9.1 Sample Preparation 
 
The cell samples obtained from the experiments were lysed and frozen at 
-80oC for MALDI-MS analysis. The cells were lysed in a lysis buffer 
containing 9.5 M urea, 2% (w/v) DTT (dithiothreitol) and 1% (w/v) OGP 
(n-octyl-beta-D-gluco-pyranoside). This enabled all the required proteins 
to be released from the cells ready for measurement. 
 
Prior to MALDI-MS analysis, the cells were thawed out, sonicated and put 
on ice. Repetitive freezing and thawing of the samples were prevented by 
aliquoting the samples in the required volumes for each experiment and 
thawing just prior to analysis on ice. 
 
2.9.2 Protein Micro assay 
A Bio-Rad protein micro assay was used to determine the protein 
concentration of all of the samples used in this study, aside from the 
serum samples. This assay proved to be the most appropriate to use as 
most other kits available were not compatible with the 9.5M urea present 
in the lysis buffer. 
 
A BSA protein standard was made up to concentrations of 0, 2, 4, 6, 8, 
10, 12, 14, 16, 18, 20 µg in water to a total volume of 800 µl. Two 
eppendorf tubes were set up for every sample with 795 µl of water and 5 
µl of sample. 5 µl of cell lysis buffer and 795 µl of water were used as the 
negative control. 200 µl of undiluted Bio-Rad protein assay dye 
concentrate was added to each eppendorf and left to incubate for 15 min 
at room temperature.100 µl of sample from each eppendorf was then 
aliquoted into a 96 well plate and the absorbance determined using a 
spectrophotometer at 595nm. 
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2.9.3   Control samples used in MALDI analysis 
 
2.9.3.1 QC samples 
 
QC samples were required on all MALDI test plates to ensure the good 
quality of the data. The samples used were obtained from human blood 
where serum was extracted, a well studied and recognised QC 
methodology used at the Nottingham Trent University. To obtain the 
serum, healthy donor blood samples were collected. After clotting at RT 
for 30 min, the collected blood was centrifuged at 2500 g for 15 min. The 
separated serum was aliquoted and stored at -80oC.  
 
An aliquot of a QC sample was diluted in 0.1% (v/v) TFA at a ratio of 1:20 
and processed along with other samples. After data acquisition by 
MALDI-MS, the spectra were checked visually.  
 
The profiles of these QC controls could be checked on each run to check 
for any potential sample processing errors both on the MALDI-MS and the 
Xcise.  For every 50 samples in an experiment, five QC samples were 
included in the run.  
 
2.9.3.2 BSA samples 
BSA samples were fundamental controls on the MALDI plate. These 
ensured the trypsin was in good working order for the tryptic digest and 
therefore peptide analysis.  Five BSA samples were included for every 
fifty samples run. The BSA was made at a concentration of 0.1 mg.ml-1 in 
water and stored at -80°C. 
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2.9.3.3  Blanks 
Blanks, which consisted of 0.1% (v/v) TFA, were used to detect any 
contamination on the MALDI plate. As all the samples had been diluted in 
0.1% TFA, analysing these blanks played a vital role in investigating the 
peaks obtained in the sample profiles. Ten blanks were included for every 
50 samples, in each run.  
 
Contamination can also occur due to unclean MALDI plates. The MALDI 
target plates are repeatedly used, and therefore the control blanks will 
reveal any contamination on the plate (i.e. from the previous samples).  
 
2.9.4     Sample processing on the Xcise robotic system 
 
An automated sample processor Xcise robotic system was utilised for 
sample preparation and processing prior to MALDI-TOF analysis. The cell 
samples from control and treated melanoma samples were diluted to 0.1 
μg.ml -1 in 0.1% (v/v) trifluoroacetic acid (TFA) for the Ma Mel 26a cells. A 
more concentrated amount was used for Ma Mel 28 and MEWO cells 
where the cells were diluted to 0.5 μg.ml-1 in 0.1% (v/v) trifluoroacetic acid 
(TFA).  
 
2.9.4.1 ZipTip Method 
 
25 µl volumes of the samples were placed into a 96 well plate. The 
positions of the samples in the 96 well plates were randomly selected 
using a Microsoft Excel computer program. They were then processed on 
the Xcise robotic system and the ZipTipping procedure was carried out. 
The samples were bound to the ZipTip with 25 cycles of binding, followed 
by two washes in 0.1% TFA, where the washes were discarded. The 
samples were eluted off of the ZipTip in 4 µl of 80% ACN + 0.1% TFA. At 
the end of the Xcise run, 1 µl of eluted samples had been spotted onto 
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the MALDI target plate followed by 1µl of sinapinic (SA) matrix solution 
containing 12 mg of sinapinic acid (SA) in 1 ml of 50% (w/v) ACN, 50% 
(w/v) TFA. In the case of tryptic peptides, 1 µl of the eluted sample 
contained 1 µl of matrix solution of 12 mg α-cyano-4-hydroxycinnamic 
acid (CHCA) in 1 mL of 50% (w/v) ACN. The samples were randomly 
spotted in duplicate on the MALDI target and then analysed by MALDI-
TOF MS. 
 
2.9.4.2 Preparation of the control calibration mixtures for MALDI-
MS 
 
Calibration mixtures were used in the study to calibrate the instrument for 
accurate mass measurements of the proteins. Every 4 spots of samples 
were calibrated according to one calibration spot in the middle.  
 
Two separate calibration mixtures were used. For proteins, protein 
calibration mix 2 (Laser Bio Labs, Cedex France), which contained 
Cytochrome C (horse heart) m/z 12361.12, Myoglobin, (horse) m/z 
16181.06, Trypsinogen m/z 23981.98 and Insulin beta chain m/z 3494.65 
(5 µl of 5mM). In the analysis of tryptic peptide samples, peptide 
calibration mix 4 (Laser Bio Labs, Cedex France) was used. This mixture 
is based on monoisotopic masses and contains Bradykinin fragment 1-5 
m/z 573.31, Angiotensin ΙΙ m/z 1046.54, Neurotensin m/z 1672.91, ACTH 
clip (18-39) m/z 2465.19 and Insulin B-chain oxidized m/z 3494.65.  
 
To spot the calibration mixtures onto the MALDI plate, equal volumes of 
the appropriate calibration solution was mixed with the relevant matrix (10 
mg.ml-1 Sinapinic acid (SA) in 50% (w/v) Acetyl nitrate (ACN)  and 
50%(w/v) Trifluoroacetic acid (TFA) for protein and 10 mg.ml-1 α-cyano-4-
hydroxycinnamic acid (CHCA) in 50%(w/v) ACN/50/%(w/v) TFA for 
peptide calibration mix). Subsequently, 1 µl of this solution was spotted 
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manually on the plate in the middle of every 4 sample spots. The 
calibration mixture was made-up fresh, spotted on the plate and dried 
overnight at room temperature prior to MALDI-MS analysis. 
 
2.9.4.3  MALDI-MS set-up and analysis 
The samples were analyzed using Axima CFR+ MALDI-TOF mass 
spectrometer (Shimadzu, Manchester UK) operated in linear mode for 
protein analysis with a mass range of 1000-20000 Da and reflectron mode 
for peptides analysis with a mass range of 800-3500 Da. The instrument 
was externally calibrated using a standard mixture of proteins or peptides 
in which 1 calibration spot was allocated for every 4 sample spots. Mass 
spectra acquisition was performed using autoquality mode for the 
peptides. 
Cell samples (lysed) diluted in
0.1%TFA to a final concentration
of 0.1mg ml or 0.5mg ml
of protein
C18 zip tip spotted on MALDI plate 
with SA and run in linear mode
(PROTEINS)
Tryptically digest sample and 
C18 zip tip spotted on MALDI plate 
with CHCA and run in reflectron
mode
(PEPTIDES)
BIOINFORMATICS
 
Figure 2.08: Summary workflow for cell sample processing and analysis using Xcise 
sample processor and MALDI-MS for mass analysis.   
 
 
2.9.4.4  Identification using MALDI MS-MS 
 
The original samples containing the ions of interest were manually zip-
tipped using a C18 column. The column was conditioned twice with 200 µl 
of 80% ACN and 200 µl of 0.1% TFA. The sample was then bound to the 
column at 1mg/ml and eluted off with increasing concentrations of ACN 
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diluted in 0.1% TFA. Concentrations used for elution were 5%, 10%, 20%, 
30%, 35%, 40%, 43%, 45%, 48%, 50%, 60%, 70%, 80% and 90% of 
ACN. Each of the eluted samples were analysed by MALDI MS- MS. 
 
 
2.9.5        Bioinformatics analysis 
 
The spectra obtained from the samples were visually checked and the 
m/z values for the peptides from 800 to 3500 Da were used. The 
approved spectra were imported to a format called ASCCI files and the 
data was smoothed and merged to reduce the dimensionality using 
SpecAlign software which is available online. The data was also baseline 
corrected to remove any background noise from the spectra. Using an in-
house programme designed by Nottingham Trent University, the data was 
investigated using stepwise analysis. This determines minimum inputs for 
correct classification of data and provides ion interaction.  
MALDI-MS data
Using in-house 
programme, 
stepwise analysis 
was carried 
out
Baseline 
correction
Smoothing
Merging
Exporting peaks 
from MALDI data
as ASCCI files
 
Figure 2.09: Summary workflow of Bioinformatics analysis   
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2.9.5.1 ANN analysis – step wise approach 
The inputs into the ANNs consisted of 23001 variables specifying the 
intensity at given binned m/z values for every sample analysed by MALDI. 
The samples were split into training (60%), test (20%) and validation or 
blind (20%) data sets. The ANNs were trained using the training set and 
the network error with regards to the predictive performance was 
monitored with the test data set, which was unseen during training. Once 
this error failed to improve for a pre-determined number of training events 
(epochs), training was terminated and the model validated on the blind 
data set. A linear regression output function was used to map the output 
variables, where the sum-squared error function was used. The training 
was performed using a back-propagation (BP) algorithm until the error no 
longer improved for 10,000 epochs, followed by a conjugate gradient 
descent (CGD) algorithm for 3000 epochs at a learning rate of 0.1 and a 
momentum of 0.5. Once this error failed to improve for a pre-determined 
number of training events, training was terminated and the model 
validated on the blind data set. This process was repeated 50 times so 
that each sample was treated as truly blind a number of times, enabling 
confidence intervals to be calculated for the network predictions on blind 
data. The inputs were ranked in ascending order based on the mean 
squared error values for the test data and the input which was performed 
with the lowest error was selected for inclusion into the subsequent step. 
Next, each of the remaining inputs were then sequentially added to the 
previous best input, creating n-1 models each containing two inputs. 
Training was repeated and performance evaluated. The model which 
showed the best capabilities to model the data was then selected and the 
process repeated, creating n-2 models each containing three inputs. This 
continued until no significant improvement was gained from the addition 
of further inputs resulting in a final model containing the proteomic pattern 
which most accurately predicted between the two outcomes. 
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Chapter 3: A novel bioluminescent assay for necrotic cell 
death 
 
 
3.1 Introduction 
 
There are several assays currently employed that can potentially be used 
for prediction of patient responses to single agent and combination 
cancer therapy. Current treatment recommendations depend on carefully 
designed clinical studies in large patient populations and provide an 
individual patient with a probability for response based on clinically 
observed response rates. Complete remission does not mean that cancer 
cells are totally eradicated from the body but that their level is beyond the 
sensitivity of the assays used to detect them (Cree, 1998; Dawson and 
Whitfield, 1996; Kurth, 1997).  These assays measure cell death in two 
different ways. There are those which are based on the detection of 
viable cells left in a population, the assumption being that any remaining 
cells have died, which may not be the case in all instances. ATP, MTS 
and resazurin measurements in figure 3.11 reveal detection only in viable 
cells, and in the early stages of apoptosis. Alternatively, there are assays 
which are based on the detection of enzymes ‘leaked’ from cells or the 
ability of dyes to pass into cells when the cell membrane has been 
compromised (necrotic). LDH release is illustrated in figure 3.01 with 
detection only seen when the cell is permeabilised. The latter, are true 
assays of cell death as once the cell membrane is permeabilised the cell 
cannot recover.  
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Figure 3.01: To show how the mechanisms of cell death can be determined by 
measuring different markers of cell viability and apoptosis in vitro.  
 
 
The assays commonly used are the necrotic endpoint measurements of 
cell death including chromium-51 release (Bachy et al., 1999); Propidium 
Iodide uptake by cells (Ormerod, 1998); or measurement of lactate 
dehydrogenase (LDH) release from cells (Korzeniewski and Callwaert, 
1983; Decker and Lohmann-Mathes 1988; Sasaki et al., 1992). 
Alternatively, the assays which are based on the detection of viable cells 
left in a population include the fluorometric assay known as Alamar Blue 
(or resazurin); the colorimetric assays, WST-1, XTT and MTS (Petty et 
al., 1995; Marshall et al., 1995) and the bioluminescent measurement of 
ATP (table 3.01).  
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There are many cytotoxicity assays but the principle techniques are listed 
below in table 3.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.01: To illustrate the fundamental cytotoxicity assays. 
 
There are several drawbacks to these assays. Chromium-51 (Cr51) 
involves the labeling of the target cells with radioactive material which is 
released upon the lysis of the cell and the resultant radioactivity 
measured. Apart from the major disadvantages associated with the 
handling of radioactive elements (Bachy et al., 1999), it also assumes that 
there has been 100% efficient loading of the target cells with the label. In 
addition, there is a great deal of spontaneous chromium51 release by 
cells, whether alive or dead, occasionally exceeding 50% over a three 
hour period. Thus, it is difficult to determine with precision how much 
chromium release is due to the drug and how much is caused by damage 
to tumor cells as opposed to non-tumor cells. Finally, because of the rapid 
spontaneous release, the duration of the assay is constrained to a period 
of only several hours. This means that long incubations with a cytotoxic 
drug is more problematic and when carrying out cell mediated cytotoxicity 
assays with target and effector cells large concentrations of the immune 
effectors is a necessity for a quick kill. 
 
Viability Assays Necrotic Assays 
Alamar Blue Chromium51 
WST-1 Propidium Iodide 
XTT LDH 
MTS  
ATP  
                                                                                                                             Chapter 3 
 
 
Susan Catherine Gill 
PhD Thesis, 2009 
96 
Flow cytometry is the conventional method for measuring cell death 
(Omerod, 1998). Propidium Iodide (P.I), a fluorochrome that fluoresces 
red when it binds to DNA or double-stranded RNA, can be used to 
measure percentage apoptosis in fixed cells and cell viability and 
membrane permeability on unfixed cells. The size, granularity and 
fluorescent properties of a cell can be investigated by the analysis of their 
forward scatter (FSC-H) indicating cell size, side scatter (SSC-H) showing 
granularity of the cell and green (FL-1) and red fluorescent (FL-2) 
markers after staining with either one or two fluorometric dyes (Ormerod, 
1998; Becton Dickinson, 1997). 
 
Flow cytometry technology has been used to measure many of the 
processes during apoptosis and necrosis as it measures cells on a per 
cell basis (Ormerod, 1998). The cells of interest can be further analysed 
by the use of cell analysing technology using, for example the 
FACScaliber. Many of the proteins involved in apoptosis, such as the anti 
apoptotic protein Bcl-2 (Steck et al., 1996), have been detected and 
quantified. The correlation between the expression of Bcl-2 to Bax has 
also been successfully investigated where peripheral blood lymphocytes 
from a chronic lymphocytic leukaemia patient were stained with 
antibodies to Bcl-2, Bax and the general B-cell marker CD19. This data 
showed the tumour cells to have higher expression of the anti apoptotic 
protein Bcl-2 (Ormerod et al., 1998). In addition, lactate dehydrogenase 
(LDH) release is commonly used as a marker for necrotic cell death 
(Valentovic and Ball, 1998; Lash et al., 1995). Most cells contain LDH and 
when these cells are lethally injured, loss of membrane integrity can be 
assessed by monitoring activity of LDH in the incubation medium.  It is 
measured by an enzymatic assay that results in the conversion of 
resazurin into resorufin and can be measured on a fluorometer. This LDH 
reaction is illustrated in figure 3.02 below: 
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Figure 3.02: A schematic diagram to show the LDH reaction 
 
The addition of LDH assay reagent directly to cells in culture eliminates 
the need to transfer an aliquot of medium to a separate plate. The 
simplified procedure reduces errors introduced by multiple pipetting steps 
and conserves the time and expense of an extra assay plate. LDH 
(140kD) is relatively stable in culture medium once it is released from 
cells with compromised membranes. However, its half-life is still only 9-10 
h, making the interpretation of data over a prolonged period difficult when 
measuring precise quantitative measurements of cytotoxicity.  In addition 
to measuring cell death, it is also possible to measure total cell numbers 
of a cell population. The procedure requires the addition of a lysis solution 
to rupture the cell membranes, followed by measuring the total amount of 
LDH present: 
 
 
% Cytotoxicity = Experimental LDH (OD490) – Background values (OD490) 
                         Maximum LDH release (OD490) + Background values (OD490) 
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Another disadvantage of the LDH assay is that culture media 
supplemented with pyruvate will slow the rate of appearance of the 
fluorescent signal because it slows the conversion of lactate to pyruvate 
by LDH. An assay containing pyruvate may require up to 30 min 
incubation to reach its optimal signal compared to the normal 10 min.  
 
As illustrated in table 3.02 below, the amount of cell killing over a given 
period of time can be determined using dyes that are reduced or oxidised 
by the electron transport chain. These assays are measured by 
evaluating the remaining viable cells in a population after their exposure 
to these dyes. AlamarBlue® is a proven cell viability indicator that uses 
the natural reducing power of living cells to convert resazurin to the 
fluorescent molecule, resorufin. The active ingredient of alamarBlue® 
(resazurin) is a nontoxic, cell permeable compound that is blue in colour 
and virtually non-fluorescent.  Upon entering cells, resazurin is reduced to 
resorufin, which produces very bright red fluorescence. Viable cells 
continuously convert resazurin to resorufin, thereby generating a 
quantitative measure of viability and cytotoxicity.  
 
 
 
 
Table 3.02: Oxidation reduction potentials in the electron transport system and 
alamarBlue®. The midpoint redox potential (Eo’) values determined at pH 7.0, at 25°C. 
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The alamarBlue® indicator is ideally set up to detect oxidation by the 
whole of the electron transport chain. As can be seen from table 3.02, the 
midpoint potential of alamarBlue® is greater than that of any of the other 
components of the electron transport chain. alamarBlue® will be reduced 
by FMNH2, FADH2, NADH, NADPH and cytochromes, since their 
midpoint potentials are lower than that for alamarBlue®. Therefore, 
alamarBlue® is an excellent detector of reduction of all the elements of 
the electron transport chain (chapter 1). Given that alamarBlue® has a 
midpoint potential greater than the midpoint potential of the cytochromes, 
it can detect oxidation by all the components of the electron transport 
chain and it does not interfere with any of the redox reactions of the 
electron transport chain. 
An alternative redox indicator is tetrazolium salt (MTT, MTS or WST-1). 
MTT has a midpoint potential of -110 mV (table 3.02), which enables MTT 
to be reduced by the electron donors FMNH2, FADH2, NADH and 
NADPH. However, since the midpoint potential of MTT is intermediate 
between that of the electron donors and cytochromes, MTT will not be 
reduced by cytochromes. Furthermore, if MTT is reduced by FMNH2, 
FADH2, NADH or NADPH and the electrons released by these donors 
will not be passed to the cytochromes as would normally happen in the 
electron transport chain. This shuts down the respiratory chain. These 
assays detect cell proliferation and cell viability in a cell population, based 
either on the red colour change resulting from cleavage of a tetrazolium 
salt by mitochondrial dehydrogenases in viable cells (Kawada et al., 
2002; Marshall et al., 1995) or the reduction of the Alamar Blue to 
produce a bright fluorescent red colour. As well as the above assays for 
measuring viability, measurement of ATP, using the luciferase-luciferin 
reaction, is an established method to assess chemotoxicity in cell lines 
and tumours and to determine tumour growth inhibition by cytotoxic 
agents. ATP is essential for all cells to carry out their specific activities 
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including programmed cell death, as it serves as the primary donor of free 
energy.  
Apoptosis is an energy driven process that requires ATP to carry out its 
specialized functions (Cree, 1998). Reports have indicated the 
requirement for ATP during Fas mediated apoptosis for active nuclear 
exchange of large molecules across the membrane (Yasuhara et al., 
1997) it has also been suggested that whilst programmed cell death 
requires ATP, it is not necessary during necrosis (Tsujimoto et al., 1997). 
Depletion in cellular ATP levels is therefore an accurate indicator of the 
viability of a cell, as all cells have an absolute requirement for ATP 
(Crouch et al., 1993).  
 
The acknowledgement in 1947 by McElroy that the luciferase reaction in 
the Firefly (Photinus pyralis) required ATP led to an extensive 
investigation into the use of bioluminescence as a measure of ATP within 
cells. It was not until the 1980’s however that bioluminescence became 
more widely used within laboratories. Up until this time only crude 
luciferase / luciferin reagents were available to the researcher; this, 
combined with the poor methods of extraction of ATP and the lack of 
commercially available luminometers, led to extensive analytical problems 
(Lundin, 1993) and halted progress within this field. The development of a 
purified luciferase with a stable light emission in the late 1970’s however 
led to bioluminescence becoming the most widely used method of 
measuring ATP due to its ease, reproducibility and sensitivity over other 
assays. 
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                                             Luciferase 
ATP + Luciferin + O2                        Oxyluciferin + AMP + Ppi + CO2 + Light 
 
                                                    Mg++ 
 
Figure 3.03:  The luciferase reaction resulting in conversion of ATP to light 
 
 
The basic luciferin-luciferase reaction involves the presence of ATP 
(released by a detergent which renders cells permeable), luciferin, 
luciferase and magnesium as illustrated in figure 3.03. If all the factors in 
the reaction mechanism are constant it can be deduced that the light 
emission is linearly related to the concentration of ATP present within the 
sample. The emitted light is then detected by a luminometer and 
expressed as the relative light units (RLUs). 
 
It became apparent from the literature that all of the assays referred to 
above have their limitations either in the sensitivity of their detection 
limits, in the actual assay procedure requiring specialist knowledge and 
making them unsuitable for all users or indeed by the fact they required 
certain assumptions to be made in advance. The aim of the current 
research was to produce a novel assay involving the measurement of the 
enzyme adenylate kinase (AK) by bioluminescence. It is a ubiquitous 
enzyme and is integral to cellular function, being found in a diverse 
number of organisms. It is present in both eukaryotes and prokaryotes 
and has a low molecular weight of 20-25 kDa. It is most abundant in the 
mitochondria of tissues such as liver and muscle in which there is 
considerable energy turnover (Squirrell and Murphy, 1997).  It catalyses 
the equilibrium reaction: 
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           AK 
Mg++ATP + AMP    Mg++ADP + ADP 
 
Figure 3.04:  The adenylate kinase reaction resulting in conversion of ADP to ATP 
 
 
Squirrell and Murphy (1995) proposed the use of the intracellular enzyme 
AK as a bacterial marker in place of ATP. They used ADP as the 
substrate to drive the reaction in the direction of ATP synthesis (figure 
3.04). In addition, Squirrell and Murphy showed that AK can act as an 
alternative to ATP as a cell marker for bacteria providing a 10-fold 
increase in detection of sensitivity. A micron-sized bacterial cell contains 
about 10-21 moles of AK compared to 10-18 moles of ATP, so there are 
approximately 1,000 molecules of ATP for every molecule of AK. The 
small size of the AK would suggest that it may offer advantages in early 
detection and assay sensitivity of cytolysis compared to the current 
available assays which detect the leakage of much larger enzymes e.g. 
LDH (140kD). The assay sensitivity and suitability would be compared 
against the currently used assays. 
 
The aim of the research in this chapter was to use AK as a cell marker 
with ATP bioluminescence as the end detection point for cytotoxicity. As 
AK was revealed to be a very promising marker in the paper by Squirrell 
and Murphy (1995) it was discovered that this enzyme could be used in 
conjunction with the luciferase assay that Lonza Bio Science had already 
designed for detecting ATP in cells and had good sensitivity. If this novel 
assay had the potential to be even more sensitive than ATP, then its 
potential use as a cytotoxicity assay could be enormous. Due to 
proprietary information the specifics of the assay work-up cannot be 
shown in this thesis but the experimental processes and assay 
performance is demonstrated with various known cell lines used by 
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pharmaceutical companies in drug discovery. An AK detection reagent 
(named ‘ToxiLight®’ in this thesis), would be designed so it could be 
added to a cell culture and allow for the detection of AK leakage from 
damaged cells. The ToxiLight® assay would be based on bioluminescent 
detection using the reaction shown in figure 3.05. The light emitted would 
then be detected by a luminometer or Beta Counter and expressed as 
relative light units (RLUs).  
 
           AK 
Mg++ATP + AMP    Mg++ADP + ADP 
 
 
 
 
Luciferase + O2 + ATP  oxyluciferin +AMP + Ppi + CO2 + LIGHT 
Figure 3.05: The adenylate kinase reaction resulting in conversion of ATP to light 
 
The sensitivity of the developed ToxiLight® reagent would be investigated 
using enzyme standards (AK; myokinase from chicken muscle) followed 
by its suitability in cell-based assays. These cell models are standard 
cytotoxicity models used by Lonza Bio Science and the cells are those 
used by many drug discovery companies. The comparison of this novel 
bioluminescent measurement of cell death to currently used 
methodologies will be investigated and the sensitivity and informative 
value of all of these assays assessed.  
 
Therefore the initial aims of my research would be to: 
 
• Develop and optimise the assay. 
• Miniaturize the assay for high throughput screening. 
• Compare its suitability for use in cytotoxicity screening. 
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3.2 Results 
 
3.2.1 Formulation and Measurement of AK  
 
 
Initial experiments were carried out to determine the optimal 
concentrations of ADP, magnesium, luciferase and luciferin in the AK 
Detection Reagent using myokinase standards (as demonstrated in figure 
3.06). Initial experiments did not show a good linear response and the 
reagent had to be optimised by altering the concentrations of both ADP 
and magnesium substrates.  Eventually it was discovered that the ADP 
was causing the stability problems due to contamination of ATP within it. 
The ADP therefore had to be purified and then re-analysed within the 
reagent. In addition, the AK assay buffer had to be optimised and tested 
using various buffers until a stable signal was produced. This work was 
carried out over an 18 month period using both myokinase standards and 
cells. The assay was later optimised further to obtain improved signal 
stability by altering the AK assay buffer. The results in this chapter show 
the optimised reagent named ToxiLight® after formulation (which cannot 
be shown due to company confidentiality).  
 
The linearity of the ToxiLight® assay was verified by performing AK 
standard curves using the enzyme ‘myokinase’, a pure AK isolated from 
chicken muscle from a starting concentration of 25 µmole-1ml-1. The 
standards were serially diluted 1:1 in distilled water and plated into a 96 
well white luminometer plate in 100 µl aliquots in at least triplicates. The 
plate was measured using a Berthold MPL3 Luminometer, following 5 min 
of incubation at room temperature. The results from the serial dilutions 
(figure 3.06) show a linear detection response (R2=0.999). As the 
concentration of myokinase standard increased, the amount of AK 
measured by the assay also increased (shown by an increase in Relative 
Light Units (RLUs) detected).  
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Figure 3.06:  Myokinase standard (chicken muscle) was serially diluted 1:1 from 25 
µmole-1ml-1, in dH20. A 100 µl volume of detection reagent was then added to a 20 µl 
sample of myokinase and the sensitivity observed. The resulting RLUs were measured 
using bioluminescence on an MPL-2 luminometer to obtain an ATP/RLU +/- the standard 
error of the mean (n=7). 
 
N = number of experiments 
 
3.2.2 Measuring AK within cells 
 
As the ToxiLight® assay had shown excellent sensitivity with myokinase 
standards, the assay testing was extended to its use with cell lines and 
also to assess if sensitivity could be affected by different volumes of a test 
sample. Experiments were conducted using known cytotoxicity models 
routinely used by Lonza BioScience, Nottingham. The main cell lines 
used are revealed in table 3.03. 
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Table 3.03: Cell lines tested for assay optimisation. 
 
Cells were either dosed with the topoisomerase I inhibitor, camptothecin 
or with the alkylating agent mitomycin-C. Suspension cells were seeded 
at 5 x 105 cells.ml-1 whereas adherent cells had an initial cell density of 1 
x 105 cells.ml-1. Various concentrations of the drugs were added to the 
cells (See Chapter 2 for details) and after incubation for the required 
period the culture medium was sampled and measured for the release of 
the enzyme AK. For the initial testing on cell lines, U937 cells were used 
and dosed with camptothecin over a 20-h incubation period. U937 cells 
are small and therefore contain less AK than other cells. If AK can be 
detected in these cells then the assay sensitivity in other cells would be 
very good. After incubation a 100 μl volume sample of the cell culture 
medium was transferred into a 96 well luminometer plate. In conjunction 
with this a 20 μl sample was transferred into a 384 well plate to assess 
potential miniaturization.     
 
 
Suspension cell lines Adherent cell lines 
Human Histiocytic Lymophoma, 
U937 
Human breast cancer cell line FM-3 
Human acute T-Lymphoblastic 
leukaemic, Jurkat 
Human Hepatocyte Carcinoma cells 
HepG2 
Human Chronic Myeloid Leukaemic, 
K562 
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Figure 3.07:  U937 cells dosed with camptothecin and incubated for 20 h. Samples of the culture 
supernatant containing cells were removed into fresh luminometer plates and were measured 
using the ToxiLight® assay on the TECAN ULTRA luminometer.  The y-axis on the left represents 
the RLUs for the 100 µl samples whereas the y-axis on the right hand side has the 20 µl samples. 
ATP/RLU +/- the standard error of the mean (n=4) 
 
Correlation between 96 and 384 well plate: R2 = 0.9963  
N = number of experiments 
 
Figure 3.07 shows a concentration dependent effect with a rise in the 
RLUs with increasing dosage of the drug. This means the RLUs 
generated denotes leakage of the enzyme AK from drug induced 
damaged cells showing the validity of this assay to detect necrotic cell 
death. In addition, these results revealed that the reaction had the 
potential for miniaturization. The correlation between the 96 and 384 well 
plate was >0.99. The 20 μl sample volumes in the 384 wells (shown on 
the right hand axis) produced less light than the 100 μl culture volumes 
(shown on the left axis) in the 96 well plates but this was predicted. The 
difference seen is due to the ratio of AK present in the samples tested. 
There is more AK present to turn over the reaction in the 100 µl sample 
than the 20 µl sample; hence you see a higher level of RLUs.  
 
 
                                                                                                                             Chapter 3 
 
 
Susan Catherine Gill 
PhD Thesis, 2009 
108 
3.2.3 Effect of measuring the ToxiLight® assay with / without cells 
present in the test sample. 
 
The addition of the ToxiLight® assay reagent directly to cells grown in 
culture plates would eliminate the need to transfer an aliquot of medium 
to a separate plate. This simplified procedure reduces errors introduced 
by multiple pipetting steps and saves the time and expense of an extra 
assay plate. However, some cells are naturally suspended in the media 
and would be present in the assay wells tested as in figure 3.07. Does the 
presence of these cells affect the results of the assay or would the media 
have to be spun down to eradicate these cells? K562 cells were the 
chosen cell lines in this experiment due to their large size and therefore 
large quantities of intracellular AK. If the presence of viable cells in media 
did have an affect on the background levels of the assay, it would be 
seen in K562 cells.  
 
To determine whether the presence of cells did have an adverse effect on 
any results obtained in figure 3.07, K562 cells were seeded at 5 x 105 
cells.ml-1 and spun down to eradicate any cells present in the media 
(chapter 2.6 for methodology).The results were compared to samples 
from another tube treated in the same manner i.e. were spun down and 
then the cells re suspended back into the media, to ensure that spinning 
down the cells had no effect, on producing a false result. Both of these 
tubes were sampled in 100 µl volumes in triplicate. The results in figure 
3.08 show no significant difference in the RLUs when measuring the 
ToxiLight® assay with or without cells present in the test sample.  
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Figure 3.08: K562 cells sampled both with and without cells present in the media. 100µl samples 
were tested in triplicate using the ToxiLight® assay on the MPL-2 luminometer. The data is 
expressed as RLUs +/- the SEM (n=5).  
 
N= number of experiments 
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3.2.4 Suitability of the ToxiLight® assay compared to           
traditional assays 
  
There is no gold standard assay used in pharmaceutical companies for 
drug screening but assays that are chosen have to be suitable for high 
through-put (HTS) use. Pharmaceutical companies test thousands of 
potential drug therapies on a weekly basis and cannot therefore use 
assays that are time-consuming, inefficient and lack sensitivity. At the 
moment for cell-based HTS, the lactate dehydrogenase (LDH) assay is 
one of the most widely used in monitoring cytotoxicity. 
 
3.2.4.1 Measuring LDH release from necrotic cells 
 
Traditionally LDH, an enzyme leaked from dying cells when their cell 
membrane loses its integrity has been used as a measure of necrotic cell 
death. The enzyme can be detected by either a colorimetric or fluorescent 
detection mechanism requiring either a spectrophotometer or a 
fluorimeter. As ToxiLight® also detects an enzyme released from dying 
cells (AK), but by means of bioluminescence, it was considered important 
to assess this new methodology against the measurement of LDH 
release. Both adherent and suspension cell models were tested in both 
methods to compare and contrast the results obtained.  
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LDH:   EC50 = 196 nM   ToxiLight: EC50 = 179 nM 
 
 
Figure 3.09:  Jurkat cells in suspension were dosed for 48 h with the topoisomerase I inhibitor, 
camptothecin. The release of AK from the cell due to cytolysis was measured using the ToxiLight® 
assay on the MPL-2 luminometer. The data is expressed as RLUs +/- the SEM (n=4). It is directly 
compared to the LDH assay, data expressed as FLUs +/- the SEM (n=4) measured using the 
Victor 2 fluorometer. 
 
N = number of experiments 
 
Figure 3.09 illustrates four cytotoxicity experiments (n=4) using Jurkat 
cells dosed with camptothecin. Jurkat cells were chosen due to their small 
size like U937 cells. They are small cells in comparison to many used and 
are known to be problematic with the LDH assay. This model would 
reveal whether or not the assays could detect small releases of cellular 
enzyme after drug treatment and was deemed as a good test for the 
ToxiLight® assay. The results in figure 3.09 revealed that the signal to 
noise ratio was better in the ToxiLight® assay with a background of 3000 
RLUs and the sensitivity levels showed detection of AK release down to 
the lowest 50 nM drug dosage. This was a promising result when 
compared to the LDH assay which had a background level of 160,000 
FLUs and did not appear to indicate any cytolysis in the cells at 50 nM. 
LDH EC50 
AK EC50 
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This improved sensitivity of the ToxiLight® assay would prove to play an 
important role in measuring the EC50 of the drug. As can be seen in figure 
3.09, the EC50 of camptothecin was shown to be only 179 nM with the 
ToxiLight® assay but 196 nM when measuring LDH release due to the 
lack of detecting cell death in small numbers of cells within the population. 
The EC50 is defined as the concentration of cytotoxic agent that provokes 
a response halfway between the baseline (bottom) and maximum 
response (top). The EC50 in the LDH assay was therefore misleading and 
inaccurate. Further experiments were carried out on adherent cells to 
back up this data and to ensure the ToxiLight® assay was still as 
sensitive with these cells. Hep G2 cells were chosen due to their frequent 
use in biotechnology and pharmaceutical companies. As revealed by 
figures 3.09 and 3.10, the results shown were reproducible. 
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
0 500 1000 2000 5000
CAM [nM]
R
LU
s
0
10000
20000
30000
40000
50000
60000
FL
U
s
ToxiLight
LDH
 
 
LDH:   EC50 = 1865nM   ToxiLight: EC50 = 1610nM 
 
 
Figure 3.10: HepG2 cells were dosed for 48 h with the topoisomerase I inhibitor, camptothecin. 
The release of AK from the cell due to cytolysis was measured using the ToxiLight® assay on the 
MPL-2 luminometer. The data is expressed as RLUs +/- the SEM (n=4). It is directly compared to 
the LDH assay, data expressed as FLUs +/- the SEM (n=4) measured using the Victor 2 
fluorometer.  Correlation between ToxiLight® and LDH: R2 = 0.99 
 
N = number of experiments 
AK EC50 
LDH EC50 
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Figure 3.10 illustrates the results obtained with adherent Hep G2 cells 
dosed with camptothecin over a 48 h period assessed using ToxiLight® 
and the LDH assays. Results validate the correlation between the two 
assays which was shown to be 0.99. Yet again, the signal to noise ratio 
was better in the ToxiLight® assay with consistently lower background 
levels in each experiment (7,000 RLUs) compared to 18,000 FLUs). In 
addition, the ToxiLight® assay revealed a larger dynamic range between 
concentrations of drug. This was illustrated by the ToxiLight® RLUs which 
increased 5 times above the control, whereas the FLUs from the LDH 
assay were less than 3 times greater than the background levels. 
Additionally, as can be noted in figure 3.09, the EC50 of camptothecin was 
shown to be lower with the ToxiLight® assay than the LDH assay. It can 
also be observed from this data that the EC50 varied significantly between 
the suspension and adherent cell model. The adherent cells showed an 
immense increase in the EC50 of camptothecin when compared to 
suspension cells showing how the same drug can have different effects 
depending on the cells being tested. 
 
The sensitivity of the ToxiLight® assay was investigated further to 
determine how many necrotic cells could be detected. Human histiocytic 
lymphoma U937 cells were lysed by freeze-thaw fracture, and cell viability 
determined with trypan blue. After showing 100% necrosis, the cells were 
diluted down from 10,000 cells to only 5 cells with a media background. 
The samples were assessed using both ToxiLight® and the CytoTox 
OneTM Assay. 
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Figure 3.11: U937 cells were lysed by freeze-thaw fracture. The cells were then serially diluted 
1:2 and then analysed by both the LDH and ToxiLight® assays. The release of AK from the cell 
due to cytolysis was measured using the ToxiLight® assay on the Wallac Betajet luminometer. 
The data is expressed as RLUs +/- the SEM (n=4). It is directly compared to the LDH assay, data 
expressed as FLUs +/- the SEM (n=4) measured using the Victor 2 fluorometer. 
 
N = number of experiments 
 
 
Figure 3.11, illustrates the how the LDH assay could no longer detect any 
significant differences above background below 313 cells per well i.e. 
from 313 cells per well down to 5 cells per well the fluorescent reading 
remains constant. The ToxiLight® assay showed significant differences 
between each cell number down to 5 necrotic cells per well above the 
background level. The reported detection limit of LDH routinely is 500 
cells per well (Promega, 2004) but at best, detection was observed down 
to 50 cells per well in this research. The sensitivity of the ToxiLight® 
assay routinely observed was 10 cells per well; this would indicate that on 
average it is 50 times more sensitive than measuring LDH release.  
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3.2.4.2 Enzyme Stability 
 
As LDH and AK are released into cell culture media it was important to 
assess the stability of the released enzymes. The reported half life of LDH 
is approximately 9 h in culture (Promega, 2004). This would indicate that 
any LDH released from dead cells more than 9 h before the assay point 
will have been degraded to some extent. To assess the stability of 
released AK and LDH, the adherent HepG2 cells were dosed with 
camptothecin and monitored for the release of the enzymes over a period 
of 4 days.  
 
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
50000
0 100 500 2000
CAM [nM]
R
LU
s
day0
day1
day2
day3
day4
 
 
Figure 3.12: Hep G2 cells were dosed with the topoisomerase I inhibitor, camptothecin. 
The release of AK from the cell due to cytolysis was measured over 4 days using the 
ToxiLight® assay on the MPL-2 luminometer (n=1). The data is expressed as RLUs +/- 
the SD.   
 
N = number of experiments 
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Figure 3.13: Hep G2 cells were dosed with the topoisomerase I inhibitor, camptothecin. 
The release of LDH from the cell due to cytolysis was measured over 4 days using the 
CytoTox OneTM assay on the Victor 2 fluorometer, data expressed as FLUs +/- the SD 
(n=1). 
 
N = number of experiments 
 
Figure 3.12, shows AK release over 4 days. 100 µl volumes were 
sampled in triplicate to assess the enzyme stability. As observed from the 
results, a good concentration dependent effect can be seen with an 
increase in AK release as the dose of camptothecin becomes more 
concentrated. Over the 4 day period the AK continued to increase 
insinuating that no AK had been degraded in the culture media which was 
still being measured effectively. These results proved AK to be very 
stable in culture with no drop in concentration observed at any of the data 
points. This was promising for experiments where prolonged exposure to 
drugs would be required. In comparison figure 3.13 represents the 
release of LDH. As seen with the ToxiLight® assay there was a good 
concentration dependent increase in FLUs as the drug concentration 
increased within each experiment on days 1 to 3. As in previous 
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experiments the 100 nM drug concentration did not detect any cell death 
above background on day 1 unlike the ToxiLight® assay. By day 2 and 3, 
there was a significant difference between all concentrations of drug both 
within each experiment and over the 2 days. However, a drop in FLUs 
was noted by day 3 in the higher concentration of drug (2000 nM) when 
compared back to the previous day. This could be due to degradation. By 
day 4, the results become non-interpretable with a fluctuation in FLUs in 
all concentrations when compared to the control cells. These control cells 
were also shown to have become necrotic by day 4 due to a lack of space 
and nutrients to grow. This meant the experiment could not be monitored 
for more than 4 days.  
 
 
3.2.4.3 Measuring Propidium Iodide uptake by necrotic cells 
 
As Propidium Iodide or P.I. uptake is a recognised method for observing 
the state of cells the efficiency of the ToxiLight® assay could only be 
verified by comparison with this methodology. Visualization of the cells 
can be carried out by P.I. on a FACScan machine, thereby obtaining 
percentages of viable and necrotic cells.  Jurkat cells were lysed through 
freeze-thaw fracture, checked by trypan blue uptake for necrosis and 
mixed with a healthy population of Jurkat cells to make 100%, 90%, 80%, 
60%, 50%, 30%, 10% and 0% necrotic mixtures. These cells were then 
sampled in both 100 µl and 20 µl volumes for the ToxiLight® assay and 
P.I. uptake was measured in correlation on a FACScan machine.  
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Figure 3.14: Jurkat cells were lysed by freeze-thaw fracture and mixed with various 
percentages of healthy cells. The release of AK due to cytolysis from 100 µl and 20 µl 
sample volumes were taken and measured using the ToxiLight® assay on the MPL-2 
luminometer. The data is expressed as RLUs +/- the SEM (n=4). It is directly compared 
to the Propidium Iodide assay where % P.I. uptake was obtained from the FACScan 
machine. 
 
Correlation between 100 µl sample (ToxiLight®) and P.I. Staining: R2 = 0.92 
Correlation between 20 µl sample (ToxiLight®) and P.I. Staining: R2 = 0.92 
 
 
As can be seen in figure 3.14, the uptake of P.I. by FACScan analysis 
showed a close correlation with ToxiLight® (R2 = 0.92). 20 μl and 100 μl 
volumes of culture medium were sampled for the ToxiLight® showing 
identical changes in RLUs as the AK levels increased and the percentage 
of freeze-thaw cells increased. The RLUs were slightly lower when 
measuring the 20 μl sample as expected due to less AK being presented 
to the assay in the well.  
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3.2.4.4 Measuring Chromium-51 release from necrotic cells 
 
Historically the “gold standard” for cell mediated cytotoxicity studies has 
been the chromium51 release assay. It was thought it may be possible to 
utilise the ToxiLight® assay for cell-mediated cytotoxicity assays. As 
there were no radioactive laboratories available at ;Lonza Bio Science, 
the assay was carried out in conjunction with a PhD student Murriam 
Ahmad at Nottingham Trent University. The project was looking at 
immune-mediated cytotoxicity and resulted in incorporating the 
experiments in monitoring Toxilight® assay. Target cells are prelabelled 
with Cr51 which is released for detection when the cells are induced to 
lyse by effector cells. In collaboration with Nottingham Trent University, 
splenocytes were harvested from a mouse immunized against CT26, 
washed twice in serum-free medium, counted and resuspended in CTL 
medium and used as effector cells. Target cells used were the 
CT26+SPS (relevant peptide for kill) and CT26 TPH (irrelevant peptide for 
kill). SPS is a known murine leukaemic virus gp70-derived H2-Ld 
restricted peptide AH-1 (SPSYVYHQF). It is an immunodominant peptide 
for CT26 cells. TPH or TPHPARIGL is a control β-galactosidase H2-Ld 
peptide. (The chromium experiment was prepared in collaboration with Dr 
Murriam Ahmad, Nottingham Trent University). 
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Figure 3.15: The CT26 SPS pulsed CTLs were used as the effector cells in the assay. 
The targets were the CT26+ SPS (relevant peptide). The release of AK from the cell due 
to cytolysis was measured using the ToxiLight® assay on the MPL-2 luminometer. The 
data is expressed as percentage of cells lysed +/- the SEM. It is directly compared to the 
chromium release assay, data expressed as percentage lysed cells +/- the SEM and 
measured on a beta counter (n=3).  
 
N = number of experiments 
Correlation between ToxiLight® and chromium (SPS); R2 = 0.98 
 
Figure 3.15 compares the ToxiLight® assay with the well-established 
chromium51 assay. The results are plotted as percentage release of either 
chromium or AK into the culture. As seen in the figure 3.15, it was 
revealed that the ToxiLight® data correlated with the chromium very 
reliably with R2 values > 0.98 with the CT26 SPS. The TPH results also 
correlated showing little increase in RLUs and absorbance readings 
(Chromium) with the irrelevant peptide and thus meant no cell death 
occurred. 
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 3.2.4.5       Measuring Cell Viability  
 
Other well-known assays were tested to determine their sensitivity 
compared to the ToxiLight® assay. These included the MTS, WST-1, 
XTT and the alamarBlue® colorimetric assays. As these assays measure 
viability rather than cell death the ToxiLight® assay cannot be compared 
directly. All of these assays were tested for their sensitivity to observe 
how many viable cells could actually be measured. Jurkat cells were 
diluted 1:2 in complete media from 1 x 106 cells.ml-1 down to background 
levels.      
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Figure 3.16: Jurkat cells were diluted 1:2 in complete media from 1 x 106 cells.ml-1. The 
absorbance assays WST-1, XTT and MTS were measured on an ELISA plate reader at 
450nM wavelength to obtain absorbance values +/- the SEM where n=5.  
 
 
N = number of experiments 
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Figure 3.17: Jurkat cells were diluted 1:2 in complete media from 1 x 106cells.ml-1. The 
above figure represents only the lower values from 25,000 cells.mL-1 to background 
levels. The alamarBlue® assay was carried out and measured using the Victor 2 
fluorometer. The data is expressed as FLUs +/- the SEM (n=3).  
 
N = number of experiments 
 
 
The results in figure 3.16 revealed a lack of sensitivity for all of these 3 
assays. The MTS and WST-1 assays could not detect below 10,000 cells 
per well when compared against background levels. The XTT assay was 
slightly better but still only had sensitivity down to 5,000 cells per well. 
After this point, the assay was only reading background levels. These 
three methods would not therefore be suitable indicators of cytotoxicity, 
as many viable cancer cells would be left undetected. Figure 3.17 shows 
the results from the alamarBlue® assay which proved to be much better 
than the colorimetric assays. Although still not sensitive enough, detection 
was much improved, measuring down to 3000 cells per well.  
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As the alamarBlue® assay proved to be the best of these viability assays, 
it was tested in a mixed cell population with a mixture of both necrotic and 
viable cells. Jurkat cells (at 10,000 cells/well) were lysed through freeze-
thaw fracture, checked by trypan blue uptake for necrosis and mixed with 
a healthy population of Jurkat cells to make 100%, 90%, 80%, 60%, 50%, 
30%, 10% and 0% necrotic mixtures. The alamarBlue® assay was 
monitored for its detection of viable cells and the ToxiLight® assay tested 
in comparison for detecting cell death.  
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Figure 3.18: Jurkat cells were lysed by freeze-thaw fracture and mixed with various 
percentages of healthy cells. The release of AK due to cytolysis from different sample 
volumes were taken and measured using the ToxiLight® assay on the MPL-2 
luminometer. The data is expressed as RLUs +/- the SEM (n=4). It is directly compared 
to the alamarBlue® assay where viable cells were measured using the Victor 2 
fluorometer. The data is expressed as FLUs +/- the SEM (n=4). 
 
N = number of experiments 
 
As the results in figure 3.18 reveal, the alamarBlue® assay proved to 
detect 40% of the viable cells (or 60% F/T on the graph) in the mixed cell 
population. As the number of viable cells had decreased considerably by 
this point this assay could no longer detect anymore in the 80 and 90% 
F/T population.  The assay therefore proved it could detect cell death but 
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only down to a limited number of cells, which would result in these viable 
cells being left undetected. 
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3.2.4.6     Measuring ATP as a Viability Cell Marker 
 
In this study, the ViaLight® Plus kit was used by adding a Nucleotide 
Releasing Reagent (NRR). NRR contains a non ionic detergent that 
permeabilises the cell membrane and allows for the release of the 
nucleotides within the cells. The cells used in this investigation were a 
human leukaemic cell line K562 (in suspension) diluted 1:2 from a 
seeding density of 5 x 103 cells.ml-1 in complete media (CM). The amount 
of ATP was then measured using the ViaLight® Plus kit in the following 
luciferin: luciferase reaction: 
 
                                      Mg++ 
       ATP + Luciferin + O2      Oxyluciferin + AMP + PPi + CO2 + LIGHT 
                                Luciferase 
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Figure 3.19: K562 cells were lysed with detergent and serially diluted 1:2 in complete 
medium. The release of AK from the cell due to cytolysis was measured using the 
ToxiLight® assay on the Wallac Betajet luminometer. The data is expressed as RLUs +/- 
the SEM (n=3). It is directly compared to the ViaLight® Plus assay on the Wallac Betajet 
luminometer, data expressed as RLUs +/- the SEM (n=3). 
 
N = number of experiments 
Correlation between ViaLight® and ToxiLight®: R2 = 0.96 
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Results from the ViaLight® Plus assay, showed an excellent correlation 
with the ToxiLight® assay >0.96 (figure 3.19). K562 cells were diluted 
down from 5,000 to 5 cells per well. The ViaLight® assay showed 
sensitivity down to 10 cells per well (60 RLUs above background). The 
ToxiLight® assay detected 5 cells per well (120 RLUs above background 
levels). These results proved the ViaLight® Plus assay to be the best 
viable assay with the extreme sensitivity required for chemotoxicity 
studies.  
 
After carrying out experiments comparing the ToxiLight® assay with 
available assays on the market, the results were encouraging. The 
ToxiLight® assay was able to directly compete with all other assays and 
had the ability to be more sensitive than any assay currently used; the 
only method giving comparable results was the ViaLight® Plus assay. In 
addition to measuring cell death, the reagents needed optimising to 
measure total cell numbers of a cell population. This would require the 
production of a lysis reagent that would be compatible with the ToxiLight® 
assay, measuring the total amount of AK present. 
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3.2.5   Optimisation of ToxiLight® assay 
 
To complete the optimisation of the ToxiLight® assay it was necessary to 
obtain a control (100%) lysis solution that all values could be referenced 
to in order to express them as percentage cytolysis. The formulation of 
this reagent is proprietary information and therefore not shown in the 
chapter. The effect of the newly designed lysis buffer was tested on cells 
and compared to a control population of cells that had been lysed by 
freeze thaw.  The human chronic myeloid leukaemic K562 cells were 
lysed and checked by trypan blue uptake for viability.  A volume 
correction reagent was added to the freeze-thaw samples to ensure the 
volumes were the same in both test wells. 
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Figure 3.20: K562 cells were lysed through ‘freeze-thaw fracture’ (F/T) or ‘ToxiLight® 
Lysis Reagent.’ The release of AK from the cell due to cytolysis was measured using the 
ToxiLight® assay on the MPL-2 luminometer. The data is expressed as RLUs +/- the 
SEM (n=7). 
 
N = number of experiments 
Correlation between F/T and 100% lysis control (ToxiLight®): R2 = 0.99 
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As figure 3.20 demonstrated, the ToxiLight® Lysis Reagent was able to 
successfully lyse the cells. In addition to this, it proved to match the 
results seen in the freeze-thaw cell population representing in 100% lysis 
of the cells. The correlation was shown to be > 0.99. The lysis reagent 
was tested on all in-house cell lines at Lonza Bio Science using both 
adherent and suspension cells and trialed at a separate site prior to 
launch. No cell line has yet to be found to be incompatible. The testing of 
all cell lines used in this project, the results all showed >0.99 correlation 
with the freeze-thaw control. To illustrate its use, the lysis reagent was to 
be tested in a cell model whereby U937 cells were dosed with 
camptothecin. Prior to measurement, a control well was lysed with the 
ToxiLight® Lysis Reagent and to back-up the data, a second control 
sample was freeze-thawed.  
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Figure 3.21: U937 cells dosed for 24 h with the topoisomerase I inhibitor, camptothecin. 
The release of AK from the cell due to cytolysis was measured using the ToxiLight® 
assay on the MPL-2 luminometer. The data is expressed as RLUs +/- the SEM (n=4). 
The ToxiLight® lysis control is compared to F/T cells which were measured at the same 
time point. 
 
N = number of experiments 
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Figure 3.21 demonstrated how well the ToxiLight® Lysis Reagent worked 
and therefore could be used as a 100% control for measuring total 
populations of cells. The results were nearly identical to the freeze-thaw 
control. This meant that a drug can be tested on a cell population and its 
effectiveness can be recorded as ‘percentage kill’ of the cells.  
 
The ToxiLight® Lysis Reagent was finally compared to the LDH assay 
which also utilised a 100% control data point for total LDH release. A 
U937 and camptothecin model was incubated for 24 h before measuring 
using both the LDH and the ToxiLight® assay, including the appropriate 
lysis controls.  
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Figure 3.22: U937 were dosed for 24 h with the topoisomerase I inhibitor, camptothecin. 
The release of LDH from the cell due to cytolysis was measured using the LDH assay on 
the Victor 2 fluorometer, data expressed as percentage lysed cells. It is directly 
compared to the ToxiLight® assay on the MPL-2, data expressed as percentage lysed 
cells (n=3). 
 
N = number of experiments 
Correlation between ToxiLight® and LDH: R2 = 0.9 
 
 
                                                                                                                             Chapter 3 
 
 
Susan Catherine Gill 
PhD Thesis, 2009 
130 
The ToxiLight® assay proved to be a good competitor for the LDH assay 
in measuring the percentage of cell death. The results correlated 
exceptionally well with an R2 value of 0.9. Figure 3.22 also showed the 
ToxiLight® assay to have a greater dynamic range than the LDH assay. 
This was seen in the percentage lysis which increased from 6% (control 
population) up to 48% necrosis with 10,000 nM camptothecin in the 
ToxiLight® assay. The LDH assay showed 28% necrosis in the control to 
60% necrosis at 10,000 nM. The control was high in the LDH assay 
making the results questionable. Both trypan blue and propidium iodide 
staining showed the control cells to be no more than 12% necrotic. 
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3.2.6       Response of ToxiLight® and ViaLight® Plus Assay to   
                     Cytostatic cells 
 
As the ToxiLight® assay measures only necrotic cells; it was decided to 
establish a model that would result in growth arrest from previous work 
carried out at Lonza Bio Science. Melanoma cells were seeded at 1 x 105 
cells.ml-1 and dosed with the alkylating agent dacarbazine. As the 
ViaLight® Plus proved to be the most sensitive viable assay tested, this 
was to be used in conjunction with the ToxiLight® assay. 
 
 
 
  
 
 
Figure 3.23: Ma Mel 28 cells were dosed for 72 h with the alkylating agent dacarbazine. 
The release of AK from the cell due to cytolysis was measured using the ToxiLight® 
assay on the MPL-2 luminometer, data expressed as RLUs +/- the SEM (n=4). It is 
directly compared to the ViaLight® Plus assay on the MPL-2 luminometer, data 
expressed as RLUs +/- the SEM (n=4). 
 
N = number of experiments 
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The results in figure 3.23 show the ViaLight® Plus assay to measure a 
reduction in ATP levels with increased dacarbazine concentrations. This 
could imply that the cells are undergoing cell death. However, the 
ToxiLight® results revealed that no cell death was occurring. The 
ToxiLight® assay results alone would suggest that the drug was having 
no effect on the cells at all. The ViaLight® Plus assay results however 
revealed the opposite i.e. the drug ‘was’ having an affect on the cells and 
cell death was occurring. If the cells were not dying but then it became 
difficult to determine what a drop in ATP actually meant. After measuring 
these cells by a FACScan to assess the cells growth cycle, it was 
revealed that the cells were in fact in growth arrest.  
 
In conclusion, through the above work performed on these melanoma 
cells, it became clear that one assay alone was insufficient to divulge the 
effect any drug has on a cell population. The use of only one assay can 
be misleading; and ideally both a viable and necrotic assay should be 
used. 
 
 
Table 3.04:  Summary of the results drawn from the study. 
 
Table 3.04 summarises the use of the ToxiLight® and ViaLight® assays, 
and represents the best necrotic and viable assays established by this 
research. The table highlights the responsiveness of these assays when 
exposed to defined conditions and demonstrates the ideology of how two 
assays would work better in combination than one assay alone. 
RLUs remain 
 constant 
RLUs remain  
constant 
RLUs 
Increase 
RLUs 
Increase 
 
RLUs 
Decrease 
RLUs 
Decrease 
RLUs remain 
 constant 
RLUs remain 
 constant 
Unresponsive Proliferative Cytostatic Cytotoxic 
ViaLight 
ToxiLight 
*Compared 
to untreated 
control 
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3.3  Discussion  
 
The work included in this chapter has examined the potential of using a 
novel bioluminescent assay with view to solving the lack of sensitivity in 
detecting low cell numbers associated with cytotoxicity assays.  
 
3.3.1 Optimisation of ToxiLight® assay 
 
The main focus of this study was to develop a novel assay based on AK 
release that could improve on the current assays already used. The 
ToxiLight® assay developed was shown to efficiently detect the release 
of AK both in a cell free system by myokinase standards (AK, chicken 
muscle) and from cell lines. All cell lines and cytotoxic agents used by 
Lonza BioScience, Nottingham UK were analysed successfully with the 
ToxiLight® assay and subsequently backed up by either P.I. uptake or 
the CytoTox OneTM (LDH) assay. The assay demonstrated how it can be 
easily miniaturized down to 384 well plates for high throughput screening 
with equally effective results. In addition, the assay is simple to run; taking 
in total 5 min to obtain the required data, and potentially can be used in 
any situation where cytotoxicity is suspected. A 100% control lysis 
reagent was also effectively produced which compared significantly to AK 
released from freeze-thawed cells (R2 = 0.99). 
 
3.3.2 ToxiLight® assay compared to traditional assays 
 
The study so far has incorporated data from well-established assays and 
techniques used for proliferation and cytotoxicity studies. Over the last 
decade colorimetric assays based on the reduction of tetrazolium salts 
have been promoted in the form of several commercial kits aimed at 
measuring cell proliferation (Petty et al., 1995; Kawada et al., 2002; 
Marshall et al., 1995). This is a high-throughput method and is proposed 
as a preferable alternative to techniques such as those based upon the 
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uptake of 3H-thymide or chromium release, both of which are radioactive. 
This study however, has shown that even the colorimetric assays are 
insufficient in detecting very low cell numbers. Their detection at best was 
only 10,000 cells per well, and represents a significant number of cells 
that would proliferate into a new tumour population, thus providing 
misleading results suggesting that the treatment successfully killed all of 
the cells. 
The alamarBlue® assay proved to be the most sensitive after the 
colorimetric assays, detecting 3000 cells above the background levels. As 
shown in table 3.02, the midpoint potential of alamarBlue® is greater than 
that of any of the other components of the electron transport chain. This 
explains its superiority over the colorimetric assays as it will be reduced 
much better. The midpoint potential of MTT is intermediate between that 
of the electron donors and cytochromes meaning that MTT will not be 
reduced by cytochromes. Even though the alamarBlue® assay proved 
superior, it still lacked sufficient sensitivity and as with the colorimetric 
assays, it also proved to be time consuming. 
The developed ToxiLight® assay was monitored alongside other well-
established methods. This study revealed that the best assays on the 
market were the LDH, ViaLightTM Plus®, and the ToxiLight®TM assays, in 
terms of ease of use, speed and sensitivity. When ToxiLight® was 
compared to each of these assays, the correlation was >0.9 for all 
experiments performed. This revealed the assay to be very reproducible. 
LDH is relatively stable but for prolonged periods of incubation in culture 
media can result in unreliable results due to its degradation after 9 h 
(Promega, 2004). It is a cytosolic enzyme that is present in animal cells. 
Moreover, it is a rapid method and reagent kits for clinical screening are 
commercially available and relatively inexpensive (Sasaki et al., 1991). 
However, the LDH assay was not as responsive as the new ToxiLight® 
assay; low concentrations of drugs showed little toxicity in comparison 
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and the cell number detection was 50 cells per well compared to the 5 
cells per well of the ToxiLight® assay. Although LDH detection proved to 
be fast and efficient, the sensitivity was not comparable to AK release 
with the LDH enzyme being less stable in culture. 
 
Propidium Iodide (P.I.) uptake is a widely used technique for measuring 
both hypodiploid peaks for cell cycle analysis and in monitoring cell 
permeability (Ormerod, 1998). It is much smaller in size (668 Da) than AK 
(36 kD) and thus measurement should be more sensitive. The 
disadvantage however, is that measuring P.I. uptake is time consuming 
and requires specialist knowledge. The results showed the ToxiLight® 
assay to be as sensitive as P.I. uptake (figure 3.14) in this research 
detecting down to as few as 5 cells per well (figure 3.11) and identifying 
cell death in very low concentrations of drug.  
 
ViaLight® Plus offers many benefits over the conventional assays by 
avoiding the use of radioisotopes and showing greater sensitivity and 
reproducibility (Crouch et al., 1993; Bradbury et al., 2000; Tsujimoto, 
1997).  Due to the speed and ease of use of this method it lends itself 
particularly well to high throughput assays and drug screening like the 
ToxiLight® assay. When compared to the ToxiLight® assay, the 
sensitivity of both these assays was excellent. Figure 3.19 demonstrated 
with lysed K562 cells how both assays could measure small amounts of 
ATP (10 cells per well) or AK (5 cells per well) released above 
background. Although both assays measured different forms of cell death 
they shared the sensitivity required in detecting changes within a cell. 
 
The data presented in this study suggests that ToxiLight® can be used as 
an indicator of necrotic cell death and is very sensitive compared to the 
conventional assays. An interesting finding was that when melanoma 
cells were dosed with dacarbazine, neither the ToxiLight® assay nor the 
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ViaLight® Plus assays on their own could identify the effects of the drug 
on the cells.  It was only when the two assays were used in conjunction 
with each other that a conclusion could be drawn from the experiment 
(figure 3.23). The ToxiLight® assay implied no cell death was present. 
However, the ViaLight® Plus assay revealed a dramatic change with a 
large reduction in ATP levels leading to the assumption that cell death 
was in fact occurring. FACScan analysis revealed that the drug had a 
cytostatic effect on the cells which proved both assays to be correct. The 
ViaLight® Plus assay was merely showing fewer cells in culture due to 
growth arrest thus the lower levels of ATP with increasing drug and the 
two assays performed together would provide a definitive answer.  
 
In conclusion, this study revealed that although the ToxiLight assay 
proved to be very sensitive, it should not be used alone unless purely 
looking for cell membrane damage or necrosis. Both a viability assay and 
an assay to detect necrosis is the best combination to use when 
analyzing the effects of a cytotoxic drug on a cell population. Ideally a 
cytolysis assay such as ToxiLight® and a proliferation assay such as 
ViaLight® Plus would be a desirable combination. As these assays are 
highly sensitive, slight changes within the cell population would be 
revealed. They would show both cell lysis, proliferation and any cytostatic 
effects over time. Detecting cytostatic effects are just as important in 
studies as the detection of toxicity and cell death.  
 
Convenient methods for the quantification of cell numbers in culture have 
proven very difficult in the past. For example, the simple and direct 
techniques such as cell counting with haemocytometer chambers or 
electronic particle counters are unsuitable for the processing of large 
numbers of samples (Marshall et al., 1995). All published reports describe 
assays utilised for the detection of either cell death or proliferation that 
are not sensitive enough in detecting any remaining resistant populations 
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of cells that are living in small cell numbers within a tumour population. It 
is this lack of sensitivity that results in cells being left undetected and 
allows them to proliferate into a new tumour population over time. 
 
Resistance is known to occur with many chemotherapy drugs. 
Experimentally, acquired resistance developed to various compounds has 
been demonstrated (Kerbal et al., 2001). Goldie and Coldman (1979) 
suggest that spontaneous mutations during tumour evolution are 
responsible for the presence of intrinsically resistant cells before 
exposure of a tumour to a cytotoxic drug. This could present itself by cell 
cytostasis or continued proliferation. Assays detecting this effect are 
crucial to clinicians before the commencement of treatment to prevent the 
patient being exposed to a drug that will not be beneficial. The ToxiLight® 
and ViaLight® Plus assays may help in studying these areas of cancer 
research. 
 
The next stage of this study was to use both the ToxiLight® and 
ViaLight® Plus assays on both primary and continuous melanoma cell 
lines. These cells would be exposed to a number of known 
chemotherapeutic drugs and monitored with various doses over time. The 
assays would be used to assess the affects of these drugs and sensitive 
and resistant cell lines were identified using the ViaLight® Plus and 
ToxiLight® assays and selected for further research. 
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Chapter 4: Utilising bioluminescent assays to assess cell 
death in melanoma cells. 
 
4.1 Introduction 
 
The incidence of melanoma has more than doubled over the last decade 
and early detection is vital to reduce mortality in these patients; surgery 
curing 95% of early stage disease (Testori et al., 2009). Balch et al. 
(1997) reported the survival rate for patients with loco regional disease to 
be 24 months and for patients with metastatic disease to be 6 months. 
This statistic has not improved today due to ineffective treatment for 
advanced melanoma. Anticancer agents commonly used in the treatment 
of melanoma do not result in clinically meaningful responses in most 
patients (Garbe, 1993), suggesting a high drug resistance for unknown 
reasons. Resistance to antineoplastic agents is a major obstacle in 
successfully treating metastatic malignant melanoma (Viatcheslav et al., 
1999; Wittig et al., 2002; Dong et al., 2002; Amiri et al., 2004) and 
common anti-cancer drugs such as taxol, cisplatin (Sersa et al., 2000; 
Leonetti et al., 1999), etoposide (Wittig et al., 2002; Lage et al., 2001), 
doxorubicin (Panneerselvam et al., 1987) and vindesine have shown no 
efficacy in large randomised trials (Soengas et al., 2003). This lack of 
selectivity of chemotherapeutic agents has raised the call for the 
development of new drug delivery systems, such as enhanced delivery of 
drugs to tumour cells by electroporation (electrochemotherapy). This 
mode of delivery has been shown to be more effective for drugs such as 
cisplatin and bleomycin and increases drug delivery to the cells, with 
insignificant side effects due to the low cisplatin doses. However 
resistance has been observed after four cycles of chemotherapy (Sersa 
et al., 2000).  
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Multidrug resistance (MDR) is a major obstacle for cancer therapy; the 
cancer may be either inherently untreatable (intrinsic resistance) or have 
progressed to develop resistance to a wide variety of anticancer agents 
over the course of treatment (acquired resistance) (La Porta, 2007). In 
general, the vast majority of anticancer drugs operate through induction of 
cell cycle arrest and cell death in either the DNA synthesis (S) or mitosis 
(M) phase of the cell cycle (Shabbits et al., 2003). Table 4.01 illustrates 
how many of the resistant drugs tested target melanoma cells. 
As previously mentioned in the introduction (chapter 1), it is well 
established that cancer is not caused by a mutation in a single gene, but 
requires genetic alterations affecting several pathways (Hanahan and 
Weinberg, 2000). P53 is one of the most commonly mutated genes in 
human cancers (>50%) and its role in malignant melanoma has been the 
subject of intense investigation (Rieber et al., 2001). An increased p53 
level due to decreased degradation of the mutant protein has been 
observed (Le et al., 2003) in metastatic melanomas but not primary 
melanomas. In 1998, Li and his research team compared the responses 
of four melanoma cell lines containing the wild-type p53 and four cell lines 
carrying the mutant p53 when exposed to cisplatin, vincristine and 
camptothecin. Results revealed low percentages (<18%) of cell survival 
with wild-type p53 compared with a greater than 55% survival of the cells 
with mutant p53 (Li et al., 1998).  
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Agents Mode of Action Specific cellular effects 
 
Nitrosoureas   
Carmustine Alkylation of nucleic acids and 
proteins 
ssDNA breaks 
Lomustine  DNA crosslinking 
Semustine  Carbamoylation of proteins 
   
Nitrogen mustard   
Cyclophosphamide Alkylation of nucleic acids DNA crosslinking 
   
Triazenes   
Dacarbazine Alkylation and methylation of 
nucleic acids 
Inhibition of nucleic acid and 
protein synthesis 
Temozolomide   
   
Antibiotics   
Anthracyclines DNA intercalating agent ssDNA breaks 
Doxorubicin 
(adriamycin) 
Free radicals DNA crosslinking 
  Inhibition of DNA and RNA 
replication 
   
Plant-derived 
products 
  
Vinca alkaloids   
Vincristine Microtubule disruption (prevent 
assembly) 
Altered cell division, motility 
Vinblastine  Intracellular transport 
   
Epipodophyllotoxins   
Etoposide Inhibition of topoisomerase II DNA breaks 
   
Taxanes Microtubule disruption (prevent 
depolymerisation) 
Altered cell division, motility 
Taxol  Intracellular transport 
Paclitaxel   
Docetaxel   
   
Hormonal analogs   
Antiestrogen Competitive inhibitor of 
endogenous estrogens 
Altered estrogen signaling 
Tamoxifen   
   
Platinum drugs   
Cisplatin DNA and protein crosslink ssDNA and dsDNA breaks 
Carboplatin  Changes in DNA structure 
  Inhibition of DNA and RNA 
synthesis 
 
Table 4.01 To illustrate treatments used and how they target melanoma 
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Recent research has looked into epigenetic events that affect cell 
transformation (Schwabe and Ubbert, 2007), which refers to changes in 
phenotype (appearance) or gene expression caused by mechanisms 
other than changes in the underlying DNA sequence. There is no 
alteration in the underlying DNA sequence of the organism; instead, non-
genetic factors cause the organism's genes to behave (or "express 
themselves") differently. The irreversible changes that occur within the 
human DNA sequence, including chromosomal deletions, amplifications, 
and gene mutations, have all been implicated in the development and 
progression of melanoma (La Porta, 2007). The most common epigenetic 
phenomenon in malignancy appears to involve histone modification and 
DNA methylation. On the whole, epigenetic profiling of melanoma is still in 
its infancy, posing an enormous challenge for researchers and clinicians. 
Histone deacetylase (HDAC) inhibitors are a promising group of 
compounds inducing differentiation, growth arrest and apoptosis in 
tumour cells in preclinical studies (Peltonen et al., 2005). The cellular 
effects of trichostatin A have been monitored in many studies (La Porta, 
2007). It is an organic compound that serves as an antifungal antibiotic 
and selectively inhibits the class I and II mammalian HDAC families of 
enzymes, preventing progression of the eukaryotic cell cycle during the 
beginning of the growth stage (Kim et al., 2000). Histone acetylation is 
carried out by HATs, while HDACs remove acetyl groups. Inhibitors of 
HDAC, such as trichostatin A (TSA) push the equilibrium towards the 
acetylated, transcriptionally active state as shown in figure 4.01. 
Increased histone acetylation leads to reversible decondensation of 
dense chromatin subcompartments (Toth et al., 2004). 
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Figure 4.01 To illustrate how the HDAC inhibitor trichostatin A interacts (Scotto, 2003) 
The relationship of trichostatin A with p53 (Halaban et al., 2009; Peltonen 
et al., 2005), p21WAF1/Cip1 (Boyle et al., 2005), p27Kip1, Fas/FasL (Kramer, 
2007; Klisovic, et al., 2003), E2F (Katsura, 2008), MHC class I and II 
(Bazhin, 2007) has been researched and shows much promise in 
melanoma treatment. Accumulating evidence has suggested that the 
histone deacetylases play a very important role in carcinogenesis, and 
histone deacetylase inhibitors (HDACIs) are being extensively studied for 
the treatment of various cancers (Muscolini et al., 2008; Habold et al., 
2008; Katsura et al., 2008). HDACIs cannot only induce growth inhibition, 
cell cycle arrest and apoptosis in cancer cells, but also increase the 
sensitivity to chemotherapy and ionizing radiation (Munshi et al., 2005). 
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The aim of the research in this chapter was to use the most sensitive 
assays available for testing tumour chemo sensitivity assays. The assays 
to be used were determined in chapter 3 of this thesis; the ToxiLight® 
and ViaLight® Plus kits. These will be used in parallel for a study 
involving primary and immortalised melanoma cells cultured in vitro. The 
cells were obtained by Nottingham Trent University as part of the OISTER 
(Outcome and Impact of Specific Treatment in European Research in 
melanoma project (EU number QLKS-CT-2000-40643) involving seven 
partners across Europe and were designed to collect tissue, serum 
samples and culture cell lines from melanoma patients with known clinical 
outcome for analysis. The remaining cell lines were obtained from 
ESTDAB (european searchable tumour cell line database; EU number 
QLRT-2000-01325). The ToxiLight® and the ViaLight® Plus kits would be 
used to acquire sensitive and resistant cell lines to various cytotoxic 
drugs. These selected cell lines will then be tested with the histone 
deacetylase drug trichostatin A for further proteomics studies undertaken 
(chapter 5). The results will be analysed by FACScan analysis, light 
microscopy and trypan blue uptake to ensure the validity of the assays. 
 
Therefore the aims of this chapter will be to: 
 
• Test the library of melanoma cell lines with the ToxiLight® and 
ViaLight® Plus kits with some known chemotoxic drugs used in 
previous melanoma studies. 
• Select sensitive and resistant cell lines to trial the histone 
deacetylase inhibitor, trichostain-A, for its potential use in 
melanoma treatment. 
• Validate the data by FACScan analysis, trypan blue uptake and 
light microscopy. 
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4.2  Results 
 
The primary melanoma cells selected for this aspect of the research were 
obtained from the OYSTER (Outcome and Impact of Specific Treatment 
in European Research in melanoma) tissue bank; the established cells 
were obtained from ESTDAB. All of the cell lines were dosed with a range 
of chemo toxic drugs; known agents that have been investigated in many 
melanoma studies over the years. Table 4.02 summarises the cells and 
the drugs used: 
 
Melanoma Cells Used Chemo Toxic Drugs Used and their mechanism 
of action 
 
ESTDAB 005 
(established) 
 
Vindesine 
 
Plant alkaloid that inhibits microtubule assembly. 
 
COLD 794 
(established) 
 
Cisplatin  
 
Alkylating agent which interferes with DNA replication. 
 
WM 1205 
(established) 
 
Doxorubicin 
 
Anti-tumour antibiotic. Binds to DNA and inhibits reverse 
transcriptase and RNA polymerase. 
 
MEWO 
(established) 
 
 
MA MEL 28 
(primary) 
 
 
MA MEL 26A 
(primary) 
 
 
 
Table 4.02:  A summary of the six melanoma cell lines chosen and the three cytotoxic drugs used 
on them. 
 
Cell cultures freshly initiated from tissues or organ pieces are called 
primary cell cultures. Cell lines may be obtained from the primary culture 
by renewed disruption of the cell layers with trypsin or any other suitable 
agent and fresh inoculation of a limited number of cells containing fresh 
medium. This process, which is repeated normally every three to four 
                                                                                                                              Chapter 4 
 
 
Susan Catherine Gill 
PhD Thesis, 2009 
145 
days, is called cell passage or subcultivation and yields secondary cells. 
After approximately 70 sub cultivation steps the cell line is called an 
established cell line. Primary cells with an extended capacity to replicate 
are called immortalised cells. Such immortalised cells frequently arise 
spontaneously after adaptation to tissue culture conditions. These cells 
possess an extended proliferative capacity in vitro, but usually possess 
an unstable genotype and may not express the same phenotypic markers 
as those observed in primary cells, having lost some or many of the 
features observed in primary cells. 
Initial experiments were carried out to ensure that all the melanoma cell 
lines were clear from mycoplasma contamination. This can result in 
possible cellular changes, including chromosome abberations, changes in 
metabolism and cell growth which then affects any research data 
obtained on the cell lines (Lonza Ltd, 2006). All cell lines used were 
screened for mycoplasma and found to be negative (materials and 
methods – chapter 2.3.6).  
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4.2.1 Measuring ATP and AK as a Cell Marker in melanoma cells. 
The most effective assays for measuring cell death/viability which were 
determined in chapter 3 (the ToxiLight® and ViaLight® Plus assays), 
were further utilised in experiments conducted on both primary and 
established melanoma cell lines. The cells were exposed to a number of 
known chemotherapeutic drugs to assess their effects on melanoma 
cells, in order to identify drug-sensitive and drug-resistant cell lines for 
further analysis.  
 
4.2.1.1 Effect of chemotoxic drugs on the ToxiLight® and ViaLight® 
Plus assays. 
 
Initial studies were conducted using both the Vialight® Plus and 
ToxiLight® assays to ensure there would be no interference from the 
chemotherapeutic agents on the assay themselves. ATP and AK 
(myokinase) standards were diluted in complete media: 0.1 µM ATP for 
the ViaLight Plus assay; and 25 µM AK for the ToxiLight® assay. 10 
µg.mL-1 of vindesine; cisplatin or doxorubicin (the highest drug 
concentration used in the experiments) was added to the prepared 
standards; with control standards retained containing no drugs. 100 μL 
volumes of standards with and without the drug were sampled for both 
the ToxiLight® and ViaLight® Plus assays. From the results obtained in 
figure 4.02, it is clearly shown that none of these drugs had any adverse 
effect on either the ToxiLight® or the ViaLight® Plus kits. The RLUs for 
the control standards (labelled ‘0’) in figures 4.02 A, B and C was not 
significantly different to the RLUs where the drugs were present (labelled 
‘10’). 
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Figure 4.02: The effects of vindesine (A); cisplatin (B) and doxorubicin (C) on the 
ToxiLight® and ViaLight® Plus kits. ATP standards were used at 0.1 µM for the 
ViaLight® Plus assay and myokinase standards (AK) at 25 µM used to test the 
ToxiLight® assay. Both drugs were diluted in the standards and compared against 
control standards only. The resulting RLUs were measured using bioluminescence on a 
Berthold MPL-2 luminometer to obtain an ATP/RLU (VL RLUs) and an AK/RLU (TL 
RLUs) +/- the standard error of the mean (n=3).  
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4.2.1.2 Effect of the chemo toxic agents on melanoma cells 
 
The primary Ma Mel 28 and Ma Mel 26a cells and the four established 
melanoma cell lines (COLD 794, ESTDAB 005, WM 1205 and MEWO) 
were dosed with the anti-tumour antibiotic, doxorubicin. All cells were 
prepared in 100 µl volumes in a 96 well culture plate with an initial cell 
density of 1 x 105 cells.ml-1. Doxorubicin was used at 0, 1, 5 and 10µg.ml-1 
and the effect of the drug monitored with both the ToxiLight® and 
ViaLight® Plus kits at 24, 48 and 72 h. Doxorubicin has been shown to 
have no efficacy in melanoma patients in large randomised trials, but it 
was hoped that using these two detection assays in conjunction with each 
other, the ex-vivo effect of doxorubicin could be determined. 
 
The results obtained in figure 4.03 with the immortalised cells dosed with 
the doxorubicin agent revealed that cell lines were sensitive to 
doxorubicin even in the lowest dose of the drug (1µg.ml-1).  The ATP 
RLUs dropped significantly in all the cells tested after 48 h in culture. The 
ToxiLight® assay also revealed the RLUs to increase significantly after 48 
hours, indicating that doxorubicin was inducing cell death. The most toxic 
effects were seen with MEWO cells (figure 4.03; D) where the increases 
in RLUs at 72 hours increased from 225 in the control to 3761 RLUs with 
10 µM doxorubicin approaching sixteen times the control value. COLD 
794 cells (figure 4.03; A) proved to be the least drug sensitive line only 
1331 RLUs in the control and 2684 RLUs with 10 µM doxorubicin; only 
twice the increase of the control. 
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Figure 4.03: The effects of doxorubicin on COLD 794 cells (A), ESTDAB 005 cells (B), 
WM 1205 cells (C) and MEWO cells (D) tested using the ToxiLight® and ViaLight® Plus 
kits. The resulting RLUs were measured using bioluminescence on a MPL-2 
luminometer to obtain an ATP/RLU (VL RLUs) and an AK/RLU (TL RLUs) +/- the 
standard error of the mean (n=3).  N = number of experiments. 
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Figure 4.04: The effects of doxorubicin on Ma Mel 28 cells (A), and Ma Mel 26a cells 
(B), tested using the ToxiLight® and ViaLight® Plus kits. The resulting RLUs were 
measured using bioluminescence on a Berthold MPL-2 luminometer to obtain an 
ATP/RLU (VL RLUs) and an AK/RLU (TL RLUs) +/- the standard error of the mean 
(n=3).  
N = number of experiments. 
The Ma Mel 26a cells (figure 4.04; B) dosed with doxorubicin showed a 
similar effect, as previously seen in figure 4.04 with a reduction in ATP 
values after 24 hours. The ToxiLight® assay demonstrated cell death due 
to the increase in RLUs (four times above the control after 72 h) showing 
AK release from the necrotic cells. In comparison, the Ma Mel 28 cells 
(figure 4.04; A) demonstrated a reduction in ATP values; however the 
ToxiLight® RLUs showed no significant change when compared to the 
control throughout the experiment. As the plasma membrane was still 
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intact in these cells this result implied that the cells were in growth arrest 
(cytostasis) without direct cytotoxicity.   
Due to the varying results obtained with doxorubicin dosing, it was 
decided to repeat these experiments on all the melanoma cells with two 
additional drugs; the alkylating agent, cisplatin and plant alkaloid, 
vindesine. As in the previous experiment, all cells were prepared in 100 µl 
volumes in 96 well culture plates with an initial cell density of 1 x 105 
cells.ml-1. Cisplatin and vindesine at 0, 1, 5 and 10 µg ml-1 were used and 
tested with the ToxiLight® and ViaLight® Plus kits at 24, 48 and 72 h.  
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Figure 4.05: The effects of cisplatin (A) and vindesine (B) on ESTDAB 005 cells tested 
using the ToxiLight® and ViaLight® Plus kits. The resulting RLUs were measured using 
bioluminescence on the Berthold MPL-2 luminometer to obtain an ATP/RLU (VL RLUs) 
and an AK/RLU (TL RLUs) +/- the standard error of the mean (n=3). 
N = number of experiments. 
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Figure 4.06: The effects of cisplatin (A) and vindesine (B) on COLD 794 cells tested 
using the ToxiLight® and ViaLight® Plus kits. The resulting RLUs were measured using 
bioluminescence on the Berthold MPL-2 luminometer to obtain an ATP/RLU (VL RLUs) 
and an AK/RLU (TL RLUs) +/- the standard error of the mean (n=3). 
N = number of experiments. 
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Figure 4.07: The effects of cisplatin (A) and vindesine (B) on WM1205 cells tested using 
the ToxiLight® and ViaLight® Plus kits. The resulting RLUs were measured using 
bioluminescence on the Berthold MPL-2 luminometer to obtain an ATP/RLU (VL RLUs) 
and an AK/RLU (TL RLUs) +/- the standard error of the mean (n=3). 
N = number of experiments. 
The results in figures 4.05 represent the ESTDAB 005 cells, figure 4.06 
the COLD 794 cells and figure 4.07 the WM 1205 cells. All three cell lines 
revealed a concentration dependent effect with cisplatin when tested with 
the ViaLight® Plus assay. The ATP RLUs reduced in correlation with 
increasing drug exposure with a drop in RLUs at 24, 48 and 72 h after 
drug treatment. In addition, the resulting data with vindesine 
demonstrated a concentration dependent effect using the ViaLight® Plus 
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assay with all three cell lines revealing the same cellular effects regarding 
ATP reduction. However, the overall reduction in ATP RLUs after 72 h 
with vindesine was not as great as that observed with cisplatin. 
Results obtained from the ToxiLight® assay (figures 4.05, 4.06 and 4.07) 
demonstrates the importance of having both ToxiLight® and ViaLight® 
Plus assays carried out in parallel. The ViaLight® Plus assay measuring 
viable cells and changes in ATP levels. If there is a reduction in RLUs, 
there are fewer cells present and the normal assumption is that they have 
been killed. By combining ToxiLight® and ViaLight® Plus assays, you can 
establish if this is an accurate assessment. If there is no increase in 
ToxiLight® there has been no compromise of the plasma membrane and 
the cells remain intact, but not proliferating. Therefore compared to 
healthy control cells which proliferated over the time course of the 
experiment, there are less cells per well. The previous ViaLight® Plus 
results with ESTDAB 005 cells (figure 4.05) implied the cisplatin and 
vindesine to induce cell death with the reduction in ATP. However, results 
from the ToxiLight® assay demonstrated that the RLUs were not 
increasing but actually reducing, inferring that no cell death was occurring 
in the cells. Again, the results of the two assays combined demonstrate 
cytostasis; the reduction in AK release with increasing doses being due to 
reduced background AK as fewer cells are present within the well.  
The data obtained with COLD 794 cells and the drug cisplatin (figure 
4.06; A) did not show significant cell death. Small increases in RLUs 
could be seen with the ToxiLight® assay after 72 h, revealing some cell 
death had occurred, but the majority of cells appeared to be cytostatic. In 
comparison, the results obtained with COLD 794 and vindesine (in figure 
4.06; B) revealed that cell death had occurred with a significant increase 
in RLUs and therefore AK was released from the cells. WM 1205 cells 
were the only cell line to show significant amounts of cell killing with the 
drug cisplatin (in figure 4.07; A), with the RLUs doubling after 24 h 
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although no further cell death appeared to occur after this time (assayed 
at 48 and 72 h) with the RLUs remaining double that of the control 
throughout the experiment. This could be due to a mixed population of 
sensitive and resistant cells within the population. With vindesine 
exposure (in figure 4.07; B), WM 1205 cells were affected to the same 
extent as with cisplatin, with only a small increase in ToxiLight® RLUs 
and thus cell death at 24 h. After 48 h, the RLUs were double that of the 
control however, no further cytotoxic effects were observed from 48 to 72 
h, which could imply the presence of a mixed population of sensitive and 
resistant cells as observed with cisplatin dosing.   
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Figure 4.08: The effects of cisplatin (A) and vindesine (B) on MEWO cells tested using 
the ToxiLight® and ViaLight® Plus kits. The resulting RLUs were measured using 
bioluminescence on the Berthold MPL-2 luminometer to obtain an ATP/RLU (VL RLUs) 
and an AK/RLU (TL RLUs) +/- the standard error of the mean (n=3). 
 
N = number of experiments. 
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Figure 4.09: The effects of cisplatin (A) and vindesine (B) on Ma Mel 28 cells tested 
using the ToxiLight® and ViaLight® Plus kits. The resulting RLUs were measured using 
bioluminescence on the Berthold MPL-2 luminometer to obtain an ATP/RLU (VL RLUs) 
and an AK/RLU (TL RLUs) +/- the standard error of the mean (n=3). 
 
N = number of experiments. 
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Figure 4.10: The effects of cisplatin (A) and vindesine (B) on Ma Mel 26a cells tested 
using the ToxiLight® and ViaLight® Plus kits. The resulting RLUs were measured using 
bioluminescence on the Berthold MPL-2 luminometer to obtain an ATP/RLU (VL RLUs) 
and an AK/RLU (TL RLUs) +/- the standard error of the mean (n=3). 
 
N = number of experiments. 
The three remaining cell lines, MEWO (figure 4.08), Ma Mel 28 (figure 
4.09) and Ma Mel 26a (figure 4.10) were tested with cisplatin and 
vindesine. All three cell lines revealed a concentration dependent effect 
with a drop in ATP RLUs observed with the ViaLight® Plus assay as the 
cisplatin dose increased.  As seen previously with the first three cell lines 
tested, the cytotoxic effects with cisplatin was more severe than with 
vindesine using the ViaLight® Plus assay, with Ma Mel 28 cells (in figure 
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4.09; B) revealing little change in RLUs with vindesine exposure. The 
effects of the drug cisplatin were noticeable after only 24 h with the RLUs 
at 50% of that in the control in all the cell lines. After 72 h, the RLUs 
further decreased to a much lower level than seen with vindesine. 
The results obtained from the ToxiLight® assay in figure 4.09 (A & B) 
mirror the results previously seen with the Ma Mel 28 cells exposed to 
doxorubicin, revealing no killing with either cisplatin or vindesine. The 
RLUs decrease slightly with increasing concentration of drug, illustrating 
cell cytostasis with fewer cells present in the culture. MEWO and Ma Mel 
26a cells showed a slight increase in RLUs, suggesting some cell death 
had occurred after 48 and 72 h with cisplatin, but the RLUs nearly 
doubled 72 h after treatment with vindesine. This was an unexpected 
result as the ViaLight® Plus data revealed a more severe drop in RLUs 
with cisplatin than vindesine. Comparing all six cell lines, most cell death 
was observed with COLD 794 cells treated with vindesine; however, 
comparison of the two drugs overall revealed variable results, with some 
cells responding better to cisplatin (WM 1205 cells) and others to 
vindesine (COLD 794 and MEWO cells). Comparing the vindesine and 
cisplatin results with the initial data obtained with doxorubicin, less cell 
death was observed overall with cisplatin and vindesine. The Ma Mel 28 
cells remained consistent, showing no cell death (cytotoxicity) with either 
doxorubicin or vindesine and very little effect with cisplatin (cytostasis). 
The Ma Mel 28 cells were therefore considered resistant to all 3 of the 
drugs used. 
From all the chemo sensitivity assays carried out, it was decided to 
choose 3 cell lines for further investigation. The Ma Mel 28 cells appeared 
resistant to the chemotherapeutic agents and were the prime choice. In 
contrast, the Ma Mel 26a cells appeared to be more sensitive and could 
be used as a direct comparison to the resistant Ma Mel 28 cells. The cell 
lines Ma Mel 26a and 28 had known clinical history and patient outcome 
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which could be used in further data interpretation. To confirm this 
difference in drug effect, both cell lines were exposed to a further three in-
house drugs (Lonza Ltd) to assess their effects with both the ToxiLight® 
and ViaLight® Plus assays. Dexamethasone is a glucocorticoid anti-
inflammatory agent, camptothecin is a DNA topoisomerase I inhibitor and 
arabinosylcytosine (Ara-C) is a selective inhibitor of DNA synthesis. Cells 
were prepared in 100 µl volumes in 96 well culture plates with an initial 
cell density of 1 x 105 cells.ml-1. Three drugs were tested at 0, 5 and 10 
µM.ml-1 with an exposure time of 72 h prior to testing with ToxiLight® and 
ViaLight® Plus assays. The vehicle control shown in figures 4.11 is 
DMSO into which all three of the drugs had been reconstituted. Although 
no interference had been seen on the ToxiLight® and ViaLight® Plus 
assays previously with DMSO, it was decided to confirm this by including 
a control to ensure no interference was seen with the assays. Complete 
media containing 0.1% DMSO (i.e. highest concentration used in the 
experiments) was added to a 96 well plate in 100 µl volumes and tested 
with both assays. A 100% lysis control was included to obtain a 
percentage of AK release figure 4.11. 
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Figure 4.11: The effects of ara-C, dexamethasone and camptothecin on the primary Ma 
Mel 28 cells (A), and Ma Mel 26a cells (B), tested using the ToxiLight® and ViaLight® 
Plus kits. The resulting RLUs were measured using bioluminescence on a Berthold 
MPL-2 luminometer to obtain an ATP/RLU (VL RLUs) and an AK/RLU (TL RLUs) +/- the 
standard deviation.  
N = number of experiments. 
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The results in figure 4.11 confirmed that the Ma Mel 28 cell line (A) was 
resistant to drug therapy with dexamethasone, with no drop in ATP 
observed at all with the ViaLight® Plus assay and consequently no killing 
was detected with the ToxiLight® assay. The drug did not even produce a 
cytostatic effect. In the presence of ara-C and camptothecin, there was an 
observable drop in ATP RLUs with the ViaLight® Plus assay but the 
ToxiLight® assay revealed little change and therefore no significant cell 
death. This result showed that some of the cell population were in growth 
arrest. In comparison, Ma Mel 26a cells did show an effect with 
camptothecin and ara-C. However as seen with Ma Mel 28, no change in 
RLUs was observed with dexamethasone with either of the assays. Ara-C 
revealed a small reduction in RLUs with the ViaLight® assay and a small 
increase in RLUs with the ToxiLight® assay, concluding that some cell 
death had occurred. Ma Mel 26a cells treated with camptothecin on the 
other hand revealed that 25% of cells had been killed after 72 h when 
compared to the 100% lysed control using the ToxiLight® assay. In 
addition, the ViaLight® RLUs dropped significantly confirming this cell 
killing within the culture. These results confirmed the choice of Ma Mel 28 
and Ma Mel 26a cells for further investigations. In addition, to these 
results, it was concluded that the vehicle control (DMSO), did not have 
any adverse effects on either the ToxiLight® or ViaLight® Plus assays 
with no significant change in RLUs observed with either assay. As the 
results did not reveal any of the remaining cell lines to be conclusively 
resistant or sensitive throughout the experiments, MEWO cells were 
selected as a third cell line for further investigation, due to current 
research which investigated it’s sensitive and resistant nature to various 
drugs (Kissel, 2006).  
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4.2.2 Investigation into the effects of trichostatin A on melanoma 
cells. 
 
Trichostatin A (a reversible inhibitor of histone deacetylase; HD) is 
thought to be a possible drug for future melanoma therapy either alone or 
used in combination (La Porta, 2007). It inhibits cell proliferation, thereby 
allowing a possible second drug to target the cells in growth arrest 
resulting in apoptosis. The effect of melanoma cell growth of this drug 
was assessed using a combination of the ToxiLight® and ViaLight® Plus 
assays to monitor cell death. The three selected cell lines Ma Mel 28, Ma 
Mel 26a cells and MEWO cells were assessed after 24, 48 and 72 h of 
exposure to trichostatin A. The results obtained were verified with 
FACScan analysis, trypan blue uptake and visually using a light 
microscope.  
 
The number of replicate samples taken at each time point was n=18 for 
MEWO, n=10 for Ma Mel 28 and n=14 for Ma Mel 26a cells. All cell based 
experiments were completed within 5 passages to ensure as few cellular 
changes within the populations as possible.  All cells were prepared either 
in 100 µl volumes in 96 well culture plates with an initial cell density of 1 x 
105 cells.ml-1 or in T25 cell culture flasks in 10 ml volumes at 1 x 105 
cells.ml-1. The ToxiLight® assay incorporated a 100% lysis control to 
quantify the amount of cell killing. Trichostatin A was added to the cells at 
0, 1 and 5 µM with an exposure time of 24, 48 and 72 h prior to testing 
with ToxiLight® and ViaLight® Plus assays. The cells prepared in flasks 
were scraped, lysed and frozen for further proteomics analysis (see 
chapter 5). 
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4.2.2.1 Effect of trichostatin A on MEWO cells 
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Figure 4.12 MEWO cells were treated with trichostatin A, incubated at 37oC for up to 72 
hours and tested every 24 hours for the effects of the drug. A represents the ViaLight® 
Plus assay; B contains the ToxiLight® data. The resulting RLUs were read on a Berthold 
MPL-2 luminometer showing ATP/RLUs +/- standard error of the mean where n=18.  
 
N = number of experiments. 
Figure 4.12 summarises the effects of trichostatin A on MEWO cells over 
72 h. The ViaLight® data reveals a concentration dependent effect with a 
dramatic reduction in RLUs with increasing drug concentration at 72 h; no 
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noticeable effect was observed after 24 h in either assay. In addition, the 
ToxiLight® assay demonstrated that the drug resulted in cell death in 22% 
of cells after 48 h and 41% of cells after 72 h of incubation. This is 
represented by the increase in ToxiLight® RLUs which indicates necrosis 
and therefore irreversible cell death. Although cells had been killed it 
appeared that the majority could be in growth arrest or remain unaffected 
by the drug.  
Microscope examination of the MEWO cells was performed at 72 h as a 
visual aid in monitoring the state of the cells: 
A    B              C 
     
      Control MEWO cells     MEWO cells, 1 µM     MEWO cells, 5 µM 
Figure 4.13 Microscopy of MEWO cells dosed with trichostatin A after 72 hours and 
taken with a light microscope (x10 lens).  
 
 
The results in figure 4.13, taken at 72 h (1 and 5 µM trichostatin A) clearly 
show that there are fewer cells present (figure 4.13, B and C). Some dead 
cells can be seen suspended in the culture media which may account for 
the 41% increase in RLUs (cell death) with the ToxiLight® assay after 72 
h. The remainder of the cells; although in fewer number, remain adherent 
and healthy confirming the ViaLight® and ToxiLight® data which implies 
cytostasis.  
 
To correlate the ToxiLight® data, propidium iodide (PI) FACScan staining 
was carried out.  The ability of the cells to exclude various dyes indicates 
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the maintenance of cell membrane integrity and hence the viability of the 
cell. PI fluoresces red when it binds to DNA but is excluded from cells 
with intact plasma membranes. 200 µl of cell culture were sampled and 
mixed with 200 μl of PI (50 μg.ml-1) and incubated for 10 min at room 
temperature. The cells were analysed to assess PI uptake with a Becton 
Dickinson FACScanTM Flow Cytometer and the results are illustrated in 
table 4.03 at 24, 48 and then 72 h; each experiment consisting of control 
cells, and cells treated with 1 and 5 µM of trichostatin A. 
  
% PI Uptake 
 
 
% Trypan Blue Uptake 
Control Cells  
Time (h) 
  
24 2.24 3 
48 4.62 2 
72 5.62 4 
1 µM TRICHOSTATIN 
A 
Time (h) 
  
24 9.20 4 
48 18.56 9 
72 31.90 18 
5 µM TRICHOSTATIN 
A 
Time (h) 
  
24 9.56 6 
48 39.46 24 
72 47.22 32 
 
Table 4.03: MEWO cells treated with trichostatin A (0, 1 and 5 µM) for 24, 48 and 72 h 
and stained with propidium iodide and compared with trypan blue uptake. The resulting 
PI uptake was measured by FACS, scanning a population of 5000 cells.   
The above data is representative of one experiment (n=1) 
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Table 4.03 shows a composite of the data produced after monitoring the 
effects of trichostatin A on MEWO cells for 24, 48 and 72 h. As can be 
seen in the controls, the MEWO cells appear healthy at 24, 48 and 72 h. 
After 24 h only 2.24% of the cell population have taken up the propidium 
iodide dye increasing to only 5.26% after 72 h. MEWO cells dosed with 1 
µM trichostatin A after 24 h reveal the percentage of cells taking up the 
dye to have increased significantly from 2.24% to 9.20% and the highest 
concentration (5 µM) of trichostatin A concludes that there has been no 
further increase in cell death with this increase in drug exposure when 
compared to the 1 µM dose of trichostatin A. 
 
The effect after a 48 h incubation with 1 µM trichostatin A; reveals a shift 
in the MEWO cell population with 18.56% of the overall population of cells 
becoming more permeable over time, taking up the dye into the cell 
membrane. Trypan blue uptake also increased from the control although 
only 9% uptake. With an increase in trichostatin A concentration to 5 µM, 
over a 48 h period of exposure, 39.46% of the cells have taken up the dye 
signifying a further increase in cell death over time, with the trypan blue 
count also increasing. MEWO cells treated with 1 µM trichostatin A after 
72 h reveal a substantial increase in cell death with prolonged drug 
exposure. The percentage of cells that have taken up the PI has 
increased to 31.90% and 18% with trypan blue. An even higher number of 
necrotic cells were recorded after prolonged treatment with 5 µM 
trichostatin A (72 h) demonstrating that 47.22% of the cells are necrotic 
with PI staining and 32% with trypan blue uptake. As the FACS data 
shows in table 4.03, a concentration dependent increase was observed 
with cells treated with trichostatin A for 48 and 72 h. After 24 h, only a few 
cells were necrotic, whereas this increased to nearly 50% after 72 h with 
5 µM trichostatin A. 
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Figure 4.14 Summary comparing the PI uptake data (A) with the ToxiLight data (B). 
MEWO cells treated with trichostatin A (0, 1 and 5 µM) for 24, 48 and 72 h.  
 
The percentages obtained by FACS analysis, although slightly higher with 
PI uptake, show similar results to that observed with the ToxiLight® assay 
(figure 4.14). Trypan blue uptake did correlate with both PI uptake and the 
ToxiLight® data although the results remained lower throughout all the 
experiments due to cells disintegrating; therefore not visible by trypan 
blue exclusion. 
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4.2.2.2 Effect of trichostatin A on Ma Mel 28 cells 
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Figure 4.15 Ma Mel 28 cells were treated with trichostatin A and incubated at 37oC for 
up to 72 h and tested every 24 h for the effects of the drug. Figure A represents the 
ViaLight® Plus assay; (B) contains the ToxiLight® data. The resulting RLUs read on an 
MPL-2 luminometer, show ATP/RLUs +/- standard error of the mean where n=10.  
 
N = number of experiments. 
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The results in figure 4.15 summarise the effects of dosing Ma Mel 28 cells 
with trichostatin A over 72 h. The ViaLight® data reveals only a slight 
drop in RLUs with 1 and 5 µM trichostatin A at 24 h, but a concentration 
dependent effect with increasing drug concentration observed at 48 and 
72 h. In contrast to the MEWO cells however, the ToxiLight® assay did 
not demonstrate any significant cell death at 24 or 48 h. After 72 h, there 
was a significant difference with the percentage of lysed cells increasing 
from 13% in the control, to 23% after 48 h, and 31% after a 72 h 
incubation time. This data combined with the ViaLight® Plus assay, which 
showed a dramatic drop in RLUs at 72 h, suggest that the majority of the 
cells were in growth arrest.  
Microscopic examination of the Ma Mel 28 cells was performed at 72 h as 
a visual aid in monitoring the state of the cells. 
A           B                   C 
    
 Control Ma Mel 28 cells        Ma Mel 28 cells dosed with 1 µM   Ma Mel 28 cells dosed with 5 µM 
 
 
Figure 4.16 Microscopy of Ma Mel 28 cells dosed with trichostatin A after 72 h and 
taken with a light microscope (x10 lens). 
 
 
Figure 4.16 shows the effect of trichostatin A at 72 h demonstrating that 
there are fewer cells present at 1 and 5 µM doses (figure 4.16, B and C) 
compared with the control. Although the pictures do not represent this 
clearly due to a lack of picture quality, there were many cells observed 
suspended in the culture media (4.16, C), accounting for the 31% 
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increase in RLUs with the ToxiLight® assay after 72 h and many of the 
cells seen lack the cellular junction that connects adherent cells with their 
adjacent neighbours. The remaining cells are shown to be adherent and 
appear healthy, although fewer in number compared to the control; this 
correlates with the ViaLight® and ToxiLight® data, indicating cytostasis. 
To further confirm the data, propidium iodide (PI) staining and trypan blue 
exclusion was carried out.  
. 
  
% PI Uptake 
 
 
% Trypan Blue Uptake 
Control Cells  
Time (h) 
  
24 7.06 4 
48 8.97 4 
72 10.43 7 
1 µM TRICHOSTATIN 
A 
Time (h) 
  
24 7.56 3 
48 12.34 6 
72 17.49 11 
5 µM TRICHOSTATIN 
A 
Time (h) 
  
24 9.95 5 
48 14.08 9 
72 27.41 16 
Table 4.04: Ma Mel 28 cells treated with trichostatin A (0, 1 and 5 µM) for 24, 48 and 72 
h and stained with propidium iodide and compared with trypan blue exclusion. 
The above data is representative of one experiment (n=1) 
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As observed with the ToxiLight® assay (figure 4.15; B), there was little 
change in PI uptake over a 24 h period. The percentage obtained with PI 
uptake after 48 h (5 µM trichostatin A) revealed a 14% increase and at 72 
h (5 µM trichostatin A), a 27% increase in PI uptake (table 4.04). This 
confirmed the ToxiLight® data, demonstrating that very few cells were 
undergoing cell death as a result of trichostatin A exposure (figure 4.17). 
Despite this, the ViaLight® Plus assay had RLUs which reduced 
considerably after 72 h, revealing the drug is having some effect on the 
cells, albeit a cytostatic effect. The results with trypan blue uptake, 
although lower, correlated with PI uptake and the ToxiLight® data, which 
showed a slight increase in necrotic cells with an increase in drug 
exposure over time. 
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Figure 4.17: Summary comparing the PI uptake data (A) with the ToxiLight data (B). Ma 
Mel 28 cells treated with trichostatin A (0, 1 and 5 µM) for 24, 48 and 72 h.  
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4.2.2.3 Effect of trichostatin A on Ma Mel 26a cells 
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Figure 4.18 Ma Mel 26a cells were treated with trichostatin A and incubated at 37oC for 
up to 72 h and tested every 24 h for the effects of the drug. Figure A represents the 
ViaLight® Plus assay, figure B contains the ToxiLight® data. The resulting RLUs were 
read on an MPL-2 luminometer, show ATP/RLUs +/- standard error of the mean where 
n=14.  
 
N = number of experiments. 
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The Ma Mel 26a cells were the final cell line to be tested with trichostatin 
A. The results summarised in figure 4.18, B revealed this cell line to have 
the highest observed cell death with the ToxiLight® assay. A 
concentration dependent increase in AK release could be seen at 24, 48 
and 72 h. After 24 hours the % lysed cells had increased from 9% in the 
control, to 18% and 23% with 1 µM and 5 µM trichostatin A respectively. 
By 72 h this had further increased to nearly 60% cell death with 5 µM of 
trichostatin A. Although this still was not 100% cell death, it was a 
significant change to the previous results observed with MEWO and Ma 
Mel 28 cells. The ViaLight® Plus data correlated with the ToxiLight®, with 
a slight decrease in RLUs after 24 h, continuing to drop at 48 and 72 h 
until the RLUs had fallen to a very low level following treatment with 5 µM 
trichostatin A.  
A            B                             C 
    
      Control Ma Mel 26a cells           Ma Mel 26a cells dosed with 1 µM    Ma Mel 26a cells dosed with 5 µM 
 
 
Figure 4.19: Microscopy assessments of Ma Mel 26a cells treated with trichostatin A 
after 72 h and taken with a light microscope (x10 lens). 
 
 
The cell morphology in figure 4.19 after 72 h of treatment with 1 and 5 µM 
trichostatin A clearly shows that there has been a large amount of cell 
death occurring within the cell population. Although the above pictures 
are not of good quality, it could be seen that the adherent junctions are no 
longer visible with 1 µM trichostatin A (B) with very few cells seeming to 
be adherent with 5 µM trichostatin A (C). This was a very promising result 
correlating with the large increase in cell death observed with the 
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ToxiLight® assay. It can be seen clearly from in figure 4.19 that cell 
morphology had deteriorated more than previously seen with the MEWO 
and Ma Mel 28 cells. To correlate the ToxiLight® data, propidium iodide 
(PI) staining and trypan blue exclusion assays were carried out.  
 
  
% PI Uptake 
 
 
% Trypan Blue Uptake 
Control Cells 
Time (h) 
  
24 3.75 2 
48 5.79 4 
72 10.76 7 
1 µM TRICHOSTATIN 
A 
Time (h) 
  
24 15.82 8 
48 20.72 28 
72 47.82 39 
5 µM TRICHOSTATIN 
A 
Time (h) 
  
24 27.49 19 
48 39.95 42 
72 67.82 82 
Table 4.05: Ma Mel 26a cells dosed with trichostatin A (0, 1 and 5 µM) at 24, 48 and 72 
h of incubation and stained with propidium iodide and compared with trypan blue 
exclusion. 
The above data is representative of one experiment (n=1) 
The data obtained with Ma Mel 26a cells treated with trichostatin A and 
stained with PI is shown in table 4.05, revealing a large proportion of the 
cell population to be necrotic. The percentage cell death assessed with PI 
uptake and trypan blue staining was greater than that in the ToxiLight® 
assay (60%) with nearly 70% stain with PI and 82% with trypan blue after 
72 h (5 µM trichostatin A). After 24 h a significant difference was 
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observed, even with 1 µM trichostatin A. The results with PI, although 
slightly higher correlated with the ToxiLight® assay (figure 4.20). The 
results with trypan blue uptake produced significantly higher results than 
both the ToxiLight® and PI staining. It appeared that nearly all of the cells 
were necrotic after 72 h of treatment with very few viable cells remaining.  
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Figure 4.20: Summary comparing the PI uptake data (A) with the ToxiLight data (B). Ma 
Mel 26a cells treated with trichostatin A (0, 1 and 5 µM) for 24, 48 and 72 h.  
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Below is a summary table of all experimental results carried out in this 
chapter: 
 
Cells Tested Drug Treatment Published Result Result from this 
research 
MEWO Cisplatin 
Vindesine 
Doxorubicin 
Trichostatin A 
Sensitive/resistant 
Sensitive/resistant 
Sensitive/resistant 
Used in 
combination 
therapy 
(sensitive) 
 
Cytostatic 
Cell death 
Cell death 
Cell death 
ESTDAB 105 Cisplatin 
Vindesine 
Doxorubicin 
Not published 
Not published 
Not published 
Resistant 
Resistant 
Cell Death 
 
WM 1205 Cisplatin 
Vindesine 
Doxorubicin 
Not published 
Not published 
Not published 
Cell death 
Cell death 
Cell death 
 
COLD 794 Cisplatin 
Vindesine 
Doxorubicin 
Not published 
Not published 
Not published 
Cytostatic 
Cell death 
Cell death 
 
Ma Mel 26a Cisplatin 
Vindesine 
Doxorubicin 
Camptothecin 
Dexamethasone 
Ara-C 
Trichostatin A 
Not published 
Not published 
Not published 
Not published 
Not published 
Not published 
Not published 
Cell death 
Cell death 
Cell death 
Cell death 
Resistant 
Cytostatic 
Cell death 
 
Ma Mel 28 Cisplatin 
Vindesine 
Doxorubicin 
Camptothecin 
Dexamethasone 
Ara-C 
Trichostatin A 
Not published 
Not published 
Not published 
Not published 
Not published 
Not published 
Not published 
Cytostatic 
Cytostatic 
Cytostatic 
Cell Death 
Resistant 
Resistant 
Cell death 
Table 4.06: Summary of the results found in this research 
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4.3 Discussion 
The work included in this chapter has examined the potential of using the 
novel bioluminescent assay ToxiLight®; and the ViaLight® Plus assays in 
parallel with a view to investigating the susceptibility of cells to various 
known chemotherapeutic agents. The study incorporated six melanoma 
cell lines, to analyse the effects chemotherapy agents have on cell 
survival using the ToxiLight®, ViaLight® Plus assay and subsequently 
P.I. uptake, trypan blue staining and light microscopy to confirm the assay 
data. 
 
The main objective of this chapter was to obtain further understanding of 
tumour chemo-sensitivity assays. The response of patients to 
chemotherapy varies immensely within the same histological tumour type 
(tumour heterogeneity). Human malignant melanoma, a tumour with a 
high potential to metastasise, is well known for its resistance to various 
anti-cancer agents (Nessling et al., 1999). The role of p53 and drug 
resistance in melanoma has been extensively studied; however, a full 
understanding of the molecular mechanisms occurring within these cells 
has not been obtained (Li et al., 1998). An investigation was undertaken 
to discover sensitive and resistant cell lines to various toxic chemotherapy 
agents; the selected cells can then be further investigated at the 
molecular level to ascertain the mechanism(s) of resistance (chapter 5).  
 
Assessment for mycoplasma contamination on all the melanoma cells 
gave a negative result, and all the drugs (doxorubicin, vindesine and 
cisplatin) were screened at their working concentrations with both the 
ToxiLight® and ViaLight® Plus assays to ensure there was no 
interference with either assay.  The standards for both AK and ATP, with 
and without the drugs showed no significant difference.  
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4.3.1 Effect of doxorubicin on melanoma cells 
 
The four cell lines, COLD 794, ESTDAB 005, WM 1205 and MEWO and 
the recently established Ma Mel 28 and Ma Mel 26a were all exposed to 
the anti-tumour antibiotic doxorubicin, with a view to establishing their 
drug sensitivity / resistance. It was concluded that the most sensitive cell 
line to doxorubicin was MEWO. The data with doxorubicin treatment is 
new and has not been found in published data. All of the cell lines 
showed a concentration dependent effect with the drug, revealing that 
doxorubicin had prevented replication of the cells. Doxorubicin is known 
to interact with DNA by intercalation and inhibition of macromolecular 
biosynthesis (Momparler et al., 1976). It inhibits the progression of the 
enzyme topoisomerase II, which “unwinds” DNA for transcription. 
Doxorubicin stabilises the topoisomerase II complex after it has broken 
the DNA chain in readiness for replication, preventing the DNA double 
helix from being resealed and thereby inhibiting the process of replication. 
Due to the consistent effects of this drug on the melanoma lines tested, it 
was difficult to differentiate sensitive from resistant cell lines.   
 
In contrast, the data produced from dosing the cells with doxorubicin, 
revealed two varying results. Doxorubicin had a cytotoxic effect on the Ma 
Mel 26a cells assessed by the ViaLight® Plus assay but no change was 
observed in the ToxiLight® assay, concluding that the drug was cytostatic 
for cell growth. The cells had been prevented from proliferating but no cell 
death was occurring. The Ma Mel 28 cell line proved to be the most 
resistant of the six lines tested and was used in subsequent experiments.  
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4.3.2 Effect of cisplatin and vindesine on melanoma cells 
 
Subsequent data with cisplatin and vindesine on all six cell lines 
demonstrated cell death in COLD 794 and WM 1205 and Ma Mel 26a 
cells by the ToxiLight® assay. WM 1205, Ma Mel 26a and MEWO cells 
were consistently sensitive to doxorubicin, cisplatin and vindesine with an 
increase in AK release in all experiments compared to the other cell lines. 
As previously mentioned MEWO cells had been previously published with 
cisplatin and vindesine (Nessling et al., 1999) revealing the sensitive 
nature of the cells to these drugs. In comparison however, no cell death 
was seen in either the ESTDAB 005 or Ma Mel 28 cells, which were 
resistant to both cisplatin and vindesine. This is new data that has not 
been published. The Ma Mel 28 cells revealed resistance to all three 
drugs tested, while ESTDAB 005 cells were only sensitive to one drug; 
doxorubicin. This led to the belief that apoptosis and cell death within 
melanoma cells could be drug specific as shown previously by Kissel 
(2006) who investigated sensitive and resistant strains of MEWO cells to 
etoposide and cisplatin.  
 
The data presented in this study suggests that the Ma Mel 28 cells could 
be used as a resistant cell line, at least in the context of cisplatin, 
doxorubicin and vindesine. Ma Mel 26a cells were sensitive to all three 
drugs and were chosen as a sensitive cell line. Both these cell lines were 
obtained from known patients with no previously published data. The 
history of the individual patients in respect to their individual therapy was 
available although the research was conducted blindly. To confirm this 
hypothesis of drug sensitive and resistant cells, three in-house drugs 
(camptothecin, ara-C and dexamethasone) were used against Ma Mel 
26a and 28 cell lines. Ma Mel 28 cells demonstrated resistance to all 
drugs except camptothecin used in the study and in addition there was no 
concentration dependent reduction in ATP with increasing exposure to 
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dexamethasone, implying the cells were also resistant to cytostasis. Ma 
Mel 26a cells were also resistant to dexamethasone, an effect not 
previously reported with these cells. With ara-C a slight drop in ATP was 
observed with both cell lines with an increase in drug exposure but no 
cytolysis observed. Camptothecin on the other hand, caused cell death in 
Ma Mel 26a cells with a drop in ATP and a significant increase in RLUs 
with the ToxiLight® assay. The conclusion from these results was that 
melanoma cells respond differently to various chemotherapeutic agents. 
One cell line may respond positively to one toxic agent but not another, 
and demonstrates that individual patients may respond differently to the 
agents used for treatment. The basis for drug resistance in melanoma is 
most likely dysregulation of apoptosis, although other mechanisms 
including drug transport, detoxification, and enhanced DNA repair may 
also play a role (Grossman and Altieri, 2004). 
 
4.3.3 An investigation into the effects of trichostatin A on melanoma 
cells. 
Histone deacetylase inhibitors (HDACIs) are a promising group of 
compounds inducing differentiation, growth arrest and apoptosis in 
tumour cells. The latter part of this study uses a combination of the 
ToxiLight® and ViaLight® Plus assays to monitor the effectiveness of the 
HDACI, trichostatin A on three melanoma cell lines. Previous studies 
concluded that the two cell lines Ma Mel 26a and Ma Mel 28 would be 
suitable for these experiments. These cells originate from patients with 
melanoma and no published has been found using them. The patient 
history is accessible for this study which was carried out blindly. A third 
cell line, MEWO, was selected for its sensitivity and its reported drug 
sensitivity in previous research (Kiesel, 2006). From the data it can be 
seen that trichostatin A does have an effect on MEWO cells, resulting in 
50% necrosis upon exposure to 5 μM; this result correlated with the 
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FACSCaliburTM and trypan blue exclusion data demonstrating although 
trypan blue uptake remained much lower than both PI and the ToxiLight® 
data, throughout the experiment, probably due to many of the dead cells 
degrading to form apoptotic bodies, not being accountable in this 
methodology. ToxiLight® on the other hand measures a stable enzyme in 
culture and should therefore be more sensitive and accurate.  
The most sensitive cell line was Ma Mel 26a, resulting in nearly 60% 
necrosis, again correlating with the data gained from the FACSCaliburTM 
analysis and trypan blue uptake. Ma Mel 28 cells proved to be resistant to 
trichostatin-A, although cytostasis was achieved with a reduction in ATP 
being observed. This was an encouraging result and suggests that 
histone deacetylase inhibitors (HDACIs) could be used in future research 
with melanoma cells. Histone acetylation is the subject of both research 
and clinical investigation (Haggarty et al., 2003). Response to HDACIs 
has also been observed by Peltonen et al., (2005), in studying the cellular 
effects of trichostatin A (TSA), on a panel of melanoma cell lines and its 
mechanism of action in relation to p53. While growth arrest was induced 
in all cell lines studied and apoptosis in the majority, these cellular effects 
were independent of the p53 status of the cells. The results from Peltonen 
et al. indicated that trichostatin A activated the apoptotic pathway in two 
out of the three cell lines tested; this could therefore provide alternative 
therapeutic approaches for melanoma treatment, whether alone or in 
combination therapy. 
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The next phase of this study was to use frozen samples of all the cell 
lines treated with and without trichostatin A and analyse changes in the 
cell proteome correlating with cytotoxicity/viability. MALDI-TOF MS 
analysis will be used to derive protein/peptide profiles.  The results from 
the MALDI analysis will then be subjected to bioinformatic analysis, using 
artificial neural networks to identify potential biomarkers that may 
associate with melanoma cell apoptosis. 
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Chapter 5: Identification of important ions using 
proteomics and bioinformatics analysis which could be 
associated with drug response. 
 
 
5.1 Introduction 
 
 
In the UK alone, more than 10,000 people are diagnosed with skin cancer 
each year.  About 3 out of every 100 cancers diagnosed (3%) are 
melanomas.  Although not a common cancer, melanoma is important 
because it is easily curable if diagnosed early.  Primary treatment 
involves surgical removal of the melanoma which results in 98% of low-
risk patients being cured. However, if the disease has progressed current 
treatment is still experimental and effective only in a small number of 
cases. There is no recent evidence to show that survival rates have 
improved due to adjuvant therapy. Serum biomarkers that are currently 
used clinically, with the ability to differentiate between high and low stage 
melanoma patients are lactate dehydrogenase (LDH), S100B and 
melanoma-inhibitory activity (MIA). These tests lack sensitivity and are 
unreliable predictors of asymptomatic and metastatic cancer (Matharoo-
Ball et al., 2007). This has resulted in a large amount of research being 
undertaken to search for melanoma biomarkers that predict a patients’ 
risk of cancer or metastasis and to monitor those receiving adjuvant 
therapies. Phenotypic expression patterns could hold the key to certain 
pathological conditions resulting in the discovery of novel biomarkers or 
as a target for new therapies. Techniques involving molecular profiling 
are not only confined to identifying macromolecules (e.g 
peptides/proteins) that could form the basis of new treatment regimes 
(Mian et al., 2003), they can even be applied as a novel methodology for 
the pathological classification of diseased tissue such as cancer (Koomen 
et al., 2005; Matharoo-Ball et al., 2007; Ball et al., 2001). 
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One approach that shows great promise is proteomic profiling, in which 
new methods for sensitive and reproducible identification and 
quantification of thousands of different proteins in cells and serum are 
being applied to analyse molecular changes in melanoma (Bernard et al., 
2003). The availability of new mass spectrometers capable of high-
throughput protein analysis has brought about powerful screening 
methods for identifying protein signatures with disease stage. The two 
most popular approaches in analysing and identifying proteins that are 
present in biological samples are MALDI (matrix assisted laser desorption 
ionisation) and SELDI (surface enhanced laser desorption ionisation) 
mass spectrometry (MS). These methods are capable of measuring 
protein profiles as a “top-down” approach, analysing intact proteins in 
complex mixtures, and peptides, a “bottom-up” approach. The robustness 
of MALDI-TOF-MS facilitates the investigation of complex samples and 
has been applied successfully using a variety of statistical pattern-
recognition tools for early cancer detection in ovarian, colorectal, breast, 
prostate, astrocytoma/glioblastoma and melanoma cancers (Mian et al., 
2005; Petricoin et al., 2002; Li et al., 2002; Matharoo-Ball et al., 2007).  
SELDI, introduced by Hutchens and Yip, utilises a sample platform using 
solid phase supports or “chips” coated with a selection of chemical or 
biochemical agents for protein separation prior to analysis by MALDI (Li 
et al., 2002). A limitation of MALDI-MS and SELDI-MS analysis is that 
identification of proteins cannot be carried out by measuring the protein 
molecular weight or m/z without the incorporation of protein digestion. 
This is usually carried out separately following 2-DE analysis of proteins 
or as in solution digestion prior to MS analysis.  
 
There has been much controversy about the methodology used regarding 
biological, technological and data mining tools that could introduce bias. 
These mainly refer to the way samples are collected, processed and 
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stored, instrumentation and data analytical methods used. The research 
team at Nottingham Trent University has employed a combination of an 
automated robotic chromatographic ZipTipTM methodology combined with 
MALDI-TOF-MS generating a powerful and sensitive analysis of samples 
(Matharoo-Ball et al., 2007). This method enables measurement at the 
protein level, with the same sample tryptically digested for measuring 
peptides (bottom-up) for identification as demonstrated in figure 5.01. 
Measurement of proteins alone would require further investigation by 
additional techniques to confirm identification. 
  
 
 Figure 5.01 A flow diagram to illustrate the procedure of mass spectrometry 
 
Due to the high number of samples and the quantity and dimensionality of 
the data produced by MALDI-TOF MS, data mining tools are essential in 
order to sort through the data for protein or peptide patterns. To produce 
accurate and sensitive predictions of important ions, the statistical 
methods used have to be very powerful. Some of the methods assessed 
include Bayesian analyses, fuzzy logic, and the computational tool 
employed in this study, artificial neural networks (ANNs). ANNs are 
divided into two main classes; supervised and unsupervised methods 
(Lancashire et al., 2005). Supervised learning involves a dataset 
consisting of both input and output data which is presented to the ANN 
during a training phase. The ANN tries to find a link between the data that 
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results in the least error adjusting the weighted links until this error falls 
below a certain threshold. Once the ANN has established a connection 
between the inputs and outputs, the model can then be utilised for 
unseen data. In comparison, unsupervised learning uses only the input 
dataset and the ANN is free to search for hidden relationships amongst 
this data (Tafeit et al., 1999). Recent studies have shown that the 
application of ANN-based approaches can be used to identify patterns 
strongly associating with specific disease stages (Matharoo-Ball et al., 
2007; Ball et al., 2002; Petricoin et al., 2002). The ANNs used in the 
present study, uses the supervised approach, learning predictive patterns 
contained within complex datasets, by adjusting and updating the 
connecting weights between the layers of the network using the back 
propagation (BP) algorithm applied to the multi-layer perceptron (MLP).  
 
 
 
 
 
 
 
 
 
Figure 5.02 To show the structure of the multi-layer perceptron ANN 
 
o Input layer: Receives input from the raw data, 
corresponding to one of the variables i.e. control (1) or drug 
treated (2). 
o Hidden layer: It is a feature detector which can classify 
non-linear data. 
o Output layer: The data from this section are the final 
results.  
 
Weighted links 
Weighted links 
Input  
layer 
Output  
layer 
Hidden  
layer 
Weighted links 
Weighted links 
Input layer  
Output layer  
Hidden layer  
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As illustrated in figure 5.02, the ANNs are trained using the input layer 
(representing independent variables), and given the resulting output or 
correct sample group. The input layer could represent the m/z value and 
intensity from a set of mass spectral profile data. (Note: The ion values 
(m/z) represent [M+H]+ ions from the MALDI-MS). The hidden layer 
represents the mathematical mechanism of the model and it learns by 
processing all the data and information it receives to find patterns 
between sample groups and passes it to the output layer via weighted 
links. The output layer is calculated by the network based on the data 
inputted, and is then compared with the actual known output. For 
example, in a classification model an output of 1 would represent a 
control sample and an output of 2 would represent a cancer-treated 
sample, and then the error between the predicted and actual outputs is 
calculated. This error demonstrates how well the ANNs are working.  
 
When using ANNs, analysing the data can be separated into three 
groups; (1) the training data as previously mentioned; (2) the test data 
where the ANNs are checked and validated for its outputs on the test set 
whilst the training occurs and (3) once training has been completed, it is 
validated by a further set of completely blind data which are applied and 
an output calculated based upon the new data (Basheer et al., 2000; 
Lancashire et al., 2005). The performance on unseen data indicates 
whether a generalised model has been obtained or not. By using multiple 
models with different unseen datasets (random sample cross validation) a 
more generalised model may be obtained with only a small sample 
number. ANNs are based on biological neurons which are highly 
organised, processing information which contains high levels of noise and 
redundancy (Ball et al., 2002). Their ability to learn and adapt, allow the 
system to modify itself enabling analysis of unseen data. ANNs have 
been used in a variety of applications including modeling, classification, 
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pattern recognition, and multivariate analysis. The stepwise approach 
used in this study is a detailed method of parameterisation, whereby ions 
are added step by step for the determination of the best subset of ions to 
predict a particular outcome. Interactions between the ions may also be 
identified in this way. The analysis is based on the hypothesis that the 
change in performance when an input is added indicates its influence on 
the model. Multiple sub models are run with input 1, then with 2, and then 
with input 3 and so on until all of the inputs are modeled separately. The 
error known as “test error” is determined for each sub model and the 
input that gives the best “test performance” and the lowest “test error” is 
selected. This is then placed with all of the remaining inputs sequentially 
in a number of sub models once more. This process continues adding 
more inputs until there is no improvement in the error revealing a subset 
of identified ions. 
 
The aim of the research in this chapter was to identify molecular factors 
that may be associated with the drug-resistant or sensitive phenotypes of 
three pre-selected malignant melanoma cell lines. To minimise criticisms 
involving bias in biomarker identification a validated, robust, and 
reproducible methodology based on MALDI-TOF-MS combined with 
bioinformatics to profile tryptic peptides was used. The three human 
melanoma cell variants exhibiting low and high levels of resistance to 
various drugs tested in chapter 4 were exposed to the histone 
deacetylase inhibitor, trichostatin A. Its effect on these cells was 
characterised using MALDI-TOF MS for peptide identification. Alterations 
in the various protein expressions were monitored over time and at 
different dose concentrations of the drug, thus simulating a situation close 
to clinical chemotherapy. ANNs were applied to the data for the cell lines 
and a panel of peptide biomarkers obtained correlating to the dose and 
time of drug exposure.  
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Figure 5.03  Schematic flow chart outlining the methodology carried out in this study 
for biomarker identification. 
 
The aims of this chapter will be to: 
 
o Prepare and optimise the samples for analysis. 
o Separate the proteins using C18 ZipTips, utilising an automated 
methodology (Xcise, Proteome Labs, Shimadzu, Manchester, UK), 
followed by tryptic digestion of the cellular proteins and a second 
C18 ZipTip for desalting and concentration of the sample. 
o To analyse the samples by MALDI-TOF MS and then visually 
inspect the data.  
 
Standard sample collection 
Freezing aliquots of sample in -80°C 
Randomization of the sample position on the Xcise 96 well 
plate and MALDI 384 plate 
Sample equalisation of  
protein 
MALDI-MS analysis 
Data pre-processing 
Bioinformatics 
ZipTip clean-up & protein analysis 
Tryptic digest & peptide analysis 
Same aliquot of sample 
Step 1. Sample  
preparation 
Step 2. Protein  
separation  
Step 3. Analysis  
and Protein  
identification   
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o Pre-process the MALDI-TOF MS spectra ready for bioinformatic 
analysis using ANNs.  
o Train and test the ANNs and allow the trained network to recognise 
key differences between drug-treated and untreated melanoma 
cells using a blind dataset.  
o Carry out MALDI-TOF MS/MS for protein identification of the tryptic 
peptide ions predicted by ANNs.  
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5.2 Results 
 
5.2.1 Protein quantification of melanoma samples 
 
Protein quantification was performed using the Bio-Rad protein micro 
assay as described in chapter 2.9.2.  The standard curve used for the 
quantification of protein in the MEWO cell samples is illustrated in the 
graph below (figure 5.04). As can be seen an R2 value of 0.98 was 
achieved from this experiment with the standard curves for Ma Mel 26a 
and Ma Mel 28 cells resulting in an R2 value of 0.97 and 0.98 
respectively.  
 
Figure 5.04 An illustration of the BSA standard curve obtained after measurement on a 
plate reader at an absorbance of 595 nm. 
 
5.2.2 Sample optimisation  
 
Once the amount of protein was quantified on all 3 cell lines, the frozen 
aliquots of the Ma Mel 26a cell lysates were corrected to 0.1 mg.ml-1 
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using 0.1% TFA prior to analysis on the MALDI-TOF MS. This 
concentration was chosen because the majority of the samples had very 
low starting protein concentrations. Samples were optimised as explained 
in chapter 2.9.3 and 2.9.4 prior to sample randomisation on the MALDI 
target plate using Microsoft Excel 2003.  Once randomised and diluted 
the samples were processed on the robotic system Xcise (Shimadzu, 
Manchester, UK).  
 
5.2.3 MALDI-TOF-MS 
 
The samples were analysed using an Axima CFR+ MALDI-TOF mass 
spectrometer (Shimadzu, Manchester UK) operated in reflectron mode 
mass range of 800-3500 Da for peptide analysis. Mass spectra 
acquisition was performed using autoquality mode, with the accumulation 
of 100 profiles and using per 5 shots per profile. After data acquisition by 
MALDI-MS, all spectra were checked visually to ensure the quality and if 
they resembled a blank profile then these were removed prior to ANN 
analysis. Figure 5.05 shows the spectra observed from six QC samples at 
various positions on the same MALDI target plate demonstrating the 
reproducibility of the MALDI-TOF MS method. There is still some slight 
variation in the intensities of some peaks even though they have been 
subjected to the same MALDI MS run, laser power and matrix. However, 
these samples undergo a cleaning procedure twice on the robotic system 
prior to MALDI analysis which may increase the variability between 
samples. Another observation of the QC samples in figure 5.05 is that 
although the spectrum obtained is highly reproducible, it is also very 
complex making many individual peaks difficult to compare and identify 
without closer inspection.  
 
 
                                                                                                                              
Chapter 5                                                                                                                          
 
 
Susan Catherine Gill 
PhD Thesis, 2009 
 
194 
 
 
 
 
 
Fi
gu
re
 5
.0
5 
E
xa
m
pl
e 
of
 t
he
 r
ep
ro
du
ci
bi
lit
y 
of
 M
A
LD
I 
M
S
 p
ro
fil
es
 in
 t
he
 1
00
0-
25
00
D
a 
m
as
s 
ra
ng
e.
 
Th
e 
fig
ur
e 
sh
ow
s 
si
x 
ra
nd
om
 Q
C
 s
am
pl
es
 a
fte
r t
ry
pt
ic
 d
ig
es
t, 
ru
n 
in
 r
ef
le
ct
ro
n 
m
od
e.
 E
ac
h 
sp
ec
tru
m
 
is
 re
pr
es
en
ta
tiv
e 
of
 a
 Q
C
 s
am
pl
e 
ru
n 
on
 d
iff
er
en
t p
os
iti
on
s 
of
 th
e 
M
A
LD
I t
ar
ge
t p
la
te
.  
 
                                                                                                                              
Chapter 5                                                                                                                          
 
 
Susan Catherine Gill 
PhD Thesis, 2009 
 
195 
5.2.4 Ma Mel 26a cells 
 
Preliminary work was carried out on the Ma Mel 26a cells to investigate 
the proteomic profile differences between drug-treated and untreated 
cells after initial dose (day 0), day 1, day 2 and day 3 after drug exposure 
for identification of biomarkers that could correctly classify differences 
between these groups. Upon visual inspection, differences were 
observed between the tryptic peptide spectra obtained from treated and 
untreated cells. The representative spectra for the peptides with 1 µM and 
5 µM trichostatin A are shown in figures 5.06 and 5.07 respectively. As 
can be seen, these spectra are too complex and the pattern differences 
between the groups are ambiguous by eye. Any visual differences seen 
between the treated and untreated cells may not necessarily mean that 
they will be important predictive markers.  
 
Differences seen in ions m/z 1321 and 1468 (figure 5.06) appear to show 
the protein being expressed less in the drug-treated cells with the 
intensity dropping at each time point measured from day 0 to day 3. 
Figure 5.07 shows an ion at 1568 which appears to increase in intensity 
over time, showing expression within the cells as they are treated with 
trichostatin A. After day 3 the intensity of the ion appears to drop again. 
Even though the samples were equalised for the initial protein 
concentration the general spectra at day 3 appeared to have a trend of 
lower intensity peptide peaks compared with days 1 and 2 of exposure. It 
was however noted from the spectra that the protein levels needed to be 
more concentrated than the 0.1 mg.ml-1 that was used, as very few 
peptide peaks could be visually seen with even less observed after 3 
days as mentioned above. There are other peaks that could also be said 
to have differences within the spectra but due to the number of samples 
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analysed and complexity of the data the application of ANN analysis was 
necessary for full data analysis.  
 
 
  
                                                                                                                              
Chapter 5                                                                                                                          
 
 
Susan Catherine Gill 
PhD Thesis, 2009 
 
197 
 
 
 
Fi
gu
re
 5
.0
6 
R
ep
re
se
nt
at
iv
e 
sp
ec
tra
 o
f 
M
a 
M
el
 2
6a
 c
el
l t
ry
pt
ic
 p
ep
tid
es
, 
af
te
r 
tre
at
m
en
t 
w
ith
 1
 µ
M
 t
ric
ho
st
at
in
 A
, 
ac
qu
ire
d 
in
 re
fle
ct
ro
n 
m
od
e.
 T
he
 re
gi
on
s 
hi
gh
lig
ht
ed
 s
ho
w
 v
is
ua
l d
iff
er
en
ce
s.
 
 
                                                                                                                              
Chapter 5                                                                                                                          
 
 
Susan Catherine Gill 
PhD Thesis, 2009 
 
198 
 
 
 
 
 
 
 
Fi
gu
re
 5
.0
7 
R
ep
re
se
nt
at
iv
e 
sp
ec
tra
 o
f M
a 
M
el
 2
6a
 c
el
l t
ry
pt
ic
 p
ep
tid
es
 a
fte
r 
tre
at
m
en
t w
ith
 5
 µ
M
 tr
ic
ho
st
at
in
 A
, 
ac
qu
ire
d 
in
 re
fle
ct
ro
n 
m
od
e.
 T
he
 re
gi
on
s 
hi
gh
lig
ht
ed
 s
ho
w
 v
is
ua
l d
iff
er
en
ce
s.
 
 
                                                                                                                              
Chapter 5                                                                                                                          
 
 
Susan Catherine Gill 
PhD Thesis, 2009 
 
199 
5.2.4.1 Bioinformatic analysis of Ma Mel 26a cells using ANNs 
Bioinformatic analysis was carried out to compare the different profiles 
obtained by MALDI-MS, using a stepwise approach. To interpret this 
highly complex data, a sophisticated algorithm (i.e. ANNs) was employed. 
Prior to ANNs analysis it was essential to reduce the data points by 
rounding (binning) the m/z values to the nearest Dalton, to increase the 
accuracy and efficiency of the analysis. Any spectra that looked like blank 
profiles or not having consistent peaks were removed prior to ASCII file 
conversion and bioinformatic analysis. A stepwise approach was utilised 
to train the data to recognise key peptide profiles that differentiated 
untreated cells versus the cells treated with the drug to give a panel of 
important biomarkers. A multi-layer perceptron ANN with a back 
propagation was used for this study as described by Lancashire et al. 
(2005) and demonstrated in figure 5.02. The m/z MALDI-MS data were 
used to train, test and validate the ANN model which was developed 
using random sample cross validation where the data is randomly split 
into three subsets.  The data consisted of n=14 experiments with each 
time point (0, 24, 48 and 72 hours) and drug treatment (0, 1, 5 µM) (i.e. 
168 datapoints (14x12)). 60% of samples from each cell line were set 
aside for training, with 20% used to test the performance of the ANNs and 
then a final 20% of the samples used as a blind or validation set of data.  
The primary ion identified by the model was used as a single input and for 
each model 50 random training/test/validation bootstrapped subsets were 
used. The model with the lowest predictive error determined the most 
important input. This identified input was then combined with a second 
input (two inputs) to train the models as described above and accordingly 
the second important ion was identified. This process was continued until 
no significant improvement in the performance of the model was obtained 
by adding new inputs. This methodology resulted in the production of a 
list of key ions, as shown in table 5.01 for Ma Mel 26a cells. These ions 
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are the most important for correctly classifying the two classes of 
samples: untreated and treated cells.   
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Stepwise 
steps 
m/z 
[M+H]+ 
Test 
Performance 
(%) 
Test 
Error 
    
Day 1 
Control 
vs 1 µM 
   
1 
2 
1082 
1680 
75 
83 
0.166 
0.141 
 
Day 2 
Control 
vs 1 µM 
   
1 
2 
3 
4 
844 
1793 
3163 
1666 
71 
85 
86 
100 
0.193 
0.126 
0.089 
0.059 
 
Day 3 
Control 
vs 1 µM 
   
1 
2 
3 
2782 
2955 
1429 
75 
75 
88 
0.191 
0.149 
0.126 
 
Day 1 
Control 
vs 5 µM 
  
 
 
1 
2 
3 
3334 
2355 
1476 
79 
79 
86 
0.157 
0.132 
0.114 
 
Day 2 
Control 
vs 5 µM 
   
1 
2 
3 
4 
3235 
1025 
2553 
1107 
71 
85 
86 
100 
0.191 
0.139 
0.109 
0.068 
 
Day 3 
Control 
vs 5 µM 
   
1 
2 
1062 
2155 
85 
86 
0.859 
0.135 
 
 
Table 5.01 Artificial Neural Network results of Ma Mel 26a cells (n=14). Table to show 
the test performances and the mean squared error for the test data sets as each input is 
added to the model. The results show the top ions that gave the best accuracy of 
prediction with the error failing to improve with subsequent additions.  
 
N = number of experiments 
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As can be seen in table 5.01, several ions have been identified as 
important in each of the models. In the control versus treatment exposure 
(1 µM) for day 1, the first step of the model identified the ion at m/z 1082 
which shows a significant difference in 75% of the data analysed; this 
was demonstrated to be the most important ion. The addition of the 
second ion at m/z 1680 increased the performance to 83% after which 
the addition of further ions did not improve the model. After day 2 of drug 
treatment a new set of ions were shown to be important with ion m/z 844 
showing a 71% performance. The addition of ions 1793, 3163, 1666 
produced a 100% performance rate. At day 3, three ions were identified, 
ion m/z 2782 being the most important with the addition of the ions 2955 
and 1429 giving a model performance of 88%. Treatment with 5 µM 
trichostatin A showed ion m/z 3334 between the groups to differentiate 
with a 79% accuracy, ions 2355 and 1476 resulted in 86% performance; 
day 2 identified four ions; 3235 (most important), 1025, 2553 and 1107, 
combined gave a 100% performance rate and at day 3, 1062 and 2155 
gave an 86% performance rate.  
 
5.2.4.2 Validation of ANNs with blind data set 
 
After training and testing of the model was completed, a new independent 
blind set of data, not previously incorporated into the model was 
presented to validate the results by evaluating the ability of the model to 
assign these new samples to the correct class. Validation samples n=5 of 
treated and n=5 of untreated for each drug concentration and drug 
exposure time were used for data analysis. For the untreated compared 
to the treated cells with 1 µM trichostatin A, the model correctly classified 
only 55% of the day 1 dataset, 45% of the day 2 dataset and 60% of the 
day 3 dataset. This series of experiments questioned the validity of the 
model and predicted ions (table 5.01) to associate and define the class of 
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samples. For the untreated compared to the treated cells with 5 µM 
trichostatin A the model also failed to predict unseen samples accurately, 
38% were correctly classified for the day 1 dataset, 48% correct for the 
day 2 dataset and only 33% classified correctly for day 3. With the 
original spectra proving inconclusive visually, due to the low 
concentration of protein, and the additional lack of good quality ANNs 
data, the biomarker ions identified within these models were considered 
to be inaccurate and were not analysed by MS/MS. The cell line could not 
be repeated at a higher protein concentration due to a lack of cell 
samples remaining. Time permitting the original experiments would have 
been repeated.  
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5.2.5 Ma Mel 28 cells 
 
Due to the low quality of spectra produced for the Ma Mel 26a cells using 
a protein concentration of 0.1 mg.ml-1, the starting protein concentration 
was increased to 0.5 mg.ml-1 for subsequent experiments. After a visual 
inspection of the peptide spectra (shown in figures 5.08 and 5.09), it can 
be seen that the increased protein levels led to a better quality spectra 
when compared to the Ma Mel 26a data  (figures 5.06 and 5.07). Visual 
differences were possible because cell spectra were equalised for the 
same peak intensity. Due to the large amount of data, only a few peaks 
were identified visually as showing differences between the treated and 
untreated cells. Ions m/z 1346, 1439 and 1618 were seen to have an 
increasing intensity when the cells were treated with 1 µM trichostatin A 
as shown in figure 5.08. Ions m/z 1482 and 1676 were the two peaks 
shown to increase in intensity (figure 5.09) with the increase in drug-
treatment to 5 µM trichostatin A. As seen previously with the Ma Mel 26a 
cells, after day 3 of treatment with 5 µM trichostatin A, the spectra has 
significantly less peptide peaks. The ions m/z 1482 and 1676 appear to 
decrease in expression in this spectrum possibly due to the secretion of 
the protein into the surrounding media or initiation of apoptotic 
mechanisms which may suggest cell death following drug exposure.   
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5.2.5.1 Bioinformatic analysis of Ma Mel 28 cells using ANNs  
 
As for Ma Mel 26a cells, data mining was conducted using ANNs to 
derive and recognise patterns that associate with drug treated and control 
cells. As can be seen in table 5.02, the ANNs have performed well in all 
the models tested. After day 1 of treatment with 1 µM trichostatin A, three 
ions were identified to be of importance. The most important ion m/z 1541 
resulted in an 88% performance rate and the addition of m/z 2191 and 
m/z 3383 gave additional support to the model resulting in a 100% 
performance. After day 2, the ion m/z 1440 gave a performance of 83% 
with the addition of the second ion m/z 2840 giving a 100% performance. 
At day 3 a single ion, m/z 1378, gave a 100% test performance.  When 
treated with 5 µM trichostatin A, some of the ions seen previously with 1 
µM trichostatin A re-appeared. After day 1, ion m/z 1817 (with a singular 
performance of 80%), combined with ions m/z 2566 and 1884 gave a 
performance of 90%. Day 2 resulted in the most important ion m/z 1430 
(81%), together with ions m/z 1440 and 1618 giving a 100% performance.  
The m/z 1440 ion had been previously identified after day 2 of treatment 
with 1 µM trichostatin A where it was the most important ion (see ion in 
red, table 5.02).  Day 3 of treatment with 5 µM trichostatin A again 
showed the re-appearance of the ion m/z 1430 where it was now seen to 
be the most important ion giving a 100% performance. 
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 *No identity found 
 
Table 5.02 Artificial Neural Network results on Ma Mel 28 cell line (n=10). Table to show 
the test performances and the mean squared error for the data sets as each input is 
added to the model. The results show the top ions that gave the best accuracy with the 
error failing to improve with subsequent additions; highlighted in red are the ions which 
appear in more than one model as a top predictive ion.  
 
N = number of experiments 
 
Stepwise 
steps 
m/z 
[M+H]+ 
Test 
Performance 
(%) 
Test 
Error 
Day 1 
Control vs 
1 µM 
   
1 
2 
3 
1541 
2191 
 3383* 
88 
88 
100 
 
0.127 
0.098 
0.060 
 
Day 2 
Control 
vs 1 µM 
   
1 
2 
1440 
2840 
83 
100 
0.120 
0.049 
 
Day 3 
Control vs 
1 µM 
   
1 1378 100 0.077 
 
Day 1 
Control vs 
5 µM 
   
1 
2 
3 
1817 
2566 
1884 
 
80 
90 
90 
 
0.162 
0.149 
0.100 
Day 2 
Control vs 
5 µM 
   
1 
2 
3 
1430* 
1440 
 1618* 
81 
94 
100 
 
0.130 
0.076 
0.035 
Day 3 
Control vs 
5 µM 
   
1 1430* 
 
100 0.017 
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A population chart was generated to test the ANNs ability to predict the 
peptide profiles correctly for individual sample. Over 50 models the ANNs 
predicted this model with an accuracy of 100%. Figure 5.10 is based on 
the single ion m/z 1430 obtained from untreated and 5 µM trichostatin 
treated cells after 72 h of treatment. The results show the model correctly 
predicted 91 % of the individual cell lines as either a control or drug-
treated sample; the misclassified samples have been circled. The ratios 
below 0.5 are assigned to the untreated control group and a ratio above 
0.5 is classified as the treated samples. It can be seen from the chart that 
all of the drug-treated cells were classified correctly (red bars) with a ratio 
of >0.5 however; the control cells had four samples misclassified with the 
remaining predicted correctly with a ratio <0.5.  
 
 
Figure 5.10 Predictive capability of ANNs trained to recognise tryptic peptide profiles 
based on the ion m/z 1430 for Ma Mel 28 cells versus control. The error bars represent 
the confidence interval. The blue bars correspond to the control samples and the red 
indicate drug treated samples. A predicted value below 0.5 indicates a control sample, 
whilst a prediction greater than 0.5 indicates a treated sample. 
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5.2.5.2 Validation of ANNs with blind data set 
 
To test the validity of the trained model further we used a completely 
independent blind dataset that had not been included in the model 
previously. This validation set to test the model included MALDI spectral 
data from n=4 treated and n=4 of untreated cells for each drug treatment 
and incubation period. For treatment of 1 µM trichostatin A compared to 
untreated cells, the samples were correctly assigned to a median 
accuracy of 84% for day 1; 96% for day 2 and 100% for day 3. Treatment 
with 5 µM trichostatin A gave a median accuracy of 66% for day 1, 94% 
for day 2 and 100% for day 3. These results suggested that the model 
was performing well and that the predictive ions identified could be used 
as biomarkers discriminating between untreated and drug treated cells. 
This proof of principle study has important implication for tailoring the 
drug treatment to patient response and a move toward personalised 
therapy. To investigate this further, it would mean repetition of 
experiments to see if the same biomarkers appear. If they do these 
markers could be representative of response to therapy. To clinically 
evaluate the data, serum samples would have to be collected in 
conjunction with these experiments as this would be more realistic at a 
clinical level i.e. cells obtained from biopsies is not an easy option. 
 
 
5.2.5.3 Identification of predicted biomarkers for Ma Mel 28 
cells 
 
The results from the blind dataset revealed the ANN model to have good 
predictive capabilities; the only exception being the control and drug-
treated cells (5 µM) at day 1, which only classified 66% of the blind data 
correctly. Therefore the biomarker ions within these models were 
considered to be those which most accurately distinguished between 
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control and treated melanoma cells for this dataset. The predictive 
peptide ions in table 5.02 were analysed by MS/MS on the Ultrafelx III 
(Bruker), a more sensitive machine than the initial MALDI data which was 
run on the Shimadzu AXIMA-CFR. Due to the complexity of biological 
samples a more rigorous pre-fractionation of the samples was carried out 
prior to MALDI-MS/MS analysis. The samples were manually C18 
ZipTipped and eluted with increasing concentrations of ACN. Only a few 
peptides were identified using the MALDI-MS-MS methodology due to the 
minimal fractionation using C18 ZipTip. This may have led to several 
overlapping peptide peaks making classification of these proteins difficult. 
Therefore the MEWO and Ma Mel 28 cell line samples were sent to 
Bruker Daltonics (Bremen, Germany) for analysis. Prior to MS/MS 
analysis a comprehensive Liquid Chromatography separation was carried 
out so that one sample was fractionated over the 384 MALDI target plate 
ensuring separation of the peptides to allow protein identity. 
 
To identify the peaks following MS/MS analysis the Mascot database 
search engine was used and the search parameter settings for the 
Mascot sequence query routine were as follows: 4 maximum missed 
cleavage, 0.8 Da tolerance was used for the singly and doubly charged 
precursor ion and 0.9 Da for the fragment ion mass. Swissprot was used 
as the reference database (human taxonomy) and trypsin was set as the 
proteolytic enzyme.  
 
The biomarker with m/z 1440 identified by ANNs as discriminatory 
between day 2 control and 1 µM and 5 µM trichostatin-A treatment was 
identified as ATP synthase with a measured m/z of 1439.7783. Protein 
identities were also found for the measured peptide with an m/z value of 
1540.77 as alpha enolase for the ANN ion m/z 1541. The predicted 
peptide ion m/z 1817 resulted in three possible identities which were ATP 
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synthase subunit beta (m/z 1815.86), tropomyosin alpha-3 chain (m/z 
1815.88) and m/z 1815.99 which belonged to 78 kDa glucose regulated 
protein. The tryptic peptide biomarker with m/z 1884 had two possible 
identities which were pyruvate kinase isozymes M1/M2 with a measured 
peak at m/z 1883.88 and a second protein identified as glutathione S-
transferase P with an m/z 1883.94. The last predicted ion identified in 
drug-treated samples from the ANNs analysis was m/z 2840 which was 
identified as trifunctional enzyme subunit beta, mitochondrial (m/z 
2840.32). All the ions with an m/z of 1541, 1817, 1884 and 2840 were 
found in drug-treated samples only and were not found in any control cell 
lines.  
 
For the peptide ion 1378 two possible peptides were identified – 
heterogeneous nuclear ribonucleoproteins A2/B1 (m/z 1377.61) and poly 
ADP-ribose polymerase 1 (m/z 1377.73). The ion with m/z 2191 was also 
identified as a component of heterogeneous nuclear ribonucleoproteins 
A2/B1 (m/z 2189.88) whilst the ion m/z 2566 from the ANN analysis was 
identified as staphylococcal nuclease domain-containing protein 1 (m/z 
2565.25). Both these peptide peaks were only found in the control 
samples.  A summary of the results are shown in table 5.03. These 
results would have to be re-analysed to assess the reproducibility of the 
data. 
 
For the ANN ions m/z 1430, 1618 and 3383 no peptide sequences were 
identified upon database searching using the appropriate MS/MS spectra. 
The identified proteins and the associated peptide peaks were noted and 
checked to ensure the peaks were present in the original MALDI-TOF-MS 
peptide spectra. Peptide profiles of m/z 1439.77 (ATP synthase) are 
shown in figure 5.11.  
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TR = drug-treated samples CON = Control samples 
 
 
Table 5.03 Table to show the peptides identified by MS/MS using ions predicted by ANNs for discrimination between untreated and 
drug-treated cells. 
Ma Me 28 ions (combined)  
ANN Ion m/z 
Identified 
Peptide sequence Mowse 
Score 
Protein                                                                               Samples  
                                                                                             
Identiifed 
1378 1377.6183 GGGGNFGPGPGSNFR 75 Heterogenous nuclear ribonucleoproteins A2/B1                  CON 
 1377.7368 TTNFAGILSQGLR 42 Poly ADP-ribose polymerase 1 
     
1440  1439.7783 VALTGLTVAEYFR 92 ATP synthase subunit beta, mitochondrial                              TR 
     
1541 1540.7742 VVIGMDVAASEFFR 124 Alpha enolase                                                                          TR 
     
1817 1815.8639 IMDPNIVGSEHYDVAR 99 ATP synthase subunit beta, mitochondrial                              TR 
 1815.8888 HIAEEADRKYEEVAR 53 Tropomyosin alpha-3 chain 
 1815.9924 IINEPTAAAIAYGLDKR 70 78kDa Glucose regulated protein 
     
1884 1883.8853 LNFSHGTHEYHAETIK 87 Pyruvate kinase isozymes M1/M2                                           TR 
 1883.9447 FQDGDLTLYQSNTILR 129 Glutathione S-transferase P 
     
2191 2189.8857 NMGGPYGGGNYGPGGSGGSGGYGGR 209 Heterogenous nuclear ribonucleoproteins A2/B1                  CON 
     
2566 2565.2588 VLPAQATEYAFAFIQVPQDDDAR 33 Staphylococcal nuclease domain-containing protein 1          CON 
 
     
2840 2840.3223 FNFLAPELPAVSEFSTSETMGHSADR 62 Trifunctional enzyme subunit beta, mitochondrial                   TR 
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The identified peptides peaks were checked for presence with the original 
spectra to confirm their presence in the samples. The peak at m/z 
1439.77 was present in most of the spectra in drug treated cell samples. 
Figure 5.11 demonstrates that this peak was observed at both 1 µM and 
5 µM trichostatin A after day 2 of treatment as identified by the ANN 
analysis. 
                                   
 
 
 
Figure 5.11 Representative mass spectra of peptides magnified using fractionated Ma 
Mel 28 cell lysate from control and trichostatin-A treated samples after day 2 of 
treatment. This spectrum illustrates the observed intensity differences of ion at m/z 
1440, present in treated melanoma but not in the control samples. 
 
 
The ion identified at m/z 1541 by ANNs predicted 88 % of the cells after 
day 1 of treatment with 1 µM trichostatin A versus control cells. Its 
presence was found in many of the samples treated with both 1 µM and 5 
µM of drug with no peaks observed in the untreated cells. Although figure 
5.12 shows the presence of ion m/z 1541 in both concentrations of 
trichostatin treated samples after day 1 of drug treatment in the raw 
MALDI spectra; this ion was not found to be an important predictive ion 
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usingthe stepwise ANNs in the 5 µM treated cells versus control samples 
for any of the drug exposure times. 
 
 
 
 
Figure 5.12 Representative mass spectra of peptides magnified using fractionated Ma 
Mel 28 cell lysate from control and trichostatin-A treated samples after day 1 of 
treatment. This spectrum illustrates the observed intensity differences of ions at m/z 
1541, present in treated melanoma but not in the control samples. 
 
The identified ion at m/z 1884 was observed in only 4 treated samples out 
of 42, where it was identified by ANNs after day 1 of treatment with 5 µM 
trichostatin A versus control melanoma Ma Mel 28 cells (figure 5.13). This 
result is not unexpected as the stepwise ANNs model predicted the top 
ion m/z 1817 which predicted 80% and the addition of 2566 increased the 
predictive performance to 90% and the third ion m/z 1884 also predicted 
90% of the cells. The ion at m/z 2566 only added 10 % of the population 
to the overall model which resulted in the presence of this ion in only 4 
drug treated samples. The ion m/z 1430.78 was found only in untreated 
cells at low intensity in the control melanoma cells only when compared 
with days 2 and 3 of drug treatment with trichostatin A but not in cells 
exposed to day 1 of treatment. 
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Figure 5.13 Representative mass spectra of peptides magnified using C18 ZipTip 
fractionated Ma Mel 28 cell lysate from an untreated control sample and a trichostatin-A 
treated sample after day 1 of treatment with 5 µM. This spectrum illustrates the 
observed intensity differences of ion at m/z 1884.04, present in treated melanoma but 
not in the control samples. 
 
5 µM trichostatin-A; 
Day 1 
Control; Day 1 
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5.2.6 MEWO cells 
 
As the protein concentration of 0.5 mg.ml-1 resulted in improved spectra 
that were of good quality for the Ma Mel 28 cells, the protein 
concentration was equalised to 0.5 mg.ml-1 for all melanoma MEWO cells 
in the following experiments.  Figures 5.14 and 5.15 illustrate the peptide 
spectra obtained. The spectra were observed visually and differences 
between the treated and untreated cells are highlighted in figures 5.14 
and 5.15. Decreasing intensity of ion m/z 1310 can be seen in figure 5.14 
for cells that were treated with 1 µM trichostatin A. As observed with the 
other two melanoma cell lines the spectra at day 3 for MEWO cells also 
contained very few peaks compared to the other days tested  as shown in 
figure 5.15 with 5 µM trichostatin A. Another ion at m/z 1440 was 
observed in figure 5.15 increasing in intensity but reduced after day 3. 
This ion may represent a drug effect resulting in the cells going into 
apoptotic death as a result of drug exposure.  
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5.2.6.1 Bioinformatic analysis of MEWO cells using ANNs  
 
ANN analysis of the MEWO data in table 5.04 revealed one ion m/z 
1439/1440 which repeatedly appeared as the most important ion. The 1 
Da mass difference in the m/z value is due to the fact that prior to ANNs 
analysis the raw MALDI data was rounded to the nearest Da to reduce 
the amount of data for bioinformatic analysis so the two m/z ions may 
belong to the same peptide. i.e. a m/z ion of 1439.4 would be rounded 
down to 1439 and a m/z value of 1439.8 would be rounded up to 1440. 
Peaks corresponding to the ions at m/z 1440 and 1439 were seen to be 
present as the first ion in day 1, day 2 and day 3 with 5 µM trichostatin A 
and in the day 1 samples of cells treated with 1 µM trichostatin A. In 
addition the same ion that was also seen and identified in the Ma Mel 28 
cells. With 1 µM trichostatin A after day 1 of dosing this ion gave a 
performance of 83% with the ion 2570 increasing this performance to 
89%. Day 2 revealed two ions, 1531 and 1677 giving a combined test 
performance of 86%. Day 3 resulted in 1133 giving 71% performance 
with the addition of the ions m/z 1934, 3082, and 1828 increasing this to 
93%. Treatment with 5 µM trichostatin A gave the ion m/z 1439 a 
performance of 94% with the ion m/z 2266 increasing this to 100% at day 
1. Again at day 2, ion m/z 1440 gave a performance of 88% with the 
second ion m/z 3372 taking this to 100%. Day 3 revealed m/z 1440 (90% 
performance) and although ion m/z 2939 did not improve the model 
performance, addition of ion m/z 1729 resulted in a 100% performance of 
the model. 
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Stepwise 
steps 
m/z 
value 
Test 
Performance 
(%) 
Test 
Error 
Day 1 
Control vs 1 
µM 
 
 
  
1 
2 
 1439  
   2570*  
   
 
83 
89 
0.157 
0.108 
Day 2 
Control vs 1 
µM 
   
1 
2 
 1531  
 1677  
   
 
85 
86 
0.176 
0.128 
Day 3 
Control vs 1 
µM 
   
1 
2 
3 
4 
1133 
1934 
  3082* 
1828 
 
71 
79 
89 
93 
 
0.198 
0.125 
0.120 
0.075 
 
Day 1 
Control vs 5 
µM 
   
1 
2 
1439 
2266 
 
94 
100 
0.101 
0.062 
 
Day 2 
Control vs 5 
µM 
   
1 
2 
 
1440 
  3372* 
 
88 
100 
 
0.102 
0.058 
 
Day 3 
Control vs 5 
µM 
   
1 
2 
3 
1440 
2939 
 1729* 
90 
90 
100 
0.126 
0.078 
0.049 
 
          * No Identify found 
 
Table 5.04 Artificial Neural Network results on MEWO cell line (n=18). Table to show the 
test performances and the mean squared error as each input is added to the model. The 
results show the top ions that gave the best accuracy with the error failing to improve 
with subsequent additions. The highlighted ions in red show the same value re-
appearing as the most important ion particularly when treated with 5 µM trichostatin A. 
 
N = number of experiments 
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The validity of the ANNs model was tested by generating a population 
chart for each individual melanoma sample assignment as drug treated or 
control using the stepwise predicted ions. Figure 5.16 is based on ions 
m/z 1439 and 2266 obtained from untreated and treated cells after day 1 
of drug treatment with 5 µM trichostatin A. The results show that the 
ANNs model correctly predicted 97% of the data as either a control or 
drug-treated sample; the misclassified samples have been circled. The 
ratios below 0.5 are assigned to the untreated control group and ratios 
above 0.5 are classified as treated samples. It can be seen that the 
majority of the control cells, with the exception of one sample, were 
classified correctly (blue bars) with a ratio of <0.5. The drug treated cells 
had two misclassified samples with the remaining predicted correctly with 
a ratio >0.5.  
 
 
 
Figure 5.16 Predictive capability of ANNs trained to recognise tryptic peptide profiles 
based on the ions m/z 1439 and 2266. The error bars represent the confidence interval. 
The blue bars correspond to the control samples and the red indicate drug treated 
samples. A predicted value below 0.5 indicates a control sample, whilst a prediction 
greater than 0.5 indicates a treated sample. 
0
0.2
0.4
0.6
0.8
1
1.2
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52
Samples
R
at
io
                                                                                                                              
Chapter 5                                                                                                                          
 
 
Susan Catherine Gill 
PhD Thesis, 2009 
 
223 
5.2.6.2 Validation of ANNs with a blind data set 
 
MEWO cell samples (n=5) for each treatment and exposure time and 
control cell samples (n=5) at each time period were used to predict the 
ANN models generated as an independent blind data set. The trained 
models were tested with a completely blind dataset to determine the 
validity of the results. For cells treated with 1 µM trichostatin A, compared 
to untreated cells, the samples were correctly assigned to a median 
accuracy of 97% for day 1; 77% for day 2 and 48% for day 3. Treatment 
with 5 µM trichostatin A gave a median accuracy of prediction 57% for 
day 1, 80% for day 2 and 88% for day 3. The high accuracy of prediction 
observed in table 5.04 infer that the model was performing well and that 
the ions identified represent possible biomarkers for drug treatment and 
exposure time. 
 
5.2.6.3 Identification of predicted biomarkers for MEWO cells 
 
The blind data was correctly classified in most of the samples except 
between control cells and treated cells (with 5 µM of drug) for day 1 
(57%) and at 1 µM trichostatin after 3 days of incubation. Therefore the 
biomarker ions within these models were considered to be those which 
most accurately distinguished peptide patterns between control and 
treated melanoma cells for this dataset. The predicted peptide ions (table 
5.05) were analysed by MS/MS to obtain the sequence and subsequent 
identity of the protein. Due to the complexity of the biological samples, a 
pre-fractionation was required before MALDI analysis. As with Ma Mel 28 
cells, the original samples were manually fractionated using a C18 column 
and eluted from the column sequentially using increasing concentrations 
of ACN diluted in 0.1% TFA. Each of the eluted samples were analysed 
by MALDI-TOF MS/MS analysis. As already mentioned in section 5.2.5.3 
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above for the Ma Mel 28 cell line, the samples for MEWO were also sent 
to Bruker Daltonics (Bremen, Germany) for further identification of 
predictive peptide ions from the ANNs analysis.   
 
A mascot search (Swissprot database) identified all three ANNs ions with 
m/z 1440/1439, 2266 and 1677 as ATP synthases with the peaks 
observed in the drug-treated samples (m/z 1439.7827; 2266.0762 and 
1676.8289). Analysis of the ANNs biomarker at m/z 1531 and 1934 were 
identified as 10 KDa heat shock protein (with a measured peak of m/z 
1529.7858) or haemoglobin subunit alpha (measured peak of m/z 
1529.7205) and GRP78 precursor respectively (measured peak m/z 
1933.9866). The ANNs ion m/z 1531 was shown to be at high intensity in 
the control cell lysates whilst the ion at m/z 1934 was present only in the 
drug-treated samples. The ANNs ion at m/z 1133 had two possible 
identities of actin, cytoplasmic 1 (with an observed peak at m/z 1132.51) 
or m/z 1132.62 as ADP/ATP translocase 2. Upon visual inspection of the 
spectra the peaks were observed in the drug-treated samples. The 
predictive tryptic peptide ions m/z 1828 and 2939 with measured peaks of 
m/z 1827.9164 belonged to eukaryotic initiator factor 4a-1 and m/z 
2928.3254 was identified as elongation factor 1-alpha 1. Very few peaks 
were observed in the original spectra for the ANNs ion m/z 1828 but 
where it was observed, it was present only in the drug-treated samples. 
The ANNs ion m/z 2939 was also observed only in drug-treated samples. 
The predictive peptide ions m/z 1729, 2570, 3082 and 3372 did not yield 
significant sequence matches (<0.05) using the MASCOT search 
engines. A summary of the identified proteins and their respective 
sequences are given in table 5.05. As previously mentioned with the Ma 
Mel 28 data, the ANNs would have to be repeated to verify the identities 
and thus the reproducibility of this methodology. 
                                                                                                                              
Chapter 5                                                                                                                          
 
 
Susan Catherine Gill 
PhD Thesis, 2009 
 
225 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TR = drug-treated samples CON = Control samples 
 
Table 5.05 Table to show the peptides identified by MS/MS using ions predicted by ANNs for discrimination between untreated 
and drug-treated cells. 
 
MEWO Ions 
ANN Ion m/z Identified Peptide sequence Mowse 
Score 
Protein                                                    Samples  
Identified                                                 identified                                                          
 
     
1133 1132.6202 QIFLGGVDKR 56 ADP/ATP translocase 2                                 TR 
 1132.5128 GYSFTTTAER 60 Actin, cytoplasmic 1 
     
1439 1440 1439.7827 VALTGLTVAEYFR 
 
67 ATP synthase subunit beta, mitochondrial    TR 
     
1531 1529.7858 VVLDDKDYFLFR 113 10kDa heat shock protein, mitochondrial      CON            
 1529.7205 VGAHAGEYGAEALER 75 Haemoglobin subunit alpha 
     
1677 1676.8289 FEDEKFEVIEKPQA. 61 ATP synthase coupling factor 6,                    TR 
mitochondrial   MOST DOSED 
     
1828 1827.9164 GIYAYGFEKPSAIQQR 
 
83 Eukaryotic initiation factor 4a-I                       TR 
     
1934 1933.9866 DNHLLGTFDLTGIPPAPR 74 GRP78 Precursor                                           TR 
 
     
2266 2266.0762 IPSAVGYQPTLATDMGTMQER 
 
71 ATP synthase subunit beta                             TR 
     
2939 2938.3254 SGDAAIVDMVPGKPMCBESFSDYPPLGR 43 Elongation factor 1-alpha 1                             TR 
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All of the identified ions were confirmed to be present in the original 
MALDI-TOF MS peptide spectra. Figure 5.17 shows the ATP synthase ion 
at m/z 1439.7827. The peak was observed in the majority of the samples 
after treatment with 5 µM trichostatin A as predicted by the ANNs 
revealing both 1439 and 1440 to be a key first ion. The ion was also 
observed in some samples treated with 1 µM trichostatin A after day 1 of 
drug-treatment. No peaks were seen in the control samples. The spectra 
in figure 5.17 demonstrate the peak seen at m/z 1439.7827 revealing its 
presence in drug-treated cells but not in control cells.   
 
 
 
 
 
Figure 5.17 Representative mass spectra of peptides magnified using fractionated 
MEWO cell lysate from control and trichostatin-A treated samples after 24 h of 
treatment. This spectrum illustrates the observed intensity differences of ions at m/z 
1439.79, present in treated melanoma but not in the control samples. 
 
 
5 µM trichostatin-A 
1 µM trichostatin-A 
Control 
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5.3 Discussion 
 
Currently there is a lack of biomarkers which predict whether a patients’ 
treatment has been successful. If peptide “fingerprints” and a panel of 
biomarkers from proteomic studies can be identified, then this would be of 
great clinical benefit to the patient (personalised medicine). In vitro 
cultured cells are currently used in many studies due to the scarcity of 
patient tissue and the results of this chapter reveal that it is possible to 
identify biomarkers from cell lines that correlate with drug treatment and 
exposure. This work examined the potential of MALDI MS based 
proteomics combined with ANN analysis to determine whether melanoma 
cell lines expressed altered peptidomic profiles following treatment and 
exposure times with the histone deacetylase inhibitor, trichostatin A.  
 
5.3.1 Sample preparation and analysis  
 
Prior to analysis by MALDI MS, the melanoma samples were adjusted to 
0.1 mg.ml-1 (Ma Mel 26a) and 0.5 mg.ml-1 (MEWO and Ma Mel 28 cell 
lines). Although analysis by MALDI MS is not quantitative, protein 
adjustment has to be carried out to identify differential intensities of the 
peaks and establish patterns between the data points. Measurement of 
the protein standards using the Bio-Rad micro-assay, gave a R2 value of 
over 0.98 on all cell lines, enabling accurate measurement of the cell 
lysate samples. The cells were then adjusted to their respective 
concentrations using 0.1% TFA; this dilution buffer was used through out 
the MALDI MS analysis.  
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5.3.2 Importance of QC in MALDI-MS analysis 
 
There has been a considerable amount of debate surrounding the use of 
SELDI-MS and MALDI-MS protein analysis, particularly with regard to the 
reproducibility of the methods (Diamandis, 2004). Critics have argued that 
reported discriminatory protein profiles have been based largely on 
experimental artefacts rather than biological differences (Matharoo-Ball et 
al., 2007). However, the methods used in this study for MALDI MS 
analysis were optimised for sample preparation and analysis carried out 
using the in-house protocol (Matharoo-Ball et al., 2007). Processing time, 
clotting times, centrifugation speeds, pre-aliquoting, storage temperature 
and the number of freeze-thaw cycles are all critically important as well as 
variation in ZipTip fractionation, MALDI crystallisation, laser irradiation, 
and sample preparation all of which influence protein/peptide outcomes. 
All samples in this study were centrifuged at a set speed and time and 
stored at -80oC until use. Freeze-thaw was limited to two cycles with 
sample preparation of each cell line carried out on ice prior to sonication 
and MALDI analysis. Sample bias reported by Petricoin et al., (2002) 
regarding the reproducibility of MALDI based approaches were tackled by 
randomising the position of samples on the target plate prior to analysis. 
Appropriate blanks, QC and BSA samples were also randomised and 
included on all plates. The blanks (0.1% TFA and matrix) were included 
to monitor contamination of the target plate; QC samples ensured a 
robust and reproducible methodology and BSA controls were used to 
confirm the efficiency of the tryptic digest and peptide acquisition. Close 
external calibration for peptides was used where the data was acquired 
from a calibration mixture spotted adjacent to each group of four sample 
spots. Poor or infrequent calibration can lead to a significant shift in the 
m/z values for the mass spectral peaks. 
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5.3.3 MALDI-MS analysis 
 
The spectra produced by MALDI MS revealed some visual differences 
between drug-treated and control melanoma and the reproducibility of the 
QC samples in figure 5.05 revealed a good correlation between all 
spectra captured on the MALDI MS. The spectra for Ma Mel 26a cells 
contained the worst peptide profiles, with very few peaks present visually 
due to the low starting protein concentration. This concentration as 
previously mentioned was chosen because the majority of the Ma Mel 
26a cells had very low total protein concentrations. This was rectified for 
the MEWO and Ma Mel 28 cells which resulted in a significantly improved 
spectral profile. When sufficient sample was available, the protein 
concentration was increased further (1 mg.ml-1) resulting in improved 
peptide spectral profile which enabled identification of the ANNs predicted 
biomarkers.  The spectra for MEWO and Ma Mel 28 cells at day 3 
showed low intensity peptide peaks compared with days 1 and 2 of drug 
treatment. Comparing this data to the results obtained in chapter 4, a 
correlation between the data can be seen. The MEWO cells were shown 
to have 50% cell death compared to 30% in the Ma Mel 28 cells after 
treatment for 3 days with 5 µM trichostatin A (chapter 4) when measured 
using the ToxiLight® and ViaLight Plus® assays. The MEWO spectra 
analysed by the MALDI-TOF MS in this study revealed very low intensity 
peptide peaks at day 3 with both 1 µM and 5 µM of drug. This may imply 
that drug treatment induces the initiation of the apoptotic pathway 
resulting in down-regulation of most proteins in drug exposed cells 
compared to untreated melanoma cells. The Ma Mel 28 cells which were 
more resilient to the drug treatment only showed a reduction in the 
peptide peaks with MALDI-TOF MS after day 3 and then only with the 
higher concentration (5µM) of trichostatin A. At this time the combinatorial 
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assays ToxiLight® and ViaLight Plus® also showed cell death due to 
drug exposure but less so with shorter drug exposure times.  
 
5.3.4 Analysis by ANNs  
 
Bioinformatic analysis acceptance criteria was based on visual inspection 
of mass spectrometric, BSA, and calibration profiles and those deemed to 
have a poor signal were removed from bioinformatic data assessment. 
The noisy and highly dimensional data obtained through proteomic 
analysis requires all aspects of data interrogation to be optimised 
including spectra pre-processing, quality control and dimensionality 
reduction. The biggest challenge in analysing data is the development of 
algorithms that can predict samples accurately into their correct groups 
for unseen or blind data. There are many data mining methods that can 
be employed and presently no single method can provide the most 
accurate and reliable analysis. 
 
The results in this study using ANN analysis, failed to validate the model 
for Ma Mel 26a cells for untreated compared to drug treated cells with 1 
µM trichostatin A and correctly classified only 55% of samples of the day 
1 dataset, 45% of the day 2 dataset and 60% of the day 3 dataset. This 
was disappointing but not unexpected due to the poor peptide spectral 
quality and the low starting protein concentration. However; it has to be 
noted that with the current and improved MS instrumentation (Bruker 
Ultraflex III) a starting concentration of 0.1 mg.ml-1 would generate good 
quality spectral profiles (unpublished data). Ma Mel 28 cells, on the other 
hand, performed well when analysed using ANNs for both the modelling 
set of samples and when tested with an independent blind dataset. ANNs 
analysis showed good predictions with the exception of one model which 
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resulted in only 66% of samples being correctly classified but the 
remaining five models assigned > 84% of samples correctly into their 
respective groups (drug-treated (both 1 and 5 µM) and untreated cells).  
 
For the MEWO cells the modelling data resulted in good prediction for all 
models between the trichostatin (1 and 5 µM) treated samples with 
increasing drug incubation times versus controls. For the blinded MEWO 
samples the ANNs predicted ions accurately classified >77% of samples 
in four of the six models, with the remaining 2 models underperforming 
(<77%). The application of blinded validation and test data in the 
modelling approach produced models with good performance on blind 
data and prevented over-fitting. In the Ma Mel 28 and MEWO melanoma 
cell lines the ion at m/z 1439/1440 appeared as predictive peptide ions in 
more than one model for both drug concentrations and exposure times. 
This ion may therefore be reflective of a marker of cell toxicity through 
apoptosis following drug exposure.  
 
Due to the poor results obtained with Ma Mel 26a cells, no further 
analysis was carried out for identification of predicted ions. Time and 
samples permitting, these cells would have been re-tested at a higher 
protein concentration. The top ions identified by the ANNs could have 
been identified following pre-fractionating the samples to further separate 
the proteins prior to MS/MS analysis. Identification of peptide ions was 
however; conducted for Ma Mel 28 and MEWO cell line. MALDI-TOF 
MS/MS was carried out following sample fractionation using sequential 
elutions of increasing organic solvent to resolve the peptide ions in order 
to help with the identification of the peptide and therefore parent protein. 
Further identification was carried out by LC-MALDI followed by MALDI-
TOF MS/MS (Bruker). 
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Protein identification of the tryptic peptide biomarker ions was achieved 
for the MEWO cells using MALDI-TOF MS/MS and LC-MALDI with the 
ANN discriminatory ion m/z 1439 identified as a peptide from protein ATP 
synthase (m/z 1439.78). Two further peptide ions were also identified 
from the protein ATP synthase (m/z 2266.0762 and 1676.8289) providing 
further evidence for its presence with the peaks observed in the spectra 
belonging to drug-treated samples only. Two identities were found for the 
ANNs ion at m/z 1133 with possible identities of beta actin (m/z 1132.51) 
or ADP/ATP translocase 2 (m/z 1132.62). Multiple identities were found 
for many of the ANNs ions in both cell lines. These proteins provided 
significant scores through the MASCOT database and because prior 
bioinformatic analysis requires reduction of the number of data points by 
binning the m/z to the nearest Dalton, it means that the ANNs predicted 
ions could represent either of the two identified proteins. A second reason 
may be due to the resolution and mass accuracy of the older MALDI 
instrument which was used for the initial MS analysis for discovery of the 
biomarkers correlating to drug treatment. However; the identity of the ions 
was carried out on a MALDI instrument with a much higher resolution and 
mass accuracy leading to a more comprehensive coverage of the 
proteome and higher protein identification rate. To confirm significance of 
the proteins immunoassays (ELISA, western blotting or 
immunohistochemistry) would have to be carried out which was beyond 
the investigations of this study. It was not possible to achieve protein 
identification of all the predictive ANNs ions using MALDI MS/MS and LC-
MALDI. A more sensitive method using ESI-MS/MS would have to be 
employed to identify these ions.  
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Successful protein identification from the tryptic peptide biomarker ions 
was gained for the Ma Mel 28 cells using MALDI-TOF MS/MS and LC-
MALDI with sequences of the ANN discriminatory ion at m/z 1440 being 
identified as a peptide belonging to the protein ATP synthase subunit 
beta (m/z 1439.7827) which was present in the drug-treated samples 
only. As already stated with the MEWO cells, multiple identities were also 
found for the Ma Mel 28 cell line for the ANN ions at m/z 1817 and 1884. 
The ANNs discriminatory ion m/z 1817 had three possible identities with 
peptides belonging to the protein ATP synthase subunit beta (observed in 
peak m/z 1815.86); tropomyosin alpha-3 chain (m/z 1815.88) or 78 kDa 
glucose regulated protein (m/z 1815.99). The final ANNs ion with m/z 
1884 had two possible identities with a peptide sequence observed for 
pyruvate kinase isozymes M1/M2 (m/z 1883.88) and glutathione S-
transferase P (m/z 1883.94). The reason for multiple identities as 
previously explained could have been due to binning the m/z to the 
nearest Dalton prior to ANN analysis and/or the mass and resolution 
accuracy of the new improved MALDI mass spectrometer. This means 
that the predictive m/z value identified by ANNs could potentially 
represent all of the identified proteins. In order to find out conclusively 
which protein was the “true biomarker” a further investigation would need 
to be carried out using Immunoassay methods.  
 
5.3.5 Clinical relevance of identified ions 
Protein identities from both Ma Mel 28 and MEWO cell lines revealed 
similar differentials between control and drug-treated samples by ANNs 
analysis with many peptide ions belonging to ATP synthases. This added 
confidence to the possibility that this biomarker could be used to predict 
therapeutic response in melanoma cells. ATP synthase or ATP5B (beta 
subunit) or H+ transporting, mitochondrial F1 complex are human genes. 
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These genes encode a subunit of mitochondrial ATP synthase which 
catalyzes ATP synthesis, during oxidative phosphorylation.  There are 
two linked subunits of ATP synthase composed of the soluble catalytic 
core, F1, and the membrane-spanning component, F0, and together they 
comprise the proton channel. The catalytic portion of mitochondrial ATP 
synthase where the identities were found consists of 5 different subunits 
(alpha, beta, gamma, delta and epsilon). Recent studies on melanoma 
have demonstrated that malignant melanoma show abnormal redox 
regulation, and although the molecular mechanisms involved are not well 
characterised, they seem to be related to oxidative stress (Locatelli et al., 
2009). ATP synthase has been demonstrated to be up regulated during 
apoptosis in a time–linked manner. This up regulation ensures that there 
is sufficient intracellular ATP levels and therefore efficient functioning of 
the mitochondrial respiratory chain for successful completion of the 
apoptotic pathway (Singh and Khar, 2005).  The presence of this protein 
in both MEWO and Ma Mel 28 cells treated with trichostatin A could 
indicate that the treatment is having a positive effect on the cells and they 
are undergoing or preparing for apoptosis. This could imply that 
prolonged exposure of the drug past the 3 days monitored in this study 
may result in a larger percentage of cells being killed. The presence of 
ATP synthase is therefore very promising especially combined with the 
ViaLight PlusTM data in chapter 4. As ATP was demonstrated to have 
dramatically reduced in the majority of the experiments tested by the 
ViaLight PlusTM assay, the implication that the mitochondria were being 
affected by the drug-treatment could imply that apoptosis is occurring and 
adds further confidence to the fact that the protein ATP synthase (which 
is involved in apoptosis) has been discovered by MALDI MS in 
conjunction with ANN analysis and identified by MALDI-MS/MS in the 
drug-treated samples. This could be a marker for apoptosis illustrating 
                                                                                                                              
Chapter 5                                                                                                                          
 
 
Susan Catherine Gill 
PhD Thesis, 2009 
 
235 
that a cytotoxic drug is having a positive effect for a patient undergoing 
treatment and should be investigated further. This study also illustrates 
that using multiple assay platforms can identify biomarkers which could 
be used for patient tailored treatments. Further investigations to monitor 
the reproducibility of this work would involve repeating the experiments 
using serum samples from patients rather than cells to see if ATP 
synthase can be found as a marker after treatment. Even though cells are 
the closest way of monitoring the tissue in vitro this is not always feasible 
due to the difficulties in obtaining cells by biopsy. Serum is easy to obtain 
from a blood sample and can be monitored over a patient’s treatment.  
Two proteins identified in the drug-treated MEWO cell lysates were beta 
actin and 10 kDa heat shock protein. Beta actin (gene name ACTB) is 
one of six different actin isoforms which have been found in humans. This 
is one of two non-muscle cytoskeletal actins. Actins are highly conserved 
proteins that are involved in cell motility, structure and integrity. The actin 
cytoskeleton controls multiple cellular functions, including cell 
morphology, movement and growth. A recent article by Dundr et al., 
earlier this year (2009) suggested that neural crest-derived tumours had 
shown expression of smooth muscle actin on some occasions but not 
consistently. It has however; been shown to play a role in metastasis by 
coordinating changes of the filaments. Yang et al., revealed the role actin 
played in stabilising the space generated by the membrane deformation 
ensuring efficient protrusion (Yang et al., 2009). Although a transient 
space can be formed without actin playing a part, the filaments were 
required to fill the space to allow the cells to protrude.  Actin (if the correct 
identity for the ANNs ion – it was one of two possible identities for the 
ANNs ion) was only present in drug-treated samples in this study and not 
controls which could imply that the cell cytoskeleton was being broken 
down due to the effects of the drug.  
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Heat shock proteins are a class of functionally related proteins whose 
expression is increased when cells are exposed to elevated temperatures 
or other stress to try to restore immature proteins or denatured proteins, 
thus protecting the cell. The expression of heat shock proteins has been 
observed in hepatocellular carcinoma (HCC) where correlation with 
tumour severity and poor outcomes of HCC patients has been observed 
(Lu et al., 2009). The presence of the heat shock protein in this study (10 
kDa heat shock protein) was present only in the control melanoma 
samples. This could be a normal house keeping protein that monitors the 
cell ensuring proper protein conformation. In addition, to the 10kDa heat 
shock protein, both the cell lines (MEWO and Ma Mel 28) revealed the 78 
kDa glucose regulated protein, a heat shock protein belonging to the heat 
shock protein-70 family. The 70 kDa heat shock protein was present in 
only drug-treated samples indicating that the cell was under stress. If 
further investigations into heat shock proteins on a larger population size 
identifies its relationship to severe melanoma cases, it may enable this 
protein to be used as a prognostic biomarker. The presence of these 
proteins has been observed in many malignant tumours, but their 
expression in association with melanoma has yet to be studied (Park et 
al., 2009). A review was published by Lee in 2007 discussing the role that 
GRP78 plays in many cancers. It was stated that the protein GRP78 or 
BIP (immunoglobulin heavy-chain binding protein) is induced under 
conditions of stress which then promotes tumour proliferation, survival, 
metastasis and resistance (Lee, 2007). Its presence is indicative of poor 
patient survival and higher pathological grade. This could be the reason 
for the presence of this protein in the melanoma samples in this study as 
it was potentially identified in both cell samples. The results from the 
ToxiLightTM assay in chapter 4 revealed only very low levels of cell death 
especially in the Ma Mel 28 cells implying resistance. Given the 
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importance of this protein in cancer cell survival, it could represent a 
prime target for anticancer agents. 
 
The ANNs ion m/z 1828 was identified as a peptide from the protein 
eukaryotic initiator factor. Protein synthesis can be divided into three 
phases: initiation, elongation and termination. Initiator factors are proteins 
that bind to the small subunit of the ribosome during the initiation of 
translation, a part of protein biosynthesis. Protein synthesis has been 
shown to considerably reduce during programmed cell death (Bushell et 
al., 2004). The presence of this protein in only a few drug-treated 
samples at low intensity could also be an indicator of apoptosis. The 
majority of the potential protein identities in both cell lines fall into three 
main categories: metabolic proteins (e.g. ATP synthase), cytoskeleton 
proteins (e.g. actin) and nuclear proteins (e.g. heterogeneous nuclear 
ribonucleoproteins A2/B1). They all imply that the cell is under stress and 
beginning to break down further supporting the previous cell assay data 
with ToxiLightTM and ViaLightTM Plus in chapter 4. The drug-treated cells 
were showing signs of stress by the decrease in ATP observed and an 
increase, although only a low percentage, in cell death. 
 
The cell lines used in this study were mostly derived from metastases 
meaning that many of the identified ions could be associated with 
metastatic disease, and may have a connection with drug 
response/treatment and exposure time (see table 5.06). Unfortunately the 
patients had little history to compare the data with due to their low 
survival rate after tissue extraction.  
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Tissue 
Number 
 
Patient 
Number 
 
Cell Line 
Code 
 
Tissue Origin 
 
Survival 
(months) since 
tissue 
extraction 
 
285 
 
 
284 
 
 
MA 000263 
 
 
MA 000336 
 
 
Ma Mel 26a 
 
 
Ma Mel 28 
 
Lymph node 
 
 
Squamous 
cell 
(skin) 
 
6.30 
 
 
4.59 
 
 
 
 
Table 5.06 Clinical information of the cell lines used in this study 
 
The identified ATP synthases mainly in the treated cells could be an 
indicator of apoptosis and thus cytotoxicity occurring in vivo for a patient 
receiving treatment. This could help in monitoring drug toxicity levels to 
prevent unnecessary over-exposure of the drug and hence drug side-
effects for the patient. To further clarify these findings further 
investigations would be required to define the in vivo role and impact of 
the identified proteins after trichostatin-A drug treatment and exposure. 
Although the study was carried out within a low passage number, it 
should be noted that changes in both the proteome and genome may 
have occurred during in vitro culture and hence there are likely to be 
differences between the original tissue and the cell line.  
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5.3.6 Conclusion 
 
Due to the limitations of tumour tissue, the research carried out on cell 
lines is of importance to identify diagnostic and prognostic markers. Other 
studies have been carried out on drug resistant cells. Urbani et al., (2005) 
examined etoposide resistance to chemotherapy in human 
neuroblastoma, discovering a number of over-expressed proteins; and 
Craven et al., (2004) studied proteins induced in response to interferon α. 
The results obtained from work presented in this chapter have revealed 
how cell lines can be used to provide useful information on markers that 
associate with drug treatment for a particular disease, especially at the 
protein level. It provides a proof of principle study that markers can be 
identified by MALDI MS analysis in conjunction with ANNs associated 
with drug-sensitive and drug-resistant cell samples. These findings could 
lead to the discovery of proteins that are of prognostic and therapeutic 
benefit with the long term outcome leading to personalised treatments for 
individuals in which a decision can be made on the best suited treatment.  
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Chapter 6: Discussion  
 
 
6.1 ToxiLight® and its use as a cytotoxicity assay 
 
The research presented in this thesis has demonstrated the design, 
optimisation and effective use of a novel bioluminescent assay for the 
analysis of cell death. The initial work illustrated the production of a novel 
assay that is sensitive, rapid and homogeneous competing against 
current methodologies already commercially available. The use of 
bioluminescence as a measurement of cell viability and cell death has 
been proven in this study to be a reliable alternative to the conventional 
methods. ToxiLight® was found to be highly sensitive both in detecting 
AK standards and low cell numbers with excellent reliability. It was able to 
measure a 96 well white walled luminometer plate in less than 5 min 
(dependent upon the transport mechanism of the luminometer used) 
showing detection limits of 10 cells per well. This sensitivity has to the 
best of my knowledge, not been identified in an assay previously making 
this assay the most sensitive measurement of cell death. Due to the low 
signal to noise levels of bioluminescence, the assay demonstrated better 
sensitivity than both fluorescent (LDH) and colorimetric assays (WST-1, 
MTT, MTS) currently utilised and does not contain any harmful 
radioactive components present in the well-renowned chromium51 release 
assay. The overall evaluation of the kits tested within this study illustrated 
that ToxiLight® proved to be the best cytotoxicity assay tested. This study 
did however highlight the need for combination assays to gain maximal 
information on the cells tested and as a result the bioluminescent kits 
ViaLight® and ToxiLight® were found to work well in conjunction with 
each other. This combination of a viability and cell death assay was 
discussed by Miret (2006) stating the need to analyse both apoptotic and 
necrotic forms of cell death. By measuring and comparing the relative 
amounts of AK and ATP within a population of cells, it was found that it 
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was possible to screen for all outcomes in a cell viability study. An 
increase in ATP values above that of the control sample would indicate 
proliferation in the cell sample, whereas samples giving lower ATP/RLUs 
to the control and showing a decrease / no change in the levels of AK 
would indicate growth arrest and a decrease in ATP and an increase in 
AK would conclude that the cells are necrotic. A good example of the 
need to measure cell viability and cell death was shown by measuring the 
effects of dacarbazine on melanoma cells. Neither the ToxiLight® assay 
nor the ViaLight® Plus assays on their own could identify the true effects 
of the drug on the cells.  It was only when the two assays were used in 
combination with each other that a conclusion of cell cytostasis could be 
drawn from the experiment (figure 3.18).  
 
Cell-based assays are being adopted with increasing frequency in drug 
discovery programs because cell systems are often inherently predictive 
of in vivo response. The use of technical optimisation in the combined kits 
allows an increase in the relevance of correlation testing, to enhance the 
chances of detecting precisely the cytotoxicity effects of drugs and to 
reduce the overall handling time and the amount of test compounds 
needed. It also allows optimal use of rare and valuable cell samples, such 
as primary cell cultures. Multiple endpoint kits may also provide hints of 
the mechanisms of toxicity. Since its launch in 2005, ToxiLight® has been 
utilised successfully by researchers for detecting the effects of drugs on 
cells in studying many diseases including cancer (Daniels et al, 2006; 
Kumarasuriyar et al., 2007; Morgan-Lappe et al., 2007; Si et al., 2008). In 
addition a paper published in 2006 by Miret compared many in vitro 
assays of cellular toxicity in HepG2 cells and concluded the ViaLight® 
Plus, ToxiLight® and caspase 3 fluorometric assays to be the most useful 
combination, again confirming the need for more than one assay to fully 
evaluate the cellular effects of a drug. Since the production of ToxiLight®, 
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a novel assay has been produced which is a 2 in 1 assay measuring both 
cell viability and cell death known as MultiTox-Fluor, it incorporates both 
fluorescence and luminescence measurements of proteases. Although it 
was not assessed in this study, this assay would be beneficial if its claims 
of sensitivity and rapid throughput are correct. However, it does possess 
obvious disadvantages, including the instability of the protease released 
upon cell death after 9 h in cell culture (Promega, 2009). This would 
result in ineffective and inconsistent measurements over a prolonged 
period of time. Future work for improving the ToxiLight® assay would be 
the inclusion of a “stop” solution which would allow for a more accurate 
measurement over time, to overcome the very rigid time restriction (of no 
more than 30 min) after addition of the AK detection reagent for analysing 
by luminometry. Ideally, a stop solution would improve the reproducibility 
for users and prevent any adverse effects of this reversible reaction. 
 
6.2 Cytotoxicity assays and melanoma study 
 
One of the main aims of the research was to obtain a drug sensitive and 
resistant melanoma cell line for further investigations into cellular 
proteomics. The combination of the ToxiLight® and ViaLight® Plus 
assays successfully identified the Ma Mel 28 cells as a vindesine, 
camptothecin and dexamethasone resistant cell line (chapter 4 of this 
thesis). The assays also revealed that the response observed with these 
cells was mainly due to a cytostatic effect to their treatment with the drugs 
ara-C, cisplatin and doxorubicin.  In contrast to the Ma Mel 28 cell line, 
the Ma Mel 26a and MEWO cell lines proved to be more sensitive overall 
to the exposure to drugs ara-C, doxorubicin, camptothecin, cisplatin and 
trichostatin A used in this study. However, not all the drugs resulted in the 
same cellular effects throughout, with responses varying within the same 
cell line. Resistance is known to occur with many chemotherapy drugs 
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and experimentally, acquired resistance has been reported to various 
compounds (Kerbel et al., 2001). Goldie and Coldman (1979) suggest 
that spontaneous mutations occurring during tumour evolution are 
responsible for the presence of intrinsically resistant cells before 
exposure of a tumour to a cytotoxic drug and this hypothesis continues to 
play a crucial role in the application of treatments (Poprach et al., 2008). 
The results gained from studies presented in this thesis revealed that 
melanoma cells respond differently to various chemotherapeutic agents. 
A cell line may respond positively to one toxic agent but not another, and 
it may be inferred that individual patients respond differently to the agents 
used for their treatment. This highlights the need for “personalised” 
therapy for all patients so they can be screened individually for their 
potential response to a given cytotoxic drug prior to administration.  
 
Melanomas are known to be intrinsically resistant to both chemotherapy 
and radiotherapy (Seetharamu et al,, 2009) and assays capable of 
detecting drug-resistance before commencement of treatment would be 
of benefit to patient management. The ToxiLight® and ViaLight® Plus 
assays could be utilised in these settings, but would rely on the use of 
techniques that reproducibly allowed primary cell cultures to be 
established. This represents an area that in the past has been difficult to 
address successfully. Current research is looking into the role cancer 
stem cells play in the resistance observed when patients undergo 
treatment. These cells are a small population of the tumour that possess 
the stem cell property of self renewal and proliferation (Gao, 2008). The 
cancer cells that undergo apoptosis when treated with a cytotoxic agent 
may be the tumour cells that have limited proliferation properties and are 
unable to renew. It is reported that cancer stem cells can resist apoptosis 
(Wei et al., 2006) and it is therefore these resistant cells which should be 
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used in the screening for biomarkers and should be considered for future 
research.  
 
6.3 The use of trichostatin A in the treatment of melanoma 
 
Previously, trichostatin A, the most potent inhibitor of histone 
deacetylase, was shown to strongly suppress growth of pancreatic 
adenocarcinoma cells (Donadelli et al., 2003). More recently the effects of 
trichostatin A on cancers including melanoma, have been widely tested 
and demonstrated to induce growth arrest and apoptosis in many studies 
(Koh et al., 2007; Khan et al., 2008). The data presented by Khan et al. 
(2008) revealed that abnormalities observed in some tumours, for 
example in the expression of MHC class I antigens may result from 
epigenetic repression. The use of trichostatin A has been shown to 
convert a tumour cell to an “antigen presenting cell” capable of activating 
IFN-gamma secreting T cells via the class I pathway (Khan et al., 2008). 
This is most likely due to T-cell engagement which without the presence 
of co-stimulatory molecules e.g. B7, would lead to T-cell apoptosis and 
clonal detection/peripheral tolerance (Zamorano et al., 2001). Trichostatin 
A has also been shown to stabilise wild-type p53, although this was not 
proven to be the cause of the observed growth arrest (Peltonen et al., 
2005). The results indicate that while the action of TSA is independent of 
p53, the activation of the apoptosis pathway by the HDAC inhibitors may 
provide further therapeutic approaches for melanoma treatment (Peltonen 
et al., 2005). The results in this thesis replicated the results observed in 
the study by Peltonen et al., where all the cell lines responded to 
treatment with the drug. Although Ma Mel 28 cell death was not observed 
until after 72 h (using 5 µM trichostatin A) the cells were non-replicating, 
indicating growth arrest.  
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It is not possible to mimic in vitro the exact condition of drug therapy, 
since many factors need to be taken into account. Melanoma patients 
undergo long treatment regimes whereas drug treatment in vitro is time 
restricted usually 24 – 72 h. The concentration of the drug at the tumour 
site will be variable depending on where the tumour is in the body, and 
the drugs pharmacokinetics: the extent and rate of absorption, 
distribution, metabolism and excretion of the drug (ADME); although in 
recent years pharmacokinetics has been better described as LADME:  
 
 Liberation - the drugs release from the formulation. 
 Absorption - the drug entering the body. 
 Distribution - the dispersion or dissemination of the drug 
throughout the fluids and tissues of the body.  
 Metabolism - the irreversible transformation of parent compounds 
into daughter metabolites.  
 Excretion - the elimination of the substances from the body. In rare 
cases, some drugs irreversibly accumulate in a tissue in the body.  
 
Future work on melanoma cells would investigate the undamaged cells by 
re-growing this hypothetically resistant population by exposing cells to 
trichostatin A over a prolonged period of time. This would prove whether 
or not a longer incubation time (beyond 3 days) would result in additional 
cytotoxic effects or whether a resistant population survives. This can then 
be compared to the original drug sensitive population for changes in the 
proteome and molecular pathways which may lead to a greater 
understanding of events within a cancer cell in vivo. This method would 
be a better way of monitoring differences between sensitive and resistant 
cells in vitro as this research resulted in findings related to ‘drug-induced’ 
effects. If the melanoma cells fail to respond to additional exposure of 
trichostatin A, a second agent in combination with trichostatin A could be 
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tested. Touma et al., (2005) combined the use of retinoic acid and 
trichostatin A, which led to increased growth inhibition in renal cell 
carcinoma. Before confirmation of the overall effects of trichostatin A, the 
results obtained in this melanoma study could be repeated on different 
cancer cell types to determine whether the same heterogeneous 
response occurs. If these results conclude a lack of commonality within a 
larger homogeneous patient population then it may be concluded that 
there is a need for assays for drug sensitivity testing: personalised 
medicine (Marko-Varga et al., 2007).  
 
6.4 The cancer cell lines proteome 
 
Proteomics has proven to be a useful tool in this study to extend our 
understanding to the molecular mechanisms associated with drug treated 
and untreated cancer cells. MS and bioinformatic analysis were 
introduced to interrogate the proteome of melanoma cells. The cell lines 
studied have revealed proteomic profiles that can be used to identify 
cellular changes resulting from the use of the chemotoxic drug, 
trichostatin A. Differences in the peptide fingerprinting profiles was 
observed that reflected the results obtained with the ToxiLight® and 
ViaLight Plus® assays. This led to the hypothesis that the differences in 
the profiles (drug treated versus control) would correlate with drug-
response and the development of resistance to drug treatment. To further 
this aspect of the study, the reproducibility of the MALDI-TOF MS 
analysis was explored. The duplication of MS data is a contentious 
subject between many researchers, as highlighted in earlier studies by 
Petricoin et al., (2002) which indicated that the data produced was not 
always replicated in further studies. However, the original work by 
Petricoin lacked vigorous quality control and standard operating 
procedures using robotic and automated sample processing. The MS 
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work carried out in chapter 5 were rigorously controlled and standardised 
including the use of an automated Xcise robotics for sample preparation; 
the inclusion of quality control to check for reproducibility; BSA controls to 
ensure the proteins had been tryptically digested; blanks to confirm there 
had been no contamination on the MALDI target plate and the 
randomisation of the samples on the MALDI plate. A problem that is often 
highlighted in proteomic research is the cut off for peak discrimination. 
Small peaks are often the same peak intensity as the baseline peaks 
themselves, but could contain important information not readily identified 
due to the lack of sensitivity of the methodology.  
 
To corroborate the peptide profile data obtained in this study, future work 
should include validation by other operators on the same and other 
instruments at more than one centre. An added parameter to consider 
upon analysing the results for peptide profile differences between the cell 
lines is that each individual cell line should undergo assay on different 
days to establish the in built error of analysis at different time points. 
Other parameters associated with cell culture and freezing conditions will 
be important to understand and crucial in removing any bias that may be 
introduced to a study. 
 
Cell lines are proving to be a valuable alternative and a pre-requisite to 
the use of tissue for genetic and proteomic studies. The availability of 
tissues to researchers has been problematic for a number of reasons: the 
lack of adequately characterized high quality tissues, increasing concerns 
due to privacy issues and the inability to obtain follow-up or clinical 
outcome of patients. Protein profiles between areas of the tissue mass 
can also alter, similar to the alteration seen with cell lines during their time 
in culture. A number of proteomic studies have been conducted whereby 
the authors have utilised cell lines to identify proteins of possible clinical 
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significance. Mian et al., (2003) studied the effects of the 
chemotherapeutic agent taxol, in resistant and sensitive breast cancer 
cell lines by examining their protein expression patterns over a treatment 
period of 96 h. Analysis of a resistant gastric cancer cell line by MALDI-
TOF MS identified nine differential expression proteins between the 
parental and resistant strains enabling the sensitization of the cells by the 
construction of a vector for Triosephosphate isomerase (TPI) which was 
found to be down-regulated (Wang et al., 2008). After transfection with 
the vector, the cells became more sensitive to several drugs and the 
resistance was shown to be reversed.  
 
6.5 Use of bioinformatics as a tool in biomarker identification 
 
Due to the enormous quantity of data obtained by proteomics it was 
necessary to evaluate the results by means of statistical algorithms 
capable of handling the dimensionality of large data sets. This prevents 
both bias and promotes faster analysis of data establishing differences or 
commonalities in protein profiles for biomarker identification. As 
previously mentioned, data pre-processing is important for reproducible 
data (Carlson et al., 2005; Petricoin et al., 2002). Although ANNs has not 
been used directly in patient treatment, the results show that it has huge 
potential to be of benefit to patients for personalised therapy in the future. 
Larger populations would improve the predictive performance of the 
ANNs resulting in a larger validation set if the data were analysed in the 
same manner as in this study i.e. 60% training set; 20% test data set and 
a 20% blind data set (Schwarzer et al., 2000).  
 
The majority of proteins identified by proteomic profiling were associated 
with either metabolic, cytoskeletal or nuclear responses in this 
investigation (ATP synthase was identified as a prominent response). 
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However, such high abundance molecules are often produced as a 
reaction to tumour presence, but could still represent valid biomarkers of 
the disease process or response to therapy (Diamandis, 2002).  As 
revealed in this study the presence of ATP synthase in both Ma Mel 28 
and MEWO cells was indicative of cell death, and it can be suggested 
that protein could be of use in diagnosis or prognosis with this or other 
drugs. Whether other drugs produce the same protein anti-inflammatory 
response or not remains to be established. Further research using a 
broader range of drugs, patient samples and different cancers should be 
conducted. A larger patient population would also benefit accuracy and 
reproducibility of ANN analysis allowing further differences and new 
cancer biomarkers to emerge; these biomarkers could provide valuable 
information that may aid in a more effective diagnosis, prognosis, and 
response to therapy. 
 
From the results obtained here using mass spectrometry and ANN 
analysis, the identity and correlation of patterns of melanoma response to 
trichostatin A has revealed differences between drug-treated and control 
melanoma cells. The responses identified upon drug exposure (e.g. ATP 
synthase in drug-treated cells) revealed that the cells had been damaged 
by the drug treatment replicating the results observed with the cytotoxicity 
assays; ViaLight® Plus and ToxiLight®. Further research investigating 
trichostatin A as a future potential agent in patient treatment would be 
required using a larger patient sample population, obtained from various 
centres. The protein identities in this study should also be confirmed by 
other methodologies including western blotting and ELISA.  
 
This methodology of using MALDI-MS and the combinatorial cell death 
assays could provide a way of monitoring the treatment of patients in the 
future. At present, there are limitations to the methodologies. The MALDI-
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MS and ANNs analysis is time consuming, equipment is expensive and 
the software requires specialist knowledge and interpretation. The 
techniques would need to be reproducible, robust, user-friendly and 
easily adapted for the high throughput screening (HTS) of therapeutic 
drugs. The biomarkers identified in this research could have potential in 
monitoring the effects of drug treatment. If ATP synthase is confirmed to 
be consistently up regulated after a patient has a positive response to 
drug treatment, then this biomarker could be a potential maker for drug 
therapy. The research would have to be repeated on a larger population, 
in different clinics and monitored using patient serum as tissue is not 
easily accessible or optional for regular monitoring.  
 
6.6     Personalised medicine 
 
Recent advances in science offers the potential to define an individuals 
risk based on their own personal “genetic make-up”. Currently, cancer 
treatment is based upon standards of care that are determined by 
averaging the response rates of clinical trials across large cohorts i.e. a 
treatment plan that is similar for the analysis of clinical trials in different 
cancer types (Mansour et al., 2008; Van't Veer et al., 2008). The 
emergence of subtypes of disease adds to the difficulty of determining the 
prognosis of patients and recommendation of the most appropriate 
treatment; the stage, grade and histological type of the cancer can affect 
how drugs localise in cancer tissue and should be taken into account. 
Personalization of treatment should be based on an individual patient’s 
clinical status, taking into account age, gender, height, weight, diet and 
environment that could be used to stratify disease status; select between 
different medications and/or tailor their dosage; provide a specific therapy 
for an individual's disease; or initiate a preventative measure that is 
particularly suited to that patient at the time of administration. Several 
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examples of approaches to personalized medicine have already been 
established in practice, such as the testing for disease-causing mutations 
in the BRCA1 and BRCA2 genes implicated in familial breast and ovarian 
cancer syndromes (Tonin et al., 2006) and the well documented herceptin 
therapy (Germano and O’Driscoll, 2009). It is hoped that in the future with 
the use of proteomic and genomic approaches to diagnosis, drug 
development and individualized therapy will improve the quality of life for 
patients with cancer (Marko-Varga et al., 2006). Better diagnosis and 
prediction of treatment outcome will prevent patients undergoing 
treatments that are unnecessary and identify, with a higher degree of 
accuracy, appropriate (personalised) therapies. 
 
.  
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